Document:

Exhibit

    Exhibit 10.6

THIRD AMENDED AND RESTATED  
SECURITIES PLEDGE AGREEMENT

THIS THIRD AMENDED AND RESTATED SECURITIES PLEDGE AGREEMENT dated as of September 25, 2019 (this “Pledge Agreement”), is entered into among ASBURY AUTOMOTIVE GROUP, INC., a Delaware corporation (the “Company”), EACH OF THE UNDERSIGNED SUBSIDIARIES OF THE COMPANY AND EACH OTHER PERSON THAT SHALL BECOME A PARTY HERETO BY EXECUTION OF A JOINDER AGREEMENT (each a “Pledgor” and, together with the Company, collectively, the “Pledgors”), and BANK OF AMERICA, N.A., as Administrative Agent (in such capacity, the “Administrative Agent”) for each of the Secured Parties (as defined in the Credit Agreement referenced below).  
RECITALS:
A.    Pursuant to a Second Amended and Restated Credit Agreement dated as of July 25, 2016 (as amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Existing Credit Agreement”), among the Company, the Subsidiaries of the Company party thereto from time to time as New Vehicle Borrowers (the “Existing New Vehicle Borrowers”) or Used Vehicle Borrowers (the “Existing Used Vehicle Borrowers” and, collectively with the Company and the Existing New Vehicle Borrowers, the “Existing Borrowers”), the Administrative Agent, Bank of America, N.A., as Revolving Swing Line Lender, New Vehicle Floorplan Swing Line Lender, Used Vehicle Floorplan Swing Line Lender and as an L/C Issuer, and the lenders party thereto from time to time (collectively, the “Existing Lenders”), the Existing Lenders agreed to provide (i) to the Company, a revolving credit facility with a letter of credit sublimit and swing line facility, (ii) to the Existing New Vehicle Borrowers, a revolving new vehicle floorplan facility, including a new vehicle swing line subfacility and (iii) to the Existing Used Vehicle Borrowers, a revolving used vehicle floorplan facility, including a used vehicle swing line subfacility.

B.    In connection with the Existing Credit Agreement, certain of the Pledgors (collectively, the “Existing Pledgors”) entered into that certain Second Amended and Restated Securities Pledge Agreement dated as of July 25, 2016 (as amended, supplemented or otherwise modified prior to the date hereof, the “Existing Pledge Agreement”) pursuant to which the Existing Pledgors pledged (the “Existing Pledge”) to the Administrative Agent for the benefit of the Secured Parties certain interests in certain subsidiaries.

C.    The Existing Borrowers have requested that the Existing Credit Agreement be amended and restated, on the terms set forth in that certain Third Amended and Restated Credit Agreement dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), among the Company, the Subsidiaries of the Company party thereto from time to time as New Vehicle Borrowers or Used Vehicle Borrowers (collectively with the Company, the “Borrowers”), the Administrative Agent, Bank of America, N.A., as Revolving Swing Line Lender, New Vehicle Floorplan Swing Line Lender, Used Vehicle Floorplan Swing Line Lender and as an L/C Issuer, and the lenders party thereto from time to time (the “Lenders”).

D.    Certain additional extensions of credit may be made from time to time for the benefit of the Pledgors or the other Loan Parties pursuant to certain Secured Cash Management Agreements and Secured Hedge Agreements (as defined in the Credit Agreement).

E.    Each Pledgor will materially benefit from the Loans to be made, and the Letters of Credit to be issued, under the Credit Agreement, and such other extensions of credit, and (i) the Company, in addition to being a Borrower, is party to the Company Guaranty pursuant to which the Company guarantees the 

Obligations of the other Loan Parties (ii) certain of the Pledgors are Vehicle Borrowers, and (iii) each Pledgor (other than the Company) is a party (as signatory or by joinder) to the Subsidiary Guaranty pursuant to which such Pledgor guarantees the Obligations of the other Loan Parties.

F.    It is a condition precedent to the Secured Parties’ obligations to amend and restate the Existing Credit Agreement and make and maintain such extensions of credit that the Pledgors shall have executed and delivered this Pledge Agreement to the Administrative Agent. 

In order to induce the Secured Parties to make and maintain extensions of credit from time to time under the Credit Agreement and such Secured Cash Management Agreements and Secured Hedge Agreements, and in further consideration of the promises and mutual covenants contained herein, the Existing Pledge Agreement is hereby amended and restated, and the parties hereto agree as follows:
1.    Certain Definitions.  All capitalized terms used but not otherwise defined herein shall have the meanings assigned thereto in the Credit Agreement.  Terms used in this Pledge Agreement that are not otherwise expressly defined herein or in the Credit Agreement, and for which meanings are provided in the Uniform Commercial Code of the State of New York (the “UCC”), shall have such meanings unless the context requires otherwise.  In addition, for purposes of this Pledge Agreement, the following terms have the following definitions:
“Facility Termination Date” means the date as of which all of the following shall have occurred:  (a) the Aggregate Commitments have terminated, (b) all Obligations have been paid in full (other than (x) contingent indemnification obligations and (y) obligations and liabilities under Secured Cash Management Agreements and Secured Hedge Agreements as to which arrangements satisfactory to the applicable Cash Management Bank or Hedge Bank have been made), and (c) all Letters of Credit have terminated or expired (other than Letters of Credit as to which other arrangements with respect thereto satisfactory to the Administrative Agent and the L/C Issuers shall have been made).

“Secured Obligations” means:

(a)     as to the Company, (i) all of its Obligations arising under the Credit Agreement, excluding Obligations arising under or in respect of the New Vehicle Floorplan Facility, (ii) its Guarantor’s Obligations (as defined in the Company Guaranty Agreement), excluding such Guarantor’s Obligations to the extent (but only to the extent) they constitute guarantees of Obligations arising under or in respect of the New Vehicle Floorplan Facility, and (iii) the payment and performance of its other obligations and liabilities (whether now existing or hereafter arising) under any of the other Loan Documents (including this Pledge Agreement) to which it is now or hereafter becomes a party and any Secured Cash Management Agreements and Secured Hedge Agreements to which any Loan Party is now or hereafter becomes a party, excluding such other obligations and liabilities arising under or in respect of the New Vehicle Floorplan Facility;
 
(b)     as to each Pledgor which is a New Vehicle Borrower, (i) all of its Obligations arising under the Credit Agreement, (ii) its Guarantor’s Obligations (as defined in the Subsidiary Guaranty to which it is a party), and (iii) the payment and performance of its other obligations and liabilities (whether now existing or hereafter arising) under any of the other Loan Documents (including this Pledge Agreement) to which it is now or hereafter becomes a party and any Secured Cash Management Agreements and Secured Hedge Agreements to which any Loan Party is now or hereafter becomes a party; and 

2

(c)     as to each Pledgor which is a Referenced Subsidiary, (i) all of its Obligations arising under the Credit Agreement, excluding Obligations arising under or in respect of the New Vehicle Floorplan Facility, (ii) its Guarantor’s Obligations (as defined in the Subsidiary Guaranty to which it is a party), excluding such Guarantor’s Obligations to the extent (but only to the extent) they constitute guarantees of Obligations arising under or in respect of the New Vehicle Floorplan Facility, and (iii) the payment and performance of its other obligations and liabilities (whether now existing or hereafter arising) under any of the other Loan Documents (including this Pledge Agreement) to which it is now or hereafter becomes a party and any Secured Cash Management Agreements and Secured Hedge Agreements to which any Loan Party is now or hereafter becomes a party, excluding such other obligations and liabilities arising under or in respect of the New Vehicle Floorplan Facility;

provided, that the Secured Obligations of a Pledgor shall exclude any Excluded Swap Obligations with respect to such Pledgor.

“Referenced Subsidiary” means each Pledgor other than (x) the Company and (y) any Pledgor which is a New Vehicle Borrower.

2.    Pledge of Pledged Interests; Other Collateral.  
(a)    As collateral security for the payment, performance and satisfaction of such Pledgor’s respective Secured Obligations, each Pledgor grants to the Administrative Agent, for the benefit of the Secured Parties, a continuing security interest in all of the following items of property in which it now has or may at any time hereafter acquire an interest or the power to transfer rights therein, and wheresoever located:
(i)    all Equity Interests in the Subsidiaries described on Schedule I attached hereto and incorporated herein (as such schedule may be amended or supplemented from time to time) other than any such Equity Interests that constitute Excluded Property, in each case, whether now existing or hereafter created or acquired (collectively, the “Pledged Interests”) (such Subsidiaries, together with all other Subsidiaries whose Equity Interests may be required to be subject to this Pledge Agreement from time to time, are referred to collectively as the “Pledged Subsidiaries”); 
(ii)    all money, securities, security entitlements and other investment property, dividends, rights, general intangibles and other property at any time and from time to time (x) declared or distributed in respect of or in exchange for or on conversion of any Pledged Interest, or (y) by its or their terms exchangeable or exercisable for or convertible into any Pledged Interest; 
(iii)    all other property of whatever character or description, including money, securities, security entitlements and other investment property, and general intangibles hereafter delivered to the Administrative Agent in substitution for or as an addition to any of the foregoing; 
(iv)    all securities accounts to which may at any time be credited any or all of the foregoing or any proceeds thereof and all certificates and instruments representing or evidencing any of the foregoing or any proceeds thereof; and

3

(v)    all proceeds of any of the foregoing.
All such Pledged Interests, certificates, instruments, cash, securities, interests, dividends, rights and other property referred to in clauses (i) through (v) of this Section 2 are herein collectively referred to as the “Collateral.”  Notwithstanding the foregoing, the grant of a security interest and collateral assignment under this Section 2 shall not extend to, and the term “Collateral” shall not include, any Excluded Property.
(b)    Subject to Section 11(a), each Pledgor agrees to deliver all certificates, instruments or other documents representing any Collateral to the Administrative Agent at such location as the Administrative Agent shall from time to time designate by written notice pursuant to Section 23 for its custody at all times until termination of this Pledge Agreement, together with such instruments of assignment and transfer as requested by the Administrative Agent.
(c)    Each Pledgor agrees to execute and deliver, or cause to be executed and delivered by other Persons, at Pledgor’s expense, all share certificates, documents, instruments, agreements, financing statements (and amendments thereto and continuations thereof), assignments, control agreements, or other writings as the Administrative Agent may reasonably request from time to time to carry out the terms of this Pledge Agreement or to protect or enforce the Administrative Agent’s Lien and security interest in the Collateral hereunder granted to the Administrative Agent for the benefit of the Secured Parties and further agrees to do and cause to be done upon the Administrative Agent’s request, at Pledgor’s expense, all things determined by the Administrative Agent to be necessary or advisable to perfect and keep in full force and effect the Lien in the Collateral hereunder granted to the Administrative Agent for the benefit of the Secured Parties, including the prompt payment of all out-of-pocket fees and expenses incurred in connection with any filings made to perfect or continue the Lien and security interest in the Collateral hereunder granted in favor of the Administrative Agent for the benefit of the Secured Parties.
(d)    All filing fees, advances, charges, costs and expenses, including all fees and expenses of counsel, incurred or paid by the Administrative Agent or any Lender in exercising any right, power or remedy conferred by this Pledge Agreement, or in the enforcement thereof, shall become a part of the Secured Obligations secured hereunder and shall be paid to the Administrative Agent for the benefit of the Secured Parties by the Pledgor in respect of which the same was incurred immediately upon demand therefor.
(e)    Each Pledgor agrees to register and cause to be registered the interest of the Administrative Agent, for the benefit of the Secured Parties, in the Collateral on its own books and records and the registration books of each of the Pledged Subsidiaries.
(f)    Each Pledgor, with respect to each of its direct Subsidiaries that is an issuer of Pledged Interests, hereby (i) consents to the pledge by any other Pledgor of any Pledged Interests in such Subsidiary and (ii) waives any rights (regardless of priority) to purchase or acquire, or offer to purchase or acquire, equity interests in such Subsidiary arising as a result of the pledge of Pledged Interests in such Subsidiary by any other Pledgor.
3.    Status of Pledged Interests.  Each Pledgor hereby represents, warrants and covenants to the Administrative Agent for the benefit of the Secured Parties, with respect to itself and the Collateral as to which it has or acquires any interest, that:

4

(a)    All of the Pledged Interests are, as of the date of execution of this Pledge Agreement or Joinder Agreement by each Pledgor pledging such Pledged Interests (such date as applicable with respect to each Pledgor, its “Applicable Date”), and shall at all times thereafter be, validly issued and outstanding, fully paid and (in the case of corporate stock) non-assessable.  As of the Applicable Date, Schedule I accurately describes the issued and outstanding Equity Interests of each Subsidiary of each Pledgor and constitute all of the issued and outstanding Equity Interests of each such Subsidiary.
(b)    The Pledgor is, as at its Applicable Date and shall at all times thereafter (subject to Dispositions permitted under the Credit Agreement) be, the sole registered and record and beneficial owner of the Pledged Interests, free and clear of all Liens, charges, equities, options, hypothecations, encumbrances and restrictions on pledge or transfer, including transfer of voting rights (other than Liens permitted under clauses (k), (l) and (q) of Section 7.02 of the Credit Agreement, the pledge hereunder and applicable restrictions pursuant to federal and state and applicable foreign securities laws).  Without limiting the foregoing, the Pledged Interests are not and will not be subject to any voting trust, shareholders agreement, right of first refusal, voting proxy, power of attorney or other similar arrangement (other than the rights hereunder in favor of the Administrative Agent or Liens permitted under clauses (k), (l) and (q) of Section 7.02 of the Credit Agreement).
(c)    At no time shall any Pledged Interests (i) be held or maintained in the form of a security entitlement or credited to any securities account or (ii) which constitute a “security” (or as to which the related Pledged Subsidiary has elected to have treated as a “security”) under Article 8 of the UCC (including, for the purposes of this Section, the Uniform Commercial Code of any other applicable jurisdiction) be maintained in the form of uncertificated securities.  With respect to Pledged Interests that are “securities” under the UCC, or as to which the issuer has elected at any time to have such interests treated as “securities” under the UCC, such Pledged Interests are, and shall at all times be, represented by the share certificates listed on Schedule I hereto, which share certificates, with stock powers duly executed in blank by the Pledgor, have been delivered to the Administrative Agent or are being delivered to the Administrative Agent simultaneously herewith or, in the case of Additional Interests as defined in Section 22, shall be delivered pursuant to Section 22. In addition, with respect to all Pledged Interests, including Pledged Interests that are not “securities” under the UCC and as to which the applicable Pledged Subsidiary has not elected to have such interests treated as “securities” under the UCC, the Pledgor has at its Applicable Date delivered to the Administrative Agent (or has previously delivered to the Administrative Agent or, in case of Additional Interests shall deliver pursuant to Section 22) Uniform Commercial Code financing statements (or appropriate amendments thereto) duly authorized by the Pledgor and naming the Administrative Agent for the benefit of the Secured Parties as “secured party,” in form, substance and number sufficient in the reasonable opinion of the Administrative Agent to be filed in all UCC filing offices and in all jurisdictions in which filing is necessary or advisable to perfect in favor of the Administrative Agent for the benefit of the Secured Parties the Lien on such Pledged Interests, together with all required filing fees.
(d)    The pledge, assignment and delivery of its Pledged Interests (along with undated stock powers executed in blank, financing statements and other agreements referred to in Section 3(c) hereof) to the Administrative Agent for the benefit of the Secured Parties pursuant to this Pledge Agreement (or any Joinder Agreement) creates or continues, as applicable, a valid and perfected first priority security interest in such Pledged Interests in favor of the Administrative Agent for the benefit of the Secured Parties, securing the payment of the Secured Obligations, assuming, in the case of the Pledged Interests which constitute certificated “securities” under the UCC (including, 

5

for the  purposes of this Section, the Uniform Commercial Code of any other applicable jurisdiction), continuous and uninterrupted possession by or on behalf of the Administrative Agent.  The Pledgor will at its own cost and expense defend the Secured Parties’ right, title and security interest in and to the Collateral against the claims and demands of all persons whomsoever.
(e)    It shall cause each of the Pledged Subsidiaries as to which it is the Pledgor not to issue any Equity Interests, or securities convertible into, or exchangeable or exercisable for, Equity Interests, at any time during the term of this Pledge Agreement unless the Pledged Interests of such Pledge Subsidiary are issued solely to either (y) such Pledgor who shall immediately comply with Sections 3 and 22 hereof with respect to such property or (z) the Company or another Pledgor who shall immediately pledge such additional Equity Interests (other than Excluded Property) to the Administrative Agent for the benefit of the Secured Parties pursuant to Section 22 or 24 hereof, as applicable, on substantially identical terms as are contained herein and deliver or cause to be delivered the appropriate documents described in Section 3(c) hereof to the Administrative Agent and take such further actions as the Administrative Agent may reasonably deem necessary in order to perfect a first priority security interest in such Equity Interests (other than Excluded Property).
(f)    The exact legal name and address, type of Person, jurisdiction of formation, jurisdiction of formation identification number (if any), and location of the chief executive office of such Pledgor are as specified on Schedule II attached hereto.  No Pledgor shall change its name, jurisdiction of formation (whether by reincorporation, merger or otherwise), or the location of its chief executive office, except upon giving not less than thirty (30) days’ prior written notice to the Administrative Agent and taking or causing to be taken all such action at such Pledgor’s expense as may be reasonably requested by the Administrative Agent to perfect or maintain the perfection of the Lien of the Administrative Agent in Collateral.
4.    Preservation and Protection of Collateral.
(a)    The Administrative Agent shall be under no duty or liability with respect to the collection, protection or preservation of the Collateral, or otherwise, beyond the use of reasonable care in the custody and preservation thereof while in its possession.
(b)    Upon the failure of any Pledgor to pay or contest taxes, charges, Liens or assessments, relating to any Collateral when required pursuant to the Credit Agreement, the Administrative Agent at its option may (following 10 days written notice to the applicable Pledgor in the event no Event of Default is then occurring, and in the event an Event of Default is then occurring, at any time) pay or contest any of them (the Administrative Agent having the sole right to determine the legality or validity and the amount necessary to discharge such taxes, charges, Liens or assessments) but shall not have any obligation to make any such payment or contest.  All sums so disbursed by the Administrative Agent, including fees and expenses of counsel, court costs, expenses and other charges related thereto, shall be payable on demand by the applicable Pledgor to the Administrative Agent and shall be additional Secured Obligations secured by the Collateral.
(c)    To the extent of any Collateral pledged hereunder, each Pledgor hereby irrevocably authorizes the Administrative Agent to file (with, or to the extent permitted by applicable law, without the signature of the Pledgor appearing thereon) financing statements (including amendments thereto and continuations and copies thereof) showing such Pledgor as “debtor” at such time or times and in all filing offices as the Administrative Agent may from time to time determine to be necessary or 

6

advisable to perfect or protect the rights of the Administrative Agent and the Secured Parties hereunder, or otherwise to give effect to the transactions herein contemplated.
5.    Default.  Upon the occurrence and during the continuance of any Event of Default, the Administrative Agent is given full power and authority, then or at any time thereafter, to sell, assign, deliver or collect the whole or any part of the Collateral, or any substitute therefor or any addition thereto, in one or more sales, with or without any previous demands or demand of performance or, to the extent permitted by law, notice or advertisement, in such order as the Administrative Agent may elect; and any such sale may be made either at public or private sale at the Administrative Agent’s place of business or elsewhere, either for cash or upon credit or for future delivery, at such price or prices as the Administrative Agent may reasonably deem fair; and the Administrative Agent or any other Secured Party may be the purchaser of any or all Collateral so sold and hold the same thereafter in its own right free from any claim of any Pledgor or right of redemption.  Demands of performance, advertisements and presence of property and sale and notice of sale are hereby waived to the extent permissible by law.  Any sale hereunder may be conducted by an auctioneer or any officer or agent of the Administrative Agent.  Each Pledgor recognizes that the Administrative Agent may be unable to effect a public sale of the Collateral by reason of certain prohibitions contained in the Securities Act of 1933, as amended (the “Securities Act”), and applicable state law, and may be otherwise delayed or adversely affected in effecting any sale by reason of present or future restrictions thereon imposed by governmental authorities, and that as a consequence of such prohibitions and restrictions the Administrative Agent may be compelled (i) to resort to one or more private sales to a restricted group of purchasers who will be obliged to agree, among other things, to acquire the Collateral for their own account, for investment and not with a view to the distribution or resale thereof, or (ii) to seek regulatory approval of any proposed sale or sales, or (iii) to limit the amount of Collateral sold to any Person or group.  Each Pledgor agrees and acknowledges that private sales so made may be at prices and upon terms less favorable to such Pledgor than if such Collateral was sold either at public sales or at private sales not subject to other regulatory restrictions, and that the Administrative Agent has no obligation to delay the sale of any of the Collateral for the period of time necessary to permit the Pledged Subsidiary to register or otherwise qualify the Collateral, even if such Pledged Subsidiary would agree to register or otherwise qualify such Collateral for public sale under the Securities Act or applicable state law.  Each Pledgor further agrees, to the extent permitted by applicable law, that the use of private sales made under the foregoing circumstances to dispose of the Collateral shall be deemed to be dispositions in a commercially reasonable manner.  Each Pledgor hereby acknowledges that a ready market may not exist for the Pledged Interests if they are not traded on a national securities exchange or quoted on an automated quotation system and agrees and acknowledges that in such event the Pledged Interests may be sold for an amount less than a pro rata share of the fair market value of the Pledged Subsidiary’s assets minus its liabilities.  In addition to the foregoing, the Secured Parties may exercise such other rights and remedies as may be available under the Loan Documents, at law (including without limitation the UCC) or in equity.
6.    Proceeds of Sale.  The net cash proceeds resulting from the collection, liquidation, sale, or other disposition of the Collateral shall be applied first to the expenses (including all fees and expenses of counsel) of retaking, holding, storing, processing and preparing for sale, selling, collecting, liquidating and the like, and then to the satisfaction of all Secured Obligations in accordance with the terms of Section 8.06 of the Credit Agreement.  Each Pledgor shall be liable to the Administrative Agent, for the benefit of the Secured Parties, and shall pay to the Administrative Agent, for the benefit of the Secured Parties, on demand any deficiency which may remain after such sale, disposition, collection or liquidation of the Collateral.
7.    Presentments, Demands and Notices.  The Administrative Agent shall not be under any duty or obligation whatsoever to make or give any presentments, demands for performances, notices of nonperformance, protests, notice of protest or notice of dishonor in connection with any obligations or 

7

evidences of indebtedness held thereby as collateral, or in connection with any obligations or evidences of indebtedness which constitute in whole or in part the Secured Obligations secured hereunder.
8.    Attorney-in-Fact.  Each Pledgor hereby appoints the Administrative Agent as the Pledgor’s attorney-in-fact for the purposes of carrying out the provisions of this Pledge Agreement and taking any action and executing any instrument which the Administrative Agent may deem necessary or advisable to accomplish the purposes hereof, which appointment is irrevocable and coupled with an interest; provided, that the Administrative Agent shall have and may exercise rights under this power of attorney only upon the occurrence and during the continuance of an Event of Default.  Without limiting the generality of the foregoing, upon the occurrence and during the continuance of a Default or an Event of Default, the Administrative Agent shall have the right and power to receive, endorse and collect all checks and other orders for the payment of money made payable to any Pledgor representing any dividend, interest payment, principal payment or other distribution payable or distributable in respect to the Collateral or any part thereof and to give full discharge for the same.
9.    Reinstatement.  The granting of a security interest in the Collateral and the other provisions hereof shall continue to be effective or be reinstated, as the case may be, if at any time any payment of any of the Secured Obligations is rescinded or must otherwise be returned by any Secured Party or is repaid by any Secured Party in whole or in part in good faith settlement of a pending or threatened avoidance claim, whether upon the insolvency, bankruptcy or reorganization of any Pledgor or any other Loan Party or otherwise, all as though such payment had not been made. The provisions of this Section 9 shall survive repayment of all of the Secured Obligations and the termination or expiration of this Pledge Agreement in any manner, including but not limited to termination upon occurrence of the Facility Termination Date.  
10.    Waiver by the Pledgors.  Each Pledgor waives to the extent permitted by applicable law (a) any right to require any Secured Party or any other obligee of the Secured Obligations to (i) proceed against any Person or entity, including without limitation any Loan Party, (ii) proceed against or exhaust any Collateral or other collateral for the Secured Obligations, or (iii) pursue any other remedy in its power, (b) any defense arising by reason of any disability or other defense of any other Person, or by reason of the cessation from any cause whatsoever of the liability of any other Person or entity, (c) any right of subrogation, (d) any right to enforce any remedy which any Secured Party or any other obligee of the Secured Obligations now has or may hereafter have against any other Person and any benefit of and any right to participate in any collateral or security whatsoever now or hereafter held by the Administrative Agent for the benefit of the Secured Parties.  Each Pledgor authorizes each Secured Party and each other obligee of the Secured Obligations without notice (except notice required by applicable law) or demand and without affecting its liability hereunder or under the Loan Documents from time to time to: (x) take and hold security, other than the Collateral herein described, for the payment of such Secured Obligations or any part thereof, and exchange, enforce, waive and release the Collateral herein described or any part thereof or any such other security; and (y) apply such Collateral or other security and direct the order or manner of sale thereof as such Secured Party or obligee in its discretion may determine.
The Administrative Agent may at any time deliver (without representation, recourse or warranty) the Collateral or any part thereof to a Pledgor and the receipt thereof by such Pledgor shall be a complete and full acquittance for the Collateral so delivered, and the Administrative Agent shall thereafter be discharged from any liability or responsibility therefor.
11.    Dividends and Voting Rights.

8

(a)    All dividends and other distributions with respect to any of the Pledged Interests shall be subject to the pledge hereunder, provided, however, that cash dividends paid to a Pledgor as record owner of the Pledged Interests, to the extent permitted by the Credit Agreement to be declared and paid, may be retained by such Pledgor so long as no Event of Default shall have occurred and be continuing, free from any Liens hereunder.
(b)    So long as no Event of Default shall have occurred and be continuing, the registration of the Collateral in the name of a Pledgor as record and beneficial owner shall not be changed and such Pledgor shall be entitled to exercise all voting and other rights and powers pertaining to the Collateral for all purposes not inconsistent with the terms of the Loan Documents.
(c)    Upon the occurrence and during the continuance of any Event of Default, all rights of the Pledgors to receive and retain cash dividends and other distributions upon the Collateral pursuant to subsection (a) above shall cease and shall thereupon be vested in the Administrative Agent for the benefit of the Secured Parties, and each Pledgor shall promptly deliver, or shall cause to be promptly delivered, all such cash dividends and other distributions with respect to the Pledged Interests to the Administrative Agent (together, if the Administrative Agent shall request, with the documents described in Sections 2(c) and 3(c) hereof or other negotiable documents or instruments so distributed) to be held by it hereunder or, at the option of the Administrative Agent, to be applied to the Secured Obligations.  Pending delivery to the Administrative Agent of such property, each Pledgor shall keep such property segregated from its other property and shall be deemed to hold the same in trust for the benefit of the Secured Parties.
(d)    Upon the occurrence and during the continuance of any Event of Default, at the option of the Administrative Agent, all rights of each of the Pledgors to exercise the voting or consensual rights and powers which it is authorized to exercise pursuant to subsection (b) above shall cease and the Administrative Agent may thereupon (but shall not be obligated to), at its request, cause such Collateral to be registered in the name of the Administrative Agent or its nominee or agent for the benefit of the Secured Parties and/or exercise such voting or consensual rights and powers as appertain to ownership of such Collateral, and to that end each Pledgor hereby appoints the Administrative Agent as its proxy, with full power of substitution, to vote and exercise all other rights as a shareholder with respect to such Pledged Interests hereunder upon the occurrence and during the continuance of any Event of Default, which proxy is coupled with an interest and is irrevocable until the Facility Termination Date, and each Pledgor hereby agrees to provide such further proxies as the Administrative Agent may reasonably request; provided, however, that the Administrative Agent in its discretion may from time to time refrain from exercising, and shall not be obligated to exercise, any such voting or consensual rights or such proxy.
12.    Continued Powers.  Until the Facility Termination Date shall have occurred, the power of sale and other rights, powers and remedies granted to the Administrative Agent for the benefit of the Secured Parties hereunder shall continue to exist and may be exercised by the Administrative Agent at any time and from time to time irrespective of the fact that any of the Secured Obligations or any part thereof may have become barred by any statute of limitations or that any part of the liability of any Pledgor may have ceased.
13.    Other Rights.  The rights, powers and remedies given to the Administrative Agent for the benefit of the Secured Parties by this Pledge Agreement shall be in addition to all rights, powers and remedies given to the Administrative Agent or any Secured Party under any Loan Document or by virtue of any statute or rule of law.  Any forbearance or failure or delay by the Administrative Agent in exercising any right, power or remedy hereunder shall not be deemed to be a waiver of such right, power or remedy, and any single or 

9

partial exercise of any right, power or remedy hereunder shall not preclude the further exercise thereof; and every right, power and remedy of the Secured Parties shall continue in full force and effect until such right, power or remedy is specifically waived in accordance with the terms of the Credit Agreement.
14.    Anti-Marshaling Provisions.  The right is hereby given by each Pledgor to the Administrative Agent, for the benefit of the Secured Parties, to make releases (whether in whole or in part) of all or any part of the Collateral agreeable to the Administrative Agent without notice to, or the consent, approval or agreement of other parties and interests, including junior lienors, which releases shall not impair in any manner the validity of or priority of the Liens and security interests in the remaining Collateral conferred hereunder, nor release any Pledgor from personal liability for the Secured Obligations.  Notwithstanding the existence of any other security interest in the Collateral held by the Administrative Agent, for the benefit of the Secured Parties, the Administrative Agent shall have the right to determine the order in which any or all of the Collateral shall be subjected to the remedies provided in this Pledge Agreement.  Each Pledgor hereby waives any and all right to require the marshaling of assets in connection with the exercise of any of the remedies permitted by applicable law or provided herein or in any Loan Document.
15.    Entire Agreement.  This Pledge Agreement and each Joinder Agreement, together with the Credit Agreement and other Loan Documents, constitutes and expresses the entire understanding between the parties hereto with respect to the subject matter hereof, and supersedes all prior negotiations, agreements and understandings, inducements, commitments or conditions, express or implied, oral or written, except as herein contained.  The express terms hereof and of the Joinder Agreements control and supersede any course of performance or usage of the trade inconsistent with any of the terms hereof and thereof.  Neither this Pledge Agreement nor any Joinder Agreement nor any portion or provision hereof or thereof may be changed, altered, modified, supplemented, discharged, canceled, terminated, or amended orally or in any manner other than as provided in the Credit Agreement.
16.    Further Assurances.  Each Pledgor agrees at its own expense to do such further acts and things, and to execute and deliver, and cause to be executed and delivered as may be necessary or advisable to give effect thereto, such additional conveyances, assignments, financing statements, control agreements, documents, certificates, stock powers, agreements and instruments, as the Administrative Agent may at any time reasonably request in connection with the administration or enforcement of this Pledge Agreement or any Joinder Agreement or related to the Collateral or any part thereof or in order better to assure and confirm unto the Administrative Agent its rights, powers and remedies for the benefit of the Secured Parties hereunder or thereunder.  Each Pledgor hereby consents and agrees that the Pledged Subsidiaries and all other Persons, shall be entitled to accept the provisions hereof and of the Joinder Agreements as conclusive evidence of the right of the Administrative Agent, on behalf of the Secured Parties, to exercise its rights, privileges, and remedies hereunder and thereunder with respect to the Collateral, notwithstanding any other notice or direction to the contrary heretofore or hereafter given by any Pledgor or any other Person to any of such Pledged Subsidiaries or other Persons.
17.    Binding Agreement; Assignment.  This Pledge Agreement and each Joinder Agreement, and the terms, covenants and conditions hereof and thereof, shall be binding upon and inure to the benefit of the parties hereto, and to their respective successors and assigns, except that no Pledgor shall be permitted to assign this Pledge Agreement, any Joinder Agreement or any interest herein or therein except as expressly permitted herein or in the Credit Agreement.  Without limiting the generality of the foregoing sentence of this Section 17, any Lender may assign to one or more Persons, or grant to one or more Persons participations in or to, all or any part of its rights and obligations under the Credit Agreement (to the extent permitted by the Credit Agreement); and to the extent of any such assignment or participation such other Person shall, to the fullest extent permitted by law, thereupon become vested with all the benefits in respect thereof granted 

10

to such Lender herein or otherwise, subject however, to the provisions of the Credit Agreement, including Article IX thereof (concerning the Administrative Agent) and Section 10.06 thereof (concerning assignments and participations).  All references herein to the Administrative Agent and to the Secured Parties shall include any successor thereof or permitted assignee, and any other obligees from time to time of the Secured Obligations.
18.    Secured Cash Management Agreements and Secured Hedging Agreements.  No Secured Party (other than the Administrative Agent) that obtains the benefit of this Pledge Agreement shall have any right to notice of any action or to consent to, direct or object to any action hereunder or otherwise in respect of the Collateral (including the release or impairment of any Collateral) other than in its capacity as a Lender and, in such case, only to the extent expressly provided in the Loan Documents.  Notwithstanding any other provision of this Pledge Agreement to the contrary, the Administrative Agent shall only be required to verify the payment of, or that other satisfactory arrangement have been made with respect to, the Secured Obligations arising under Secured Cash Management Agreements and Secured Hedge Agreements to the extent the Administrative Agent has received written notice of such Obligations, together with such supporting documentation as it may request, from the applicable Cash Management Bank or Hedge Bank, as the case may be.  Each Secured Party not a party to the Credit Agreement that obtains the benefit of this Pledge Agreement shall be deemed to have acknowledged and accepted the appointment of the Administrative Agent pursuant to the terms of the Credit Agreement, and that with respect to the actions and omissions of the Administrative Agent hereunder or otherwise relating hereto that do or may affect such Secured Party, the Administrative Agent and each of its Related Parties shall be entitled to all the rights, benefits and immunities conferred under Article IX of the Credit Agreement.
19.    Severability.  The provisions of this Pledge Agreement are independent of and separable from each other.  If any provision hereof shall for any reason be held invalid or unenforceable, such invalidity or unenforceability shall not affect the validity or enforceability of any other provision hereof, but this Pledge Agreement shall be construed as if such invalid or unenforceable provision had never been contained herein.
20.    Counterparts.  This Pledge Agreement may be executed in any number of counterparts each of which when so executed and delivered shall be deemed an original, and it shall not be necessary in making proof of this Pledge Agreement to produce or account for more than one such counterpart executed by the Pledgor against whom enforcement is sought.  Without limiting the foregoing provisions of this Section 20, the provisions of Section 10.10 of the Credit Agreement shall be applicable to this Pledge Agreement.
21.    Termination.  Subject to the provisions of Section 9, this Pledge Agreement and each Joinder Agreement, and all obligations of the Pledgors hereunder (excluding those obligations and liabilities that expressly survive such termination) shall terminate without delivery of any instrument or performance of any act by any party on the Facility Termination Date.  Upon such termination of this Pledge Agreement, the Administrative Agent shall, at the sole expense of the Pledgors, promptly deliver to the Pledgors the certificates evidencing its shares of Pledged Interests (and any other property received as a dividend or distribution or otherwise in respect of such Pledged Interests to the extent then held by the Administrative Agent as additional Collateral hereunder), together with any cash then constituting the Collateral not then sold or otherwise disposed of in accordance with the provisions hereof, and take such further actions at the request of the Pledgors as may be necessary to effect the same.
22.    Additional Interests.  If any Pledgor shall at any time acquire or hold any additional Pledged Interests, including any Pledged Interests issued by any Subsidiary not listed on Schedule I hereto to the extent such Pledged Interests do not constitute Excluded Property, which are required to be subject to a Lien pursuant to any provision of the Credit Agreement (any such shares being referred to herein as the “Additional 

11

Interests”), such Pledgor shall deliver to the Administrative Agent for the benefit of the Secured Parties (i) a Pledge Agreement Supplement in the form of Exhibit A hereto with respect to such Additional Interests duly completed and executed by such Pledgor and (iii) any other document required in connection with such Additional Interests as described in Section 3(c).  Each Pledgor shall comply with the requirements of this Section 22 concurrently with the acquisition of any such Additional Interests or, in the case of Additional Interests to which Section 6.14 of the Credit Agreement applies, within the time period specified in such Section or elsewhere in the Credit Agreement with respect to such Additional Interests; provided, however, that the failure to comply with the provisions of this Section 22 shall not impair the Lien on Additional Interests conferred hereunder.
23.    Notices.  Any notice required or permitted hereunder shall be given (a) with respect to any Pledgor, at the address of the Company indicated in Schedule 10.02 of the Credit Agreement and (b) with respect to the Administrative Agent or any other Secured Party, at the Administrative Agent’s address indicated in Schedule 10.02 of the Credit Agreement.  All such addresses may be modified, and all such notices shall be given and shall be effective, as provided in Section 10.02 of the Credit Agreement for the giving and effectiveness of notices and modifications of addresses thereunder.
24.    Joinder.  Each Person who shall at any time execute and deliver to the Administrative Agent a Joinder Agreement and who is identified therein as a “Pledgor” shall thereupon irrevocably, absolutely and unconditionally become a party hereto and obligated hereunder as a Pledgor and shall have thereupon pursuant to Section 2 hereof granted a security interest in and collaterally assigned and pledged to the Administrative Agent for the benefit of the Secured Parties all Pledged Interests which it has at its Applicable Date or thereafter acquires any interest or the power to transfer, and all references herein and in the other Loan Documents to the Pledgors or to the parties to this Pledge Agreement shall be deemed to include such Person as a Pledgor hereunder.  Each Joinder Agreement shall be accompanied by the Supplemental Schedules referred to therein, appropriately completed with information relating to the Pledgor executing such Joinder Agreement and its property. Each of the applicable Schedules attached hereto shall be deemed amended and supplemented without further action by such information reflected on the Supplemental Schedules to each such Joinder Agreement.
25.    Rules of Interpretation.  The rules of interpretation contained in Section 1.03 of the Credit Agreement shall be applicable to this Pledge Agreement and each Joinder Agreement and are hereby incorporated by reference.  All representations and warranties contained herein shall survive the delivery of documents and any Credit Extensions referred to herein or secured hereby.
26.    Governing Law; Waivers.
(a)    THIS PLEDGE AGREEMENT AND EACH JOINDER AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS EXECUTED, AND TO BE FULLY PERFORMED, IN SUCH STATE.
(b)    EACH PLEDGOR HEREBY EXPRESSLY AND IRREVOCABLY AGREES AND CONSENTS THAT ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS PLEDGE AGREEMENT OR ANY JOINDER AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREIN OR THEREIN MAY BE INSTITUTED IN ANY STATE OR FEDERAL COURT SITTING IN NEW YORK COUNTY, STATE OF NEW YORK, UNITED STATES OF AMERICA AND, BY THE EXECUTION AND DELIVERY OF THIS PLEDGE AGREEMENT OR A JOINDER AGREEMENT, EXPRESSLY WAIVES 

12

ANY OBJECTION THAT IT MAY HAVE NOW OR HEREAFTER TO THE LAYING OF THE VENUE OR TO THE JURISDICTION OF ANY SUCH SUIT, ACTION OR PROCEEDING, AND IRREVOCABLY SUBMITS GENERALLY AND UNCONDITIONALLY TO THE JURISDICTION OF ANY SUCH COURT IN ANY SUCH SUIT, ACTION OR PROCEEDING.
(c)    EACH PLEDGOR AGREES THAT SERVICE OF PROCESS MAY BE MADE BY PERSONAL SERVICE OF A COPY OF THE SUMMONS AND COMPLAINT OR OTHER LEGAL PROCESS IN ANY SUCH SUIT, ACTION OR PROCEEDING, OR BY REGISTERED OR CERTIFIED MAIL (POSTAGE PREPAID) TO THE ADDRESS OF SUCH PLEDGOR PROVIDED IN SECTION 23 OR BY ANY OTHER METHOD OF SERVICE PROVIDED FOR UNDER THE APPLICABLE LAWS IN EFFECT IN THE STATE OF NEW YORK.
(d)    NOTHING CONTAINED IN SUBSECTIONS (b) OR (c) HEREOF SHALL PRECLUDE THE ADMINISTRATIVE AGENT FROM BRINGING ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS PLEDGE AGREEMENT OR ANY JOINDER AGREEMENT OR THE OTHER LOAN DOCUMENTS IN THE COURTS OF ANY PLACE WHERE ANY PLEDGOR OR ANY OF SUCH PLEDGOR’S PROPERTY OR ASSETS MAY BE FOUND OR LOCATED.  TO THE EXTENT PERMITTED BY THE APPLICABLE LAWS OF ANY SUCH JURISDICTION, EACH PLEDGOR HEREBY IRREVOCABLY SUBMITS TO THE JURISDICTION OF ANY SUCH COURT AND EXPRESSLY WAIVES, IN RESPECT OF ANY SUCH SUIT, ACTION OR PROCEEDING, OBJECTION TO THE EXERCISE OF JURISDICTION OVER IT AND ITS PROPERTY BY ANY SUCH OTHER COURT OR COURTS WHICH NOW OR HEREAFTER, BY REASON OF ITS PRESENT OR FUTURE DOMICILE, OR OTHERWISE, MAY BE AVAILABLE UNDER APPLICABLE LAW.
(e)    IN ANY ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY RIGHTS OR REMEDIES UNDER OR RELATED TO THIS PLEDGE AGREEMENT OR ANY JOINDER AGREEMENT OR ANY AMENDMENT, INSTRUMENT, DOCUMENT OR AGREEMENT DELIVERED OR THAT MAY IN THE FUTURE BE DELIVERED IN CONNECTION WITH THE FOREGOING, EACH PARTY HEREBY AGREES, TO THE EXTENT PERMITTED BY APPLICABLE LAW, THAT ANY SUCH ACTION, SUIT OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY AND HEREBY WAIVES, TO THE EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT SUCH PERSON MAY HAVE TO TRIAL BY JURY IN ANY SUCH ACTION, SUIT OR PROCEEDING.
(f)    EACH PLEDGOR HEREBY EXPRESSLY WAIVES ANY OBJECTION IT MAY HAVE THAT ANY COURT TO WHOSE JURISDICTION IT HAS SUBMITTED PURSUANT TO THE TERMS HEREOF IS AN INCONVENIENT FORUM.

13

27.    Amendment and Restatement. Notwithstanding this amendment and restatement of the Existing Pledge Agreement, (i) all of the indebtedness, liabilities and obligations owing by the Pledgors or any other Person under the Existing Pledge Agreement shall continue as obligations hereunder, as amended hereby, and shall be and remain secured by this Pledge Agreement, (ii) the Existing Pledge shall continue as a security interest hereunder, as amended hereby, and (iii) this Pledge Agreement is given as a substitution of, and not as a payment of the indebtedness, liabilities and obligations of the Pledgors under, the Existing Pledge Agreement and neither the execution and delivery of this Pledge Agreement nor the consummation of any other transaction contemplated hereunder is intended to constitute a novation of the Existing Pledge Agreement or the Existing Pledge created thereunder.

[Signature Pages Follow]

14

IN WITNESS WHEREOF, the parties have duly executed this Pledge Agreement on the day and year first written above.
PLEDGORS:
ASBURY AUTOMOTIVE GROUP, INC.
By:    /s/ Matthew Pettoni                
Typed Name:    Matthew Pettoni            
Typed Title:    Vice President and Treasurer        

    
AF MOTORS, L.L.C.
ANL, L.P.
ARKANSAS AUTOMOTIVE SERVICES, L.L.C.
ASBURY AR NISS L.L.C.
ASBURY ATLANTA AC L.L.C.
ASBURY ATLANTA AU L.L.C.
ASBURY ATLANTA BM L.L.C.
ASBURY ATLANTA CHEV, LLC
ASBURY ATLANTA CHEVROLET L.L.C.
ASBURY ATLANTA FORD, LLC
ASBURY ATLANTA HON L.L.C.
ASBURY ATLANTA HUND L.L.C.
ASBURY ATLANTA INF L.L.C.
ASBURY ATLANTA INFINITI L.L.C.
ASBURY ATLANTA JAGUAR L.L.C.
ASBURY ATLANTA K L.L.C.
ASBURY ATLANTA LEX L.L.C.
ASBURY ATLANTA NIS II, LLC
ASBURY ATLANTA NIS L.L.C.
ASBURY ATLANTA TOY 2 L.L.C.
ASBURY ATLANTA TOY L.L.C.
ASBURY ATLANTA VB L.L.C.
ASBURY ATLANTA VL L.L.C.
ASBURY AUTOMOTIVE ARKANSAS DEALERSHIP HOLDINGS L.L.C.
ASBURY AUTOMOTIVE ARKANSAS L.L.C.
ASBURY AUTOMOTIVE ATLANTA II L.L.C.
ASBURY AUTOMOTIVE ATLANTA L.L.C.
ASBURY AUTOMOTIVE BRANDON, L.P.
ASBURY AUTOMOTIVE CENTRAL FLORIDA, L.L.C.
By:    /s/ Matthew Pettoni                
Typed Name:    Matthew Pettoni            
Typed Title:    Treasurer                

Asbury Automotive Group, Inc.
THIRD AMENDED AND RESTATED SECURITIES PLEDGE AGREEMENT
Signature Page

PLEDGORS, continued:

ASBURY AUTOMOTIVE DELAND, L.L.C.
ASBURY AUTOMOTIVE FRESNO L.L.C.
ASBURY AUTOMOTIVE GROUP L.L.C.
ASBURY AUTOMOTIVE JACKSONVILLE GP L.L.C.
ASBURY AUTOMOTIVE JACKSONVILLE, L.P.
ASBURY AUTOMOTIVE MANAGEMENT L.L.C.
ASBURY AUTOMOTIVE MISSISSIPPI L.L.C.
ASBURY AUTOMOTIVE NORTH CAROLINA DEALERSHIP HOLDINGS L.L.C. 
ASBURY AUTOMOTIVE NORTH CAROLINA L.L.C.
ASBURY AUTOMOTIVE NORTH CAROLINA MANAGEMENT L.L.C.
ASBURY AUTOMOTIVE NORTH CAROLINA REAL ESTATE HOLDINGS L.L.C.
ASBURY AUTOMOTIVE OREGON L.L.C.
ASBURY AUTOMOTIVE SOUTHERN CALIFORNIA L.L.C.
ASBURY AUTOMOTIVE ST. LOUIS II L.L.C.
ASBURY AUTOMOTIVE ST. LOUIS, L.L.C.
ASBURY AUTOMOTIVE TAMPA GP L.L.C.
ASBURY AUTOMOTIVE TAMPA, L.P.
ASBURY AUTOMOTIVE TEXAS L.L.C.
ASBURY AUTOMOTIVE TEXAS REAL ESTATE HOLDINGS L.L.C.
ASBURY AUTOMOTIVE WEST, LLC
ASBURY CH MOTORS L.L.C.
ASBURY CO SUB, LLC
ASBURY DELAND HUND, LLC
ASBURY DELAND IMPORTS 2, L.L.C.
ASBURY FRESNO IMPORTS L.L.C.
ASBURY FT. WORTH FORD, LLC
ASBURY GEORGIA TOY, LLC
ASBURY IN CBG, LLC
ASBURY IN CDJ, LLC
ASBURY IN CHEV, LLC
ASBURY IN FORD, LLC
ASBURY IN HON, LLC
ASBURY IN TOY, LLC
ASBURY INDY CHEV, LLC
ASBURY JAX AC, LLC
ASBURY JAX FORD, LLC
By:    /s/ Matthew Pettoni                
Typed Name:    Matthew Pettoni            
Typed Title:    Treasurer                

Asbury Automotive Group, Inc.
THIRD AMENDED AND RESTATED SECURITIES PLEDGE AGREEMENT
Signature Page

PLEDGORS, continued:

ASBURY JAX HOLDINGS, L.P.
ASBURY JAX HON L.L.C.
ASBURY JAX K L.L.C.
ASBURY JAX MANAGEMENT L.L.C.
ASBURY JAX VW L.L.C.
ASBURY MS CHEV L.L.C.
ASBURY MS GRAY-DANIELS L.L.C.
ASBURY NO CAL NISS L.L.C.
ASBURY SACRAMENTO IMPORTS L.L.C.
ASBURY SC JPV L.L.C.
ASBURY SC LEX L.L.C.
ASBURY SC TOY L.L.C.
ASBURY SO CAL DC L.L.C.
ASBURY SO CAL HON L.L.C.
ASBURY SO CAL NISS L.L.C.
ASBURY SOUTH CAROLINA REAL ESTATE HOLDINGS L.L.C.
ASBURY ST. LOUIS CADILLAC L.L.C.
ASBURY ST. LOUIS FSKR, L.L.C.
ASBURY ST. LOUIS LEX L.L.C.
ASBURY ST. LOUIS LR L.L.C.
ASBURY ST. LOUIS M L.L.C.
ASBURY TAMPA MANAGEMENT L.L.C.
ASBURY TEXAS D FSKR, L.L.C.
ASBURY TEXAS H FSKR, L.L.C.
ASBURY-DELAND IMPORTS, L.L.C.
ATLANTA REAL ESTATE HOLDINGS L.L.C.
AVENUES MOTORS, LTD.
BAYWAY FINANCIAL SERVICES, L.P.
BFP MOTORS L.L.C.
C & O PROPERTIES, LTD.
CAMCO FINANCE II L.L.C.
CFP MOTORS L.L.C.
CH MOTORS L.L.C.
CHO PARTNERSHIP, LTD.
CK CHEVROLET L.L.C.
CK MOTORS LLC
CN MOTORS L.L.C.
COGGIN AUTOMOTIVE CORP.
COGGIN CARS L.L.C.
COGGIN CHEVROLET L.L.C.
COGGIN MANAGEMENT, L.P.
By:    /s/ Matthew Pettoni                
Typed Name:    Matthew Pettoni            
Typed Title:    Treasurer                

Asbury Automotive Group, Inc.
THIRD AMENDED AND RESTATED SECURITIES PLEDGE AGREEMENT
Signature Page

PLEDGORS, continued:

CP-GMC MOTORS L.L.C.
CROWN ACURA/NISSAN, LLC
CROWN CHH L.L.C.
CROWN CHO L.L.C.
CROWN CHV L.L.C.
CROWN FDO L.L.C.
CROWN FFO HOLDINGS L.L.C.
CROWN FFO L.L.C.
CROWN GAC L.L.C.
CROWN GBM L.L.C.
CROWN GCA L.L.C.
CROWN GDO L.L.C.
CROWN GHO L.L.C.
CROWN GNI L.L.C.
CROWN GPG L.L.C.
CROWN GVO L.L.C.
CROWN HONDA, LLC
CROWN MOTORCAR COMPANY L.L.C.
CROWN PBM L.L.C.
CROWN RIA L.L.C.
CROWN RIB L.L.C.
CROWN SJC L.L.C.
CROWN SNI L.L.C.
CSA IMPORTS L.L.C.
ESCUDE-NN L.L.C.
ESCUDE-NS L.L.C.
ESCUDE-T L.L.C.
FLORIDA AUTOMOTIVE SERVICES L.L.C.
HFP MOTORS L.L.C.
JC DEALER SYSTEMS, LLC
KP MOTORS L.L.C.
MCDAVID AUSTIN-ACRA, L.L.C.
MCDAVID FRISCO-HON, L.L.C.
MCDAVID GRANDE, L.L.C.
MCDAVID HOUSTON-HON, L.L.C.
MCDAVID HOUSTON-NISS, L.L.C.
MCDAVID IRVING-HON, L.L.C.
MCDAVID OUTFITTERS, L.L.C.
MCDAVID PLANO-ACRA, L.L.C.
MID-ATLANTIC AUTOMOTIVE SERVICES, L.L.C.
MISSISSIPPI AUTOMOTIVE SERVICES, L.L.C.
MISSOURI AUTOMOTIVE SERVICES, L.L.C.
By:    /s/ Matthew Pettoni                
Typed Name:    Matthew Pettoni            
Typed Title:    Treasurer                

Asbury Automotive Group, Inc.
THIRD AMENDED AND RESTATED SECURITIES PLEDGE AGREEMENT
Signature Page

PLEDGORS, continued:

NP FLM L.L.C.
NP MZD L.L.C.
NP VKW L.L.C.
PLANO LINCOLN-MERCURY, INC.
PRECISION COMPUTER SERVICES, INC.
PRECISION ENTERPRISES TAMPA, INC.
PRECISION INFINITI, INC.
PRECISION MOTORCARS, INC.
PRECISION NISSAN, INC.
PREMIER NSN L.L.C.
PREMIER PON L.L.C.
PRESTIGE BAY L.L.C.
PRESTIGE TOY L.L.C.
Q AUTOMOTIVE BRANDON  FL, LLC
Q AUTOMOTIVE CUMMING GA, LLC
Q AUTOMOTIVE FT. MYERS FL, LLC
Q AUTOMOTIVE GROUP L.L.C.
Q AUTOMOTIVE HOLIDAY FL, LLC
Q AUTOMOTIVE JACKSONVILLE FL, LLC
Q AUTOMOTIVE KENNESAW GA, LLC
Q AUTOMOTIVE ORLANDO FL, LLC
Q AUTOMOTIVE TAMPA FL, LLC
SOUTHERN ATLANTIC AUTOMOTIVE SERVICES, L.L.C.
TAMPA HUND, L.P.
TAMPA KIA, L.P.
TAMPA LM, L.P.
TAMPA MIT, L.P.
TEXAS AUTOMOTIVE SERVICES, L.L.C.
THOMASON AUTO CREDIT NORTHWEST, INC.
THOMASON DAM L.L.C.
THOMASON FRD L.L.C.
THOMASON HUND L.L.C.
THOMASON PONTIAC-GMC L.L.C.
WMZ MOTORS, L.P.
WTY MOTORS, L.P.
By:    /s/ Matthew Pettoni                
Typed Name:    Matthew Pettoni            
Typed Title:    Treasurer                

Asbury Automotive Group, Inc.
THIRD AMENDED AND RESTATED SECURITIES PLEDGE AGREEMENT
Signature Page

ADMINISTRATIVE AGENT:

BANK OF AMERICA, N.A., 
as Administrative Agent
By:    /s/ Linda K. Lov                
Typed Name:    Linda K. Lov                
Typed Title:    Assistant Vice President            

Asbury Automotive Group, Inc.
THIRD AMENDED AND RESTATED SECURITIES PLEDGE AGREEMENT
Signature Page

SCHEDULE I
	
							
	Grantor
	Subsidiary
	Jurisdiction 
of
Formation
	Class 
or Type
of
Shares
	Total
Amount of
Class or
Type
Outstanding
(if
applicable)
	Total
Amount
Pledged
	Certificate Number (if applicable)

	Asbury Automotive Deland, L.L.C.
	AF Motors, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Jax Management L.L.C.
	ANL, L.P.
	Delaware
	N/A
	N/A
	1%
	Uncertificated

	Asbury Jax Holdings, L.P.
	ANL, L.P.
	Delaware
	N/A
	N/A
	99%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Arkansas Automotive Services, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Arkansas Dealership Holdings L.L.C.
	Asbury AR Niss L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta L.L.C.
	Asbury Atlanta AC L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta L.L.C.
	Asbury Atlanta AU L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta L.L.C.
	Asbury Atlanta BM L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta II L.L.C.
	Asbury Atlanta CHEV, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta L.L.C.
	Asbury Atlanta Chevrolet L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta II L.L.C.
	Asbury Atlanta Ford, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta L.L.C.
	Asbury Atlanta Hon L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta II L.L.C.
	Asbury Atlanta Hund L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta L.L.C.
	Asbury Atlanta Inf L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta L.L.C.
	Asbury Atlanta Infiniti L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta L.L.C.
	Asbury Atlanta Jaguar L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta II L.L.C.
	Asbury Atlanta K L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta II L.L.C.
	Asbury Atlanta Lex L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta L.L.C.
	Asbury Atlanta Nis II, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta L.L.C.
	Asbury Atlanta Nis L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta II L.L.C.
	Asbury Atlanta Toy 2 L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta II L.L.C.
	Asbury Atlanta Toy L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta L.L.C.
	Asbury Atlanta VB L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta L.L.C.
	Asbury Atlanta VL L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

Schedule I - 1

	
							
	Grantor
	Subsidiary
	Jurisdiction 
of
Formation
	Class 
or Type
of
Shares
	Total
Amount of
Class or
Type
Outstanding
(if
applicable)
	Total
Amount
Pledged
	Certificate Number (if applicable)

	Asbury Automotive Arkansas L.L.C.
	Asbury Automotive Arkansas Dealership Holdings L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive Arkansas L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive Atlanta II L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive Atlanta L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Tampa Management L.L.C.
	Asbury Automotive Brandon, L.P.
	Delaware
	N/A
	N/A
	1%
	Uncertificated

	Asbury Automotive Tampa, L.P.
	Asbury Automotive Brandon, L.P.
	Delaware
	N/A
	N/A
	99%
	Uncertificated

	Asbury Automotive Jacksonville, L.P.
	Asbury Automotive Central Florida, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Jacksonville, L.P.
	Asbury Automotive Deland, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive Fresno L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group, Inc.
	Asbury Automotive Group L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive Jacksonville GP L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Jacksonville GP L.L.C.
	Asbury Automotive Jacksonville, L.P.
	Delaware
	N/A
	N/A
	1%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive Jacksonville, L.P.
	Delaware
	N/A
	N/A
	99%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive Management L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive Mississippi L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina L.L.C.
	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive North Carolina L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Asbury Automotive North Carolina Management L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive North Carolina Real Estate Holdings L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive Oregon L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

Schedule I - 2

	
							
	Grantor
	Subsidiary
	Jurisdiction 
of
Formation
	Class 
or Type
of
Shares
	Total
Amount of
Class or
Type
Outstanding
(if
applicable)
	Total
Amount
Pledged
	Certificate Number (if applicable)

	Asbury Automotive Group L.L.C.
	Asbury Automotive Southern California L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive St. Louis II L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive St. Louis, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive Tampa GP L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Tampa GP L.L.C.
	Asbury Automotive Tampa, L.P.
	Delaware
	N/A
	N/A
	1%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive Tampa, L.P.
	Delaware
	N/A
	N/A
	99%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive Texas L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Texas L.L.C.
	Asbury Automotive Texas Real Estate Holdings L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Asbury Automotive West, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Coggin Automotive Corp.
	Asbury CH Motors L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive West, LLC
	Asbury CO SUB, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Deland, L.L.C.
	Asbury Deland Hund, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Jacksonville, L.P.
	Asbury Deland Imports 2, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Fresno L.L.C.
	Asbury Fresno Imports L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Texas L.L.C.
	Asbury Ft. Worth Ford, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta II L.L.C.
	Asbury Georgia TOY, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive St. Louis, L.L.C.
	Asbury IN CBG, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive St. Louis, L.L.C.
	Asbury IN CDJ, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive St. Louis, L.L.C.
	Asbury IN Chev, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive St. Louis, L.L.C.
	Asbury Indy Chev, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive St. Louis, L.L.C.
	Asbury IN Ford, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive St. Louis, L.L.C.
	Asbury IN HON, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive St. Louis, L.L.C.
	Asbury IN TOY, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Jacksonville, L.P.
	Asbury Jax AC, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Jacksonville, L.P.
	Asbury Jax Ford, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

Schedule I - 3

	
							
	Grantor
	Subsidiary
	Jurisdiction 
of
Formation
	Class 
or Type
of
Shares
	Total
Amount of
Class or
Type
Outstanding
(if
applicable)
	Total
Amount
Pledged
	Certificate Number (if applicable)

	Asbury Jax Management L.L.C.
	Asbury Jax Holdings, L.P.
	Delaware
	N/A
	N/A
	1%
	Uncertificated

	Asbury Automotive Jacksonville, L.P.
	Asbury Jax Holdings, L.P.
	Delaware
	N/A
	N/A
	99%
	Uncertificated

	Asbury Automotive Jacksonville, L.P.
	Asbury Jax Hon L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Jacksonville, L.P.
	Asbury Jax K L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Jacksonville, L.P.
	Asbury Jax Management L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Jacksonville, L.P.
	Asbury Jax VW L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Mississippi L.L.C.
	Asbury MS CHEV L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Mississippi L.L.C.
	Asbury MS Gray-Daniels L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Fresno L.L.C.
	Asbury No Cal Niss L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Fresno L.L.C.
	Asbury Sacramento Imports L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta II L.L.C.
	Asbury SC JPV L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta II L.L.C.
	Asbury SC LEX L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta II L.L.C.
	Asbury SC Toy L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Southern California L.L.C.
	Asbury So Cal DC L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Southern California L.L.C.
	Asbury So Cal Hon L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Southern California L.L.C.
	Asbury So Cal Niss L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Atlanta L.L.C.
	Asbury South Carolina Real Estate Holdings L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive St. Louis, L.L.C.
	Asbury St. Louis Cadillac L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive St. Louis, L.L.C.
	Asbury St. Louis FSKR, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive St. Louis II L.L.C.
	Asbury St. Louis Lex L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive St. Louis, L.L.C.
	Asbury St. Louis LR L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive St. Louis, L.L.C.
	Asbury St. Louis M L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Tampa, L.P.
	Asbury Tampa Management L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Texas L.L.C.
	Asbury Texas D FSKR, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

Schedule I - 4

	
							
	Grantor
	Subsidiary
	Jurisdiction 
of
Formation
	Class 
or Type
of
Shares
	Total
Amount of
Class or
Type
Outstanding
(if
applicable)
	Total
Amount
Pledged
	Certificate Number (if applicable)

	Asbury Automotive Texas L.L.C.
	Asbury Texas H FSKR, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Deland Imports 2, L.L.C.
	Asbury-Deland Imports, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Atlanta Real Estate Holdings L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Jax Management L.L.C.
	Avenues Motors, Ltd.
	Florida
	N/A
	N/A
	1%
	Uncertificated

	Asbury Jax Holdings, L.P.
	Avenues Motors, Ltd.
	Florida
	N/A
	N/A
	99%
	Uncertificated

	Asbury Jax Management L.L.C.
	Bayway Financial Services, L.P.
	Delaware
	N/A
	N/A
	1%
	Uncertificated

	Asbury Jax Holdings, L.P.
	Bayway Financial Services, L.P.
	Delaware
	N/A
	N/A
	99%
	Uncertificated

	Coggin Automotive Corp.
	BFP Motors L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Jax Management L.L.C.
	C & O Properties, Ltd.
	Florida
	N/A
	N/A
	1%
	Uncertificated

	Asbury Jax Holdings, L.P.
	C & O Properties, Ltd.
	Florida
	N/A
	N/A
	99%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Camco Finance II L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Coggin Automotive Corp.
	CFP Motors L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Coggin Automotive Corp.
	CH Motors L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Jax Management L.L.C.
	CHO Partnership, LTD.
	Florida
	N/A
	N/A
	1%
	Uncertificated

	Asbury Jax Holdings, L.P.
	CHO Partnership, LTD.
	Florida
	N/A
	N/A
	99%
	Uncertificated

	Asbury Automotive Central Florida, L.L.C.
	CK Chevrolet L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Central Florida, L.L.C.
	CK Motors LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Coggin Automotive Corp.
	CN Motors L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Precision Enterprises Tampa, Inc.
	Coggin Automotive Corp.
	Florida
	Common Stock
	75,750
	100%
	19

	Asbury Automotive Jacksonville, L.P.
	Coggin Cars L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Jacksonville, L.P.
	Coggin Chevrolet L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Jax Management L.L.C.
	Coggin Management, L.P.
	Delaware
	N/A
	N/A
	1%
	Uncertificated

	Asbury Jax Holdings, L.P.
	Coggin Management, L.P.
	Delaware
	N/A
	N/A
	99%
	Uncertificated

	Coggin Automotive Corp.
	CP-GMC Motors L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

Schedule I - 5

	
							
	Grantor
	Subsidiary
	Jurisdiction 
of
Formation
	Class 
or Type
of
Shares
	Total
Amount of
Class or
Type
Outstanding
(if
applicable)
	Total
Amount
Pledged
	Certificate Number (if applicable)

	Asbury Automotive North Carolina Real Estate Holdings L.L.C.
	Crown Acura/Nissan, LLC
	North 
Carolina
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown CHH L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown CHO L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown CHV L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown FDO L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown FFO Holdings L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Crown FFO Holdings L.L.C.
	Crown FFO L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown GAC L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown GBM L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown GCA L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown GDO L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown GHO L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown GNI L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown GPG L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown GVO L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

Schedule I - 6

	
							
	Grantor
	Subsidiary
	Jurisdiction 
of
Formation
	Class 
or Type
of
Shares
	Total
Amount of
Class or
Type
Outstanding
(if
applicable)
	Total
Amount
Pledged
	Certificate Number (if applicable)

	Asbury Automotive North Carolina Real Estate Holdings L.L.C.
	Crown Honda, LLC
	North  Carolina
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown Motorcar Company L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown PBM L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown RIA L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown RIB L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown SJC L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Crown SNI L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Jacksonville, L.P.
	CSA Imports L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Mississippi L.L.C.
	Escude-NN L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Mississippi L.L.C.
	Escude-NS L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Mississippi L.L.C.
	Escude-T L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Florida Automotive Services L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Coggin Automotive Corp.
	HFP Motors L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Tampa, L.P.
	JC Dealer Systems, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Jacksonville, L.P.
	KP Motors L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Texas L.L.C.
	McDavid Austin-Acra L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Texas L.L.C.
	McDavid Frisco-Hon L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Texas L.L.C.
	McDavid Grande L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Texas L.L.C.
	McDavid Houston-Hon, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Texas L.L.C.
	McDavid Houston-Niss, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Texas L.L.C.
	McDavid Irving-Hon, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Texas L.L.C.
	McDavid Outfitters, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

Schedule I - 7

	
							
	Grantor
	Subsidiary
	Jurisdiction 
of
Formation
	Class 
or Type
of
Shares
	Total
Amount of
Class or
Type
Outstanding
(if
applicable)
	Total
Amount
Pledged
	Certificate Number (if applicable)

	Asbury Automotive Texas L.L.C.
	McDavid Plano-Acra, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Mid-Atlantic Automotive Services, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Mississippi Automotive Services, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Missouri Automotive Services, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Arkansas Dealership Holdings L.L.C.
	NP FLM L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Arkansas Dealership Holdings L.L.C.
	NP MZD L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Arkansas Dealership Holdings L.L.C.
	NP VKW L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Precision Enterprises Tampa, Inc.
	Plano Lincoln-Mercury, Inc.
	Delaware
	Common Stock
	5,581
	100%
	11

	Precision Enterprises Tampa, Inc.
	Precision Computer Services, Inc.
	Florida
	Common Stock
	100
	100%
	5

	Asbury Automotive Group, Inc.
	Precision Enterprises Tampa, Inc.
	Florida
	Common Stock
	8,926
	100%
	10

	Precision Enterprises Tampa, Inc.
	Precision Infiniti, Inc.
	Florida
	Common Stock
	10,000
	100%
	4

	Precision Enterprises Tampa, Inc.
	Precision Motorcars, Inc.
	Florida
	Common Stock
	460,000
	100%
	8

	Precision Enterprises Tampa, Inc.
	Precision Nissan, Inc.
	Florida
	Common Stock
	100
	100%
	4

	Asbury Automotive Arkansas Dealership Holdings L.L.C.
	Premier NSN L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Arkansas Dealership Holdings L.L.C.
	Premier Pon L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Arkansas Dealership Holdings L.L.C.
	Prestige Bay L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

Schedule I - 8

	
							
	Grantor
	Subsidiary
	Jurisdiction 
of
Formation
	Class 
or Type
of
Shares
	Total
Amount of
Class or
Type
Outstanding
(if
applicable)
	Total
Amount
Pledged
	Certificate Number (if applicable)

	Asbury Automotive Arkansas Dealership Holdings L.L.C.
	Prestige TOY L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Q Automotive Group L.L.C.
	Q Automotive Brandon FL, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Q Automotive Group L.L.C.
	Q Automotive Cumming GA, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Q Automotive Group L.L.C.
	Q Automotive Ft. Myers FL, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Q Automotive Group L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Q Automotive Group L.L.C.
	Q Automotive Holiday FL, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Q Automotive Group L.L.C.
	Q Automotive Jacksonville FL, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Q Automotive Group L.L.C.
	Q Automotive Kennesaw GA, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Q Automotive Group L.L.C.
	Q Automotive Orlando FL, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Q Automotive Group L.L.C.
	Q Automotive Tampa FL, LLC
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Southern Atlantic Automotive Services, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Tampa Management L.L.C.
	Tampa Hund, L.P.
	Delaware
	N/A
	N/A
	1%
	Uncertificated

	Asbury Automotive Tampa, L.P.
	Tampa Hund, L.P.
	Delaware
	N/A
	N/A
	99%
	Uncertificated

	Asbury Tampa Management L.L.C.
	Tampa Kia, L.P.
	Delaware
	N/A
	N/A
	1%
	Uncertificated

	Asbury Automotive Tampa, L.P.
	Tampa Kia, L.P.
	Delaware
	N/A
	N/A
	99%
	Uncertificated

	Asbury Tampa Management L.L.C.
	Tampa LM, L.P.
	Delaware
	N/A
	N/A
	1%
	Uncertificated

	Asbury Automotive Tampa, L.P.
	Tampa LM, L.P.
	Delaware
	N/A
	N/A
	99%
	Uncertificated

	Asbury Tampa Management L.L.C.
	Tampa Mit, L.P.
	Delaware
	N/A
	N/A
	1%
	Uncertificated

	Asbury Automotive Tampa, L.P.
	Tampa Mit, L.P.
	Delaware
	N/A
	N/A
	99%
	Uncertificated

	Asbury Automotive Group L.L.C.
	Texas Automotive Services, L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Precision Enterprises Tampa, Inc.
	Thomason Auto Credit Northwest, Inc.
	Oregon
	Common Stock
	1,053
	100%
	101R

	Asbury Automotive Oregon L.L.C.
	Thomason Dam L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Oregon L.L.C.
	Thomason FRD L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Oregon L.L.C.
	Thomason Hund L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

	Asbury Automotive Oregon L.L.C.
	Thomason Pontiac-GMC L.L.C.
	Delaware
	N/A
	N/A
	100%
	Uncertificated

Schedule I - 9

	
							
	Grantor
	Subsidiary
	Jurisdiction 
of
Formation
	Class 
or Type
of
Shares
	Total
Amount of
Class or
Type
Outstanding
(if
applicable)
	Total
Amount
Pledged
	Certificate Number (if applicable)

	Asbury Tampa Management L.L.C.
	WMZ Motors, L.P.
	Delaware
	N/A
	N/A
	1%
	Uncertificated

	Asbury Automotive Tampa, L.P.
	WMZ Motors, L.P.
	Delaware
	N/A
	N/A
	99%
	Uncertificated

	Asbury Tampa Management L.L.C.
	WTY Motors, L.P.
	Delaware
	N/A
	N/A
	1%
	Uncertificated

	Asbury Automotive Tampa, L.P.
	WTY Motors, L.P.
	Delaware
	N/A
	N/A
	99%
	Uncertificated

. 

Schedule I - 10

SCHEDULE II
	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	Asbury Automotive Group, Inc.
	Corporation
	Delaware
	3493496
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	AF Motors, L.L.C.
	Limited Liability 
Company
	Delaware
	3110583
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	ANL, L.P.
	Limited Partnership
	Delaware
	2880404
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Arkansas Automotive Services, L.L.C.
	Limited Liability 
Company
	Delaware
	4751782
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury AR Niss L.L.C.
	Limited Liability 
Company
	Delaware
	3901962
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta AC L.L.C.
	Limited Liability 
Company
	Delaware
	2686370
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta AU L.L.C.
	Limited Liability 
Company
	Delaware
	3378171
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta BM L.L.C.
	Limited Liability 
Company
	Delaware
	3665863
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta CHEV, LLC
	Limited Liability Company
	Delaware
	6739392
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta Chevrolet L.L.C.
	Limited Liability 
Company
	Delaware
	2680108
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta Ford, LLC
	Limited Liability 
Company
	Delaware
	5322047
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 1

	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	Asbury Atlanta Hon L.L.C.
	Limited Liability 
Company
	Delaware
	2686368
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta Hund L.L.C.
	Limited Liability 
Company
	Delaware
	5323963
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta Inf L.L.C.
	Limited Liability 
Company
	Delaware
	4332455
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta Infiniti L.L.C.
	Limited Liability 
Company
	Delaware
	3378170
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta Jaguar L.L.C.
	Limited Liability 
Company
	Delaware
	3231632
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta K L.L.C.
	Limited Liability 
Company
	Delaware
	5324209
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta Lex L.L.C.
	Limited Liability 
Company
	Delaware
	2686367
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta Nis II, LLC
	Limited Liability 
Company
	Delaware
	5764929
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta Nis L.L.C.
	Limited Liability 
Company
	Delaware
	4332456
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta Toy 2 L.L.C.
	Limited Liability 
Company
	Delaware
	5323831
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta Toy L.L.C.
	Limited Liability 
Company
	Delaware
	4456930
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 2

	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	Asbury Atlanta VB L.L.C.
	Limited Liability 
Company
	Delaware
	5212809
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Atlanta VL L.L.C.
	Limited Liability 
Company
	Delaware
	3665862
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Arkansas Dealership Holdings L.L.C.
	Limited Liability 
Company
	Delaware
	2954929
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Arkansas L.L.C.
	Limited Liability 
Company
	Delaware
	2923557
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Atlanta II L.L.C.
	Limited Liability 
Company
	Delaware
	4499752
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Atlanta L.L.C.
	Limited Liability 
Company
	Delaware
	2632708
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Brandon, L.P.
	Limited Partnership
	Delaware
	3043466
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Central Florida, L.L.C.
	Limited Liability 
Company
	Delaware
	3025476
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Deland, L.L.C.
	Limited Liability 
Company
	Delaware
	3110578
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Fresno L.L.C.
	Limited Liability 
Company
	Delaware
	3630396
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Group L.L.C.
	Limited Liability 
Company
	Delaware
	2896956
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 3

	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	Asbury Automotive Jacksonville GP L.L.C.
	Limited Liability 
Company
	Delaware
	2824699
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Jacksonville, L.P.
	Limited Partnership
	Delaware
	2824925
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Management L.L.C.
	Limited Liability 
Company
	Delaware
	2459461
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Mississippi L.L.C.
	Limited Liability 
Company
	Delaware
	3413187
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive North Carolina Dealership Holdings L.L.C.
	Limited Liability 
Company
	Delaware
	2902156
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive North Carolina L.L.C.
	Limited Liability 
Company
	Delaware
	2898669
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive North Carolina Management L.L.C.
	Limited Liability 
Company
	Delaware
	2912342
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive North Carolina Real Estate Holdings L.L.C.
	Limited Liability 
Company
	Delaware
	2899084
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Oregon L.L.C.
	Limited Liability 
Company
	Delaware
	2902157
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Southern California L.L.C.
	Limited Liability 
Company
	Delaware
	3683008
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive St. Louis II L.L.C.
	Limited Liability 
Company
	Delaware
	4556493
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 4

	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	Asbury Automotive St. Louis, L.L.C.
	Limited Liability 
Company
	Delaware
	2686371
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Tampa GP L.L.C.
	Limited Liability 
Company
	Delaware
	2835280
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Tampa, L.P.
	Limited Partnership
	Delaware
	2835863
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Texas L.L.C.
	Limited Liability 
Company
	Delaware
	2772119
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive Texas Real Estate Holdings L.L.C.
	Limited Liability 
Company
	Delaware
	4373912
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Automotive West LLC
	Limited Liability Company
	Delaware
	7463965
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury CH Motors L.L.C.
	Limited Liability 
Company
	Delaware
	5192484
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury CO SUB, LLC
	Limited Liability Company
	Delaware
	7463960
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Deland Hund, LLC
	Limited Liability 
Company
	Delaware
	5497021
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Deland Imports 2, L.L.C.
	Limited Liability 
Company
	Delaware
	3185222
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Fresno Imports L.L.C.
	Limited Liability 
Company
	Delaware
	3630377
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 5

	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	Asbury Ft. Worth Ford, LLC
	Limited Liability 
Company
	Delaware
	5617874
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Georgia TOY, LLC
	Limited Liability 
Company
	Delaware
	6739391
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury IN CBG, LLC
	Limited Liability 
Company
	Delaware
	7147802
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury IN CDJ, LLC
	Limited Liability 
Company
	Delaware
	7147806
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury IN Chev, LLC
	Limited Liability 
Company
	Delaware
	6210681
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Indy Chev, LLC
	Limited Liability 
Company
	Delaware
	7147790
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury IN Ford, LLC
	Limited Liability 
Company
	Delaware
	7147811
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury IN HON, LLC
	Limited Liability 
Company
	Delaware
	6526707
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury IN TOY, LLC
	Limited Liability 
Company
	Delaware
	7435254
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Jax AC, LLC
	Limited Liability 
Company
	Delaware
	4294930
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Jax Ford, LLC
	Limited Liability 
Company
	Delaware
	5694629
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 6

	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	Asbury Jax Holdings, L.P.
	Limited Partnership
	Delaware
	2898317
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Jax Hon L.L.C.
	Limited Liability 
Company
	Delaware
	4383883
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Jax K L.L.C.
	Limited Liability 
Company
	Delaware
	3957324
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Jax Management L.L.C.
	Limited Liability 
Company
	Delaware
	2858533
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Jax VW L.L.C.
	Limited Liability 
Company
	Delaware
	4383889
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury MS CHEV L.L.C.
	Limited Liability 
Company
	Delaware
	3982115
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury MS Gray-Daniels L.L.C.
	Limited Liability 
Company
	Delaware
	3383012
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury No Cal Niss L.L.C.
	Limited Liability 
Company
	Delaware
	3820684
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Sacramento Imports L.L.C.
	Limited Liability 
Company
	Delaware
	3749120
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury SC JPV L.L.C.
	Limited Liability 
Company
	Delaware
	4875313
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury SC LEX L.L.C.
	Limited Liability 
Company
	Delaware
	4875991
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 7

	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	Asbury SC Toy L.L.C.
	Limited Liability 
Company
	Delaware
	4875312
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury So Cal DC L.L.C.
	Limited Liability 
Company
	Delaware
	3745847
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury So Cal Hon L.L.C.
	Limited Liability 
Company
	Delaware
	3745851
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury So Cal Niss L.L.C.
	Limited Liability 
Company
	Delaware
	3761090
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury South Carolina Real Estate Holdings L.L.C.
	Limited Liability 
Company
	Delaware
	4890931
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury St. Louis Cadillac L.L.C.
	Limited Liability 
Company
	Delaware
	2829606
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury St. Louis FSKR, L.L.C.
	Limited Liability 
Company
	Delaware
	4737816
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury St. Louis Lex L.L.C.
	Limited Liability 
Company
	Delaware
	2827814
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury St. Louis LR L.L.C.
	Limited Liability 
Company
	Delaware
	2827813
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury St. Louis M L.L.C.
	Limited Liability 
Company
	Delaware
	4857999
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Tampa Management L.L.C.
	Limited Liability 
Company
	Delaware
	2881341
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 8

	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	Asbury Texas D FSKR, L.L.C.
	Limited Liability 
Company
	Delaware
	4737822
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury Texas H FSKR, L.L.C.
	Limited Liability 
Company
	Delaware
	4737821
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Asbury-Deland Imports, L.L.C.
	Limited Liability 
Company
	Delaware
	3110580
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Atlanta Real Estate Holdings L.L.C.
	Limited Liability 
Company
	Delaware
	2878627
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Avenues Motors, Ltd.
	Limited Partnership
	Florida
	A96000000626
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Bayway Financial Services, L.P.
	Limited Partnership
	Delaware
	2880409
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	BFP Motors L.L.C.
	Limited Liability 
Company
	Delaware
	3733630
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	C & O Properties, Ltd.
	Limited Partnership
	Florida
	A24567
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Camco Finance II L.L.C.
	Limited Liability 
Company
	Delaware
	2977640
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	CFP Motors L.L.C.
	Limited Liability 
Company
	Delaware
	5265630
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	CH Motors L.L.C.
	Limited Liability 
Company
	Delaware
	5265599
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	CHO Partnership, LTD.
	Limited Partnership
	Florida
	A99000001328
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 9

	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	CK Chevrolet L.L.C.
	Limited Liability 
Company
	Delaware
	3025479
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	CK Motors LLC
	Limited Liability 
Company
	Delaware
	3025483
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	CN Motors L.L.C.
	Limited Liability 
Company
	Delaware
	5265581
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Coggin Automotive Corp.
	Corporation
	Florida
	358922
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Coggin Cars L.L.C.
	Limited Liability 
Company
	Delaware
	3152923
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Coggin Chevrolet L.L.C.
	Limited Liability 
Company
	Delaware
	3152926
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Coggin Management, L.P.
	Limited Partnership
	Delaware
	2881141
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	CP-GMC Motors L.L.C.
	Limited Liability 
Company
	Delaware
	5265479
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown Acura/Nissan, LLC
	Limited Liability 
Company
	North 
Carolina
	395567
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown CHH L.L.C.
	Limited Liability 
Company
	Delaware
	2912328
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown CHO L.L.C.
	Limited Liability 
Company
	Delaware
	3624798
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 10

	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	Crown CHV L.L.C.
	Limited Liability 
Company
	Delaware
	2912330
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown FDO L.L.C.
	Limited Liability 
Company
	Delaware
	3500156
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown FFO Holdings L.L.C.
	Limited Liability 
Company
	Delaware
	3185229
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown FFO L.L.C.
	Limited Liability 
Company
	Delaware
	3093733
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown GAC L.L.C.
	Limited Liability 
Company
	Delaware
	2912334
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown GBM L.L.C.
	Limited Liability 
Company
	Delaware
	2912343
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown GCA L.L.C.
	Limited Liability 
Company
	Delaware
	3584465
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown GDO L.L.C.
	Limited Liability 
Company
	Delaware
	2912335
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown GHO L.L.C.
	Limited Liability 
Company
	Delaware
	2912331
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown GNI L.L.C.
	Limited Liability 
Company
	Delaware
	2912363
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown GPG L.L.C.
	Limited Liability 
Company
	Delaware
	2912319
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 11

	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	Crown GVO L.L.C.
	Limited Liability 
Company
	Delaware
	2958448
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown Honda, LLC
	Limited Liability 
Company
	North 
Carolina
	395566
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown Motorcar Company L.L.C.
	Limited Liability 
Company
	Delaware
	3408799
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown PBM L.L.C.
	Limited Liability 
Company
	Delaware
	4391369
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown RIA L.L.C.
	Limited Liability 
Company
	Delaware
	2912322
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown RIB L.L.C.
	Limited Liability 
Company
	Delaware
	2912323
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown SJC L.L.C.
	Limited Liability 
Company
	Delaware
	3699951
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Crown SNI L.L.C.
	Limited Liability 
Company
	Delaware
	3696551
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	CSA Imports L.L.C.
	Limited Liability 
Company
	Delaware
	3191595
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Escude-NN L.L.C.
	Limited Liability 
Company
	Delaware
	3154579
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Escude-NS L.L.C.
	Limited Liability 
Company
	Delaware
	3154573
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 12

	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	Escude-T L.L.C.
	Limited Liability 
Company
	Delaware
	3154569
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Florida Automotive Services L.L.C.
	Limited Liability 
Company
	Delaware
	3996125
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	HFP Motors L.L.C.
	Limited Liability 
Company
	Delaware
	3398830
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	JC Dealer Systems, LLC
	Limited Liability 
Company
	Delaware
	3391707
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	KP Motors L.L.C.
	Limited Liability 
Company
	Delaware
	3429268
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	McDavid Austin-Acra, L.L.C.
	Limited Liability 
Company
	Delaware
	4374093
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	McDavid Frisco-Hon, L.L.C.
	Limited Liability 
Company
	Delaware
	4374031
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	McDavid Grande, L.L.C.
	Limited Liability 
Company
	Delaware
	4373918
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	McDavid Houston-Hon, L.L.C.
	Limited Liability 
Company
	Delaware
	4373904
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	McDavid Houston-Niss, L.L.C.
	Limited Liability 
Company
	Delaware
	4373926
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	McDavid Irving-Hon, L.L.C.
	Limited Liability 
Company
	Delaware
	4373915
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 13

	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	McDavid Outfitters, L.L.C.
	Limited Liability 
Company
	Delaware
	4374082
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	McDavid Plano-Acra, L.L.C.
	Limited Liability 
Company
	Delaware
	4373993
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Mid-Atlantic Automotive Services, L.L.C.
	Limited Liability 
Company
	Delaware
	4751779
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Mississippi Automotive Services, L.L.C.
	Limited Liability 
Company
	Delaware
	4751784
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Missouri Automotive Services, L.L.C.
	Limited Liability 
Company
	Delaware
	4751788
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	NP FLM L.L.C.
	Limited Liability 
Company
	Delaware
	2955258
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	NP MZD L.L.C.
	Limited Liability 
Company
	Delaware
	2955278
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	NP VKW L.L.C.
	Limited Liability 
Company
	Delaware
	2955279
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Plano Lincoln-Mercury, Inc.
	Corporation
	Delaware
	2298220
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Precision Computer Services, Inc.
	Corporation
	Florida
	J87060
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Precision Enterprises Tampa, Inc.
	Corporation
	Florida
	F60178
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 14

	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	Precision Infiniti, Inc.
	Corporation
	Florida
	K38869
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Precision Motorcars, Inc.
	Corporation
	Florida
	324224
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Precision Nissan, Inc.
	Corporation
	Florida
	J41851
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Premier NSN L.L.C.
	Limited Liability 
Company
	Delaware
	2955308
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Premier Pon L.L.C.
	Limited Liability 
Company
	Delaware
	2954768
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Prestige Bay L.L.C.
	Limited Liability 
Company
	Delaware
	2955282
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Prestige TOY L.L.C.
	Limited Liability 
Company
	Delaware
	2955280
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Q Automotive Brandon FL, LLC
	Limited Liability 
Company
	Delaware
	5425708
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Q Automotive Cumming GA, LLC
	Limited Liability 
Company
	Delaware
	5555595
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Q Automotive Ft. Myers FL, LLC
	Limited Liability 
Company
	Delaware
	5571453
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Q Automotive Group L.L.C.
	Limited Liability 
Company
	Delaware
	5425703
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 15

	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	Q Automotive Holiday FL, LLC
	Limited Liability 
Company
	Delaware
	6016214
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Q Automotive Jacksonville FL, LLC
	Limited Liability 
Company
	Delaware
	5497026
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Q Automotive Kennesaw GA, LLC
	Limited Liability 
Company
	Delaware
	5633076
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Q Automotive Orlando FL, LLC
	Limited Liability 
Company
	Delaware
	5553767
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Q Automotive Tampa FL, LLC
	Limited Liability 
Company
	Delaware
	6043100
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Southern Atlantic Automotive Services, L.L.C.
	Limited Liability 
Company
	Delaware
	3996127
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Tampa Hund, L.P.
	Limited Partnership
	Delaware
	2898224
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Tampa Kia, L.P.
	Limited Partnership
	Delaware
	2898222
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Tampa LM, L.P.
	Limited Partnership
	Delaware
	2924753
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Tampa Mit, L.P.
	Limited Partnership
	Delaware
	2898220
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Texas Automotive Services, L.L.C.
	Limited Liability 
Company
	Delaware
	4751790
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 16

	
					
	Name of Pledger
	Type of Person
	Jurisdiction of
Formation
	Jurisdiction of Formation
Identification
Number
	Address of
Chief Executive Office

	Thomason Auto Credit Northwest, Inc.
	Corporation
	Oregon
	352322-89
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Thomason Dam L.L.C.
	Limited Liability 
Company
	Delaware
	2960883
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Thomason FRD L.L.C.
	Limited Liability 
Company
	Delaware
	2911238
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Thomason Hund L.L.C.
	Limited Liability 
Company
	Delaware
	2911246
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	Thomason Pontiac-GMC L.L.C.
	Limited Liability 
Company
	Delaware
	3575295
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	WMZ Motors, L.P.
	Limited Partnership
	Delaware
	2885115
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

	WTY Motors, L.P.
	Limited Partnership
	Delaware
	2898215
	2905 Premiere Parkway, Suite 300
Duluth, GA 30097

Schedule II - 17

EXHIBIT A

FORM OF PLEDGE AGREEMENT SUPPLEMENT
THIS PLEDGE AGREEMENT SUPPLEMENT  dated as of _____________, 20__ (this “Pledge Agreement Supplement”), is made by _______________________________, a ________________ (the “Pledgor”), in favor of BANK OF AMERICA, N.A., in its capacity as Administrative Agent (the “Administrative Agent”) for the Secured Parties (as defined in the Pledge Agreement referenced below; all capitalized terms used but not defined herein shall have the meanings given to such terms in such Pledge Agreement).

RECITALS:

A.    The Pledgor is party to that certain Third Amended and Restated Securities Pledge Agreement dated as of September 25, 2019 (as in effect on the date hereof,  the “Pledge Agreement”), among ASBURY AUTOMOTIVE GROUP, INC., a Delaware corporation (the “Company”), certain of its Subsidiaries and the Administrative Agent.

B.    The Pledgor has acquired rights in the Pledged Interests listed on Annex A to this Pledge Agreement Supplement (the “Additional Interests”) and desires to pledge, and evidence its prior pledge, to the Administrative Agent for the benefit of the Secured Parties all of the Additional Interests in accordance with the terms of the Credit Agreement and the Pledge Agreement.

In order to induce the Secured Parties to from time to time make and maintain extensions of credit under the Credit Agreement and Secured Cash Management Agreements and Secured Hedge Agreements, the Pledgor hereby agrees as follows:

1.    Affirmations.  The Pledgor hereby reaffirms and acknowledges the pledge and collateral assignment to, and the grant of security interest in, the Additional Interests contained in the Pledge Agreement (as collateral security for the payment, performance and satisfaction of its respective Secured Obligations) and pledges, collaterally assigns and grants to the Administrative Agent for the benefit of the Secured Parties, as collateral security for the payment, performance and satisfaction of its respective Secured Obligations, a first priority lien and security interest in, the Additional Interests and all of the following:
(a)    all money, securities, security entitlements and other investment property, dividends, rights, general intangibles and other property at any time and from time to time (x) declared or distributed in respect of or in exchange for or on conversion of any or all of the Additional Interests or (y) by its or their terms exchangeable or exercisable for or convertible into any Additional Interest or other Pledged Interest;
(b)    all other property of whatever character or description, including money, securities, security entitlements and other investment property, and general intangibles hereafter delivered to the Administrative Agent in substitution for or as an addition to any of the foregoing;
(c)    all securities accounts to which may at any time be credited any or all of the foregoing or any proceeds thereof and all certificates and instruments representing or evidencing any of the foregoing or any proceeds thereof; and
(d)    all proceeds of any of the foregoing.

Exhibit A - 1

The Pledgor hereby acknowledges, agrees and confirms by its execution of this Pledge Agreement Supplement that the Additional Interests constitute “Pledged Interests” under and are subject to the Pledge Agreement, and the items of property referred to in clauses (a) through (d) above (the “Additional Collateral”) shall collectively constitute “Collateral” under and are subject to the Pledge Agreement.  Each of the representations and warranties with respect to Pledged Interests and Collateral contained in the Pledge Agreement is hereby made by the Pledgor with respect to the Additional Interests and the Additional Collateral, respectively.  The Pledgor further represents and warrants that Annex A attached to this Pledge Agreement Supplement contains a true, correct and complete description of the Additional Interests, and that all other documents required to be furnished to the Administrative Agent pursuant to Section 3(c) of the Pledge Agreement in connection with the Additional Collateral have been delivered or are being delivered simultaneously herewith to the Administrative Agent.  The Pledgor further acknowledges that Schedule I to the Pledge Agreement shall be deemed, as to it, to be supplemented as of the date hereof to include the Additional Interests as described on Annex A to this Pledge Agreement Supplement.
2.    Counterparts.  This Pledge Agreement Supplement may be executed in any number of counterparts each of which when so executed and delivered shall be deemed an original, and it shall not be necessary in making proof of this Pledge Agreement Supplement to produce or account for more than one such counterpart executed by the Pledgor.  Without limiting the foregoing provisions of this Section 2, the provisions of Section 10.10 of the Credit Agreement shall be applicable to this Pledge Agreement.

3.    Governing Law; Venue; Waiver of Jury Trial.  The provisions of Section 26 of the Pledge Agreement are hereby incorporated by reference as if fully set forth herein.

IN WITNESS WHEREOF, the Pledgor has caused this Pledge Agreement Supplement to be duly executed by it’s authorized officer as of the day and year first above written.
PLEDGOR:
                                                    
By:____________________________________
Typed Name:                    
Typed Title:                    

 

Exhibit A - 2

ANNEX A
(to Pledge Agreement Supplement of __________ dated __________)
Additional Interests

	
						
	Name of Pledgor
	Name, Jurisdiction of Formation and Type of Entity of Pledged Subsidiary
	Class or Type of Equity Interest
	Total Amount of Class or Type Outstanding (if applicable)
	

Total Amount Pledged
	Certificate Number (if applicable)

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

Annex A to Exhibit AEX-10.1

 Exhibit 10.1 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)
WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT 

FOR INTRAMURAL-PHS CLINICAL RESEARCH 
 This
Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of
Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).

 This Cover Page identifies the Parties to this CRADA: 

The U.S. Department of Health and Human Services, as represented by 

National Cancer Institute 

an Institute or Center (hereinafter referred to as the “IC”) of the 

National Institutes of Health 

and 
 Intrexon Corporation,

 hereinafter referred to as “Intrexon”, 

having offices at 20374 Seneca Meadows Parkway, Germantown MD 20876, 

created and operating under the laws of Virginia. 

and 
 ZIOPHARM Oncology, Inc.,

 hereinafter referred to as “ZIOPHARM”, 

having offices at One First Avenue, Paris Building 34, Boston, MA 02129, 

created and operating under the laws of Delaware. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 1 of 42	  		  	Revised May 15, 2014

 COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT 

FOR INTRAMURAL-PHS CLINICAL RESEARCH 

Article 1. INTRODUCTION 
 This CRADA between IC and
Collaborator will be effective when signed by the Parties, which are identified on both the Cover Page and the Signature Page. The official contacts for the Parties are identified on the Contacts Information Page. Publicly available information
regarding this CRADA appears on the Summary Page. The research and development activities that will be undertaken by IC and Collaborator in the course of this CRADA are detailed in the Research Plan, attached as Appendix A. The staffing, funding,
and materials contributions of the Parties are set forth in Appendix B. Any changes to the model CRADA are set forth in Appendix C. 
 Article 2.
DEFINITIONS 
 The terms listed in this Article will carry the meanings indicated throughout the CRADA. To the extent a definition of a term as provided
in this Article is inconsistent with a corresponding definition in the applicable sections of either the United States Code (U.S.C.) or the Code of Federal Regulations (C.F.R.), the definition in the U.S.C. or C.F.R. will control. 

“Adverse Event” or “AE” means any untoward medical occurrence associated with the use of a
Test Article in humans, whether or not considered related to the Test Article (21 C.F.R §§ 312.32, 308.3; see also FDA Good Clinical Practice Guideline, International Conference on Harmonisation (ICH) E6: “Good Clinical Practice:
Consolidated Guidance, 62 Federal Register 25,691 (1997)). 
 “Affiliate” means any corporation or other business
entity controlled by, controlling, or under common control with Collaborator at any time during the term of the CRADA. For this purpose, “control” means direct or indirect beneficial ownership of at least fifty percent (50%) of the
voting stock or at least fifty percent (50%) interest in the income of the corporation or other business entity. 
 “Annual
Report” means the report of progress of an IND-associated investigation that IC, as the IND Sponsor, must submit to the FDA within sixty (60) days of the anniversary of the effective date of the IND (pursuant to 21 C.F.R.§
312.33). 
 “Background Invention” means an Invention conceived and first actually reduced to practice before the
Effective Date. 
 “Clinical Investigator” means, in accordance with 21 C.F.R. § 312.3, an individual who
actually conducts a clinical investigation, that is, who directs the administration or dispensation of Test Article to a subject, and who assumes responsibility for studying Human Subjects, for recording and ensuring the integrity of research data,
and for protecting the welfare and safety of Human Subjects. 
 “Collaborator Material” means all tangible materials not
first produced in the performance of this CRADA that are owned or controlled by Collaborator and used in the performance of the Research Plan. The term “Collaborator Materials” does not include “Test Article” (defined below).

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 2 of 42	  		  	Revised May 15, 2014

 “Confidential Information” means confidential scientific, business,
financial information, or Identifiable Private Information provided that the information does not include: 
  

	 	(a)	 information that is publicly known or that is available from public sources; 

 

	 	(b)	 information that has been made available by its owner to others without a confidentiality obligation;

  

	 	(c)	 information that is already known by the receiving Party, or information that is independently created or
compiled by the receiving Party without reference to or use of the provided information; or 

  

	 	(d)	 information that relates to potential hazards or cautionary warnings associated with the production, handling,
or use of the subject matter of the Research Plan. 

 “Cooperative Research and Development Agreement” or
“CRADA” means this Agreement, entered into pursuant to the Federal Technology Transfer Act of 1986, as amended (15 U.S.C. §§ 3710a et seq.), and Executive Order 12591 of April 10, 1987. 

“CRADA Data” means all recorded information first produced in the performance of the Research Plan. 

“CRADA Materials” means all tangible materials first produced in the performance of the Research Plan other than CRADA
Data. 
 “CRADA Principal Investigator(s)” or “CRADA PI(s)” means the person(s) designated by the
Parties who will be responsible for the scientific and technical conduct of the Research Plan. The CRADA PI may also be a Clinical Investigator. 

“CRADA Subject Invention” means any Invention of either or both Parties, conceived or first actually reduced to
practice in the performance of the Research Plan. 
 “Drug Master File” or “DMF” is described in 21
C.F.R. Part 314.420. A DMF is a submission to the FDA that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs.

 “Effective Date” means the date of the last signature of the Parties executing this Agreement. 

“Government” means the Government of the United States of America. 

“Human Subject” means, in accordance with the definition in 45 C.F.R. § 46.102(f), a living individual about whom
an investigator conducting research obtains: 
  

	 	(a)	 data through intervention or interaction with the individual; or 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 3 of 42	  		  	Revised May 15, 2014

	 	(b)	 Identifiable Private Information. 

“IC Materials” means all tangible materials not first produced in the performance of this CRADA that are owned or
controlled by IC and used in the performance of the Research Plan. 
 “IND” means an “Investigational New
Drug Application”, filed in accordance with 21 C.F.R. Part 312 under which clinical investigation of an experimental drug or biologic (Test Article) is performed in Human Subjects in the United States or intended to support a United States
licensing action. 
 “Identifiable Private Information” or “IPI” about a Human Subject means private
information from which the identity of the subject is or may readily be ascertained. Regulations defining and governing this information include 45 C.F.R. Part 46 and 21 C.F.R. Part 50. 

“Institutional Review Board” or “IRB” means, in accordance with 45 C.F.R. Part 46, 21 C.F.R. Part 56,
and other applicable regulations, an independent body comprising medical, scientific, and nonscientific members, whose responsibility is to ensure the protection of the rights, safety, and well-being of the Human Subjects involved in a study. 

“Invention” means any invention or discovery that is or may be patentable or otherwise protected under Title 35 of the
United States Code, or any novel variety of plant which is or may be protectable under the Plant Variety Protection Act, 7 U.S.C. §§ 2321 et seq. 

“Investigator’s Brochure” means, in accordance with the definition in 21 C.F.R. § 312.23(a)(5), a document
containing information about the Test Article, including animal screening, preclinical toxicology, and detailed pharmaceutical data, including a description of possible risks and side effects to be anticipated on the basis of prior experience with
the drug or related drugs, and precautions, such as additional monitoring, to be taken as part of the investigational use of the drug. 

“Patent Application” means an application for patent protection for a CRADA Subject Invention with the United States
Patent and Trademark Office (“U.S.P.T.O.”) or the corresponding patent-issuing authority of another nation. 

“Patent” means any issued United States patent, any international counterpart(s), and any corresponding grant(s) by a
non-U.S. government in place of a patent. 
 “Placebo” means an inactive substance identical in appearance to the
material being tested that is used to distinguish between drug action and suggestive effect of the material under study. 

“Protocol” means the formal, detailed description of a study to be performed as provided for in the Research Plan. It
describes the objective(s), design, methodology, statistical considerations, and organization of a trial. For the purposes of this CRADA, the term, Protocol, for clinical research involving Human Subjects, includes any and all associated documents,
including informed consent forms, to be provided to Human Subjects and potential participants in the study. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 4 of 42	  		  	Revised May 15, 2014

 “Raw Data” means the primary quantitative and empirical data first
collected from experiments and clinical trials conducted within the scope of this CRADA. 
 “Research Plan” means the
statement in Appendix A of the respective research and development commitments of the Parties. The Research Plan should describe the provisions for sponsoring the IND, clinical and safety monitoring, and data management. 

“Sponsor” means, in accordance with the definition in 21 C.F.R. § 312.3, an organization or individual who assumes legal
responsibility for supervising or overseeing clinical trials with Test Articles, and is sometimes referred to as the IND holder. 

“Steering Committee” means the research and development team whose composition and responsibilities with regard to the
research performed under this CRADA are described in Appendix A. 
 “Summary Data” means any extract or summary of the Raw
Data, generated either by, or on behalf of, IC or by, or on behalf of, Collaborator. Summary Data may include extracts or summaries that incorporate IPI. 

“Test Article” means, in accordance with 21 C.F.R. § 50.3 (j), any drug (including a biological product), medical device,
food additive, color additive, electronic product, or any other article subject to regulation under the Federal Food, Drug, and Cosmetic Act that is intended for administration to humans or animals, including a drug or biologic as identified in the
Research Plan and Appendix B, that is used within the scope of the Research Plan. The Test Article may also be referred to as Investigational Agent, Study Material, or Study Product. 

Article 3. COOPERATIVE RESEARCH AND DEVELOPMENT 
  

	3.1	 Performance of Research and Development. The research and development activities to be carried out under
this CRADA will be performed solely by the Parties identified on the Cover Page, unless specifically stated elsewhere in the Agreement. The CRADA PIs will be responsible for coordinating the scientific and technical conduct of this project on behalf
of their employers. Any Collaborator employees who will work at IC facilities will be required to sign an agreement appropriately modified in view of the terms of this CRADA. 

 

	3.2	 Research Plan. The Parties recognize that the Research Plan describes the collaborative research
and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify
them through an amendment, according to Paragraph 13.6. 

  

	3.3	 Use and Disposition of Collaborator Materials and IC Materials. The Parties agree to use Collaborator
Materials and IC Materials only in accordance with the Research Plan and Protocol(s), not to transfer these materials to third parties except in accordance with the Research Plan and Protocol(s) or as approved by the owning or providing Party, and,
upon expiration or termination of the CRADA, to dispose of these materials as directed by the owning or providing Party. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 5 of 42	  		  	Revised May 15, 2014

	3.4	 Third-Party Rights in Collaborator’s CRADA Subject Inventions. If Collaborator has received (or
will receive) support of any kind from a third party in exchange for rights in any of Collaborator’s CRADA Subject Inventions, Collaborator agrees to ensure that its obligations to the third party are both consistent with Articles 6 through 8
and subordinate to Article 7 of this CRADA. 

  

	3.5	 Disclosures to IC. Prior to execution of this CRADA, Collaborator agrees to disclose to IC all instances
in which outstanding royalties are due under a PHS license agreement and in which Collaborator had a PHS license terminated in accordance with 37 C.F.R. § 404.10. These disclosures will be treated as Confidential Information upon request by
Collaborator in accordance with the definition in Article 2 and Paragraphs 8.3 and 8.4. 

  

	3.6	 Clinical Investigator Responsibilities. The Clinical Investigator will be required to submit, or to
arrange for submission of, each Protocol associated with this CRADA to the IRB. In addition to the Protocol all associated documents, including informational documents and advertisements, must be reviewed and approved by the IRB before starting the
research. The research will be done in strict accordance with the Protocol(s) and no substantive changes in a finalized Protocol will be made unless mutually agreed upon, in writing, by the Parties. Research will not commence (or will continue
unchanged, if already in progress) until each substantive change to a Protocol, including those required by either the FDA or the IRB, has been integrated in a way acceptable to the Parties, submitted to the FDA (if applicable) and approved by the
IRB. 

  

	3.7	 Investigational Applications. 

 

	 	3.7.1	 If an IND is required, IC will be the IND Sponsor and will submit an IND. All Clinical Investigators must have
completed registration documents on file (1572 forms). 

  

	 	3.7.2	 When IC files the IND, Collaborator agrees to provide IC background data and information necessary to support
the IND. Collaborator further agrees to provide a letter of cross-reference to all pertinent regulatory filings sponsored by Collaborator. Collaborator’s employees will be reasonably available to respond to inquiries from the FDA regarding
information and data contained in the Collaborator’s IND, DMF, other filings, or other information and data provided to IC by the Collaborator pursuant to this Article 3. 

 

	 	3.7.3	 If Collaborator supplies Confidential Information to IC in support of an IND filed by IC, this information will
be protected in accordance with the corresponding confidentiality provisions of Article 8. 

  

	 	3.7.4	 Collaborator may sponsor its own clinical trials and hold its own IND for studies performed outside the scope
of this CRADA. These studies, however, should not adversely affect the ability to accomplish the goal of the Research Plan, for example, by competing for the same study population. All data from those clinical trials are proprietary to Collaborator
for purposes of this CRADA. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 6 of 42	  		  	Revised May 15, 2014

	3.8	 Test Article Information and Supply. Collaborator agrees to provide IC without charge and on a schedule
that will ensure adequate and timely performance of the research, a sufficient quantity of formulated and acceptably labeled, clinical-grade Test Article (and, as required by the Protocol(s), Placebo) to complete the clinical trial(s) agreed to and
approved under this CRADA. Collaborator will provide a Certificate of Analysis to IC for each lot of the Test Article provided. 

  

	3.9	 Test Article Delivery and Usage. Collaborator will ship the Test Article and, if required, Placebo to IC
in containers marked in accordance with 21 C.F.R. § 312.6. IC agrees that the Clinical Investigators will keep appropriate records and take reasonable steps to ensure that the Test Article is used in accordance with the Protocol(s) and
applicable FDA regulations. In addition, IC agrees that the Test Article (and all Confidential Information supplied by Collaborator relating to the Test Article) will be used solely for the conduct of the CRADA research and development activities.
Furthermore, IC agrees that no analysis or modification of the Test Article will be performed without Collaborator’s prior written consent. At the completion of the Research Plan, any unused quantity of Test Article will be returned to
Collaborator or disposed as directed by Collaborator. Pharmacy contacts at IC will be determined by IC and communicated to Collaborator. 

  

	3.10	 Monitoring. Subject to the restrictions in Article 8 concerning IPI, and with reasonable advance notice
and at reasonable times, IC will permit Collaborator or its designee(s) to monitor the conduct of the research, as well as to audit source documents containing Raw Data, to the extent necessary to verify compliance with FDA Good Clinical Practice
(International Conference on Harmonisation (ICH) E6: “Good Clinical Practice: Consolidated Guidance; 62 Federal Register 25, 691 (1997)) and the Protocol(s). 

 

	3.11	 FDA Meetings/Communications. All meetings with the FDA concerning any clinical trial within the scope of
the Research Plan will be discussed by Collaborator and IC in advance. Each Party reserves the right to take part in setting the agenda for, to attend, and to participate in these meetings. IC will provide Collaborator with copies of FDA meeting
minutes, all transmittal letters for IND submissions, IND safety reports, formal questions and responses that have been submitted to the FDA, Annual Reports, and official FDA correspondence, pertaining either to the INDs under this CRADA or to the
Clinical Investigators on Protocols performed in accordance with the Research Plan, except to the extent that those documents contain the proprietary information of a third party or dissemination is prohibited by law. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 7 of 42	  		  	Revised May 15, 2014

 Article 4. REPORTS 
  

	4.1	 Interim Research and Development Reports. The CRADA PIs should exchange information regularly, in
writing. This exchange may be accomplished through meeting minutes, detailed correspondence, circulation of draft manuscripts, Steering Committee reports, copies of Annual Reports and any other reports updating the progress of the CRADA research.
However, the Parties must exchange updated Investigator’s Brochure, formulation and preclinical data, and toxicology findings, as they become available. 

  

	4.2	 Final Research and Development Reports. The Parties will exchange final reports of their results within
six (6) months after the expiration or termination of this CRADA. These reports will set forth the technical progress made; any publications arising from the research; and the existence of invention disclosures of potential CRADA Subject
Inventions and/or any corresponding Patent Applications. 

  

	4.3	 Fiscal Reports. If Collaborator has agreed to provide funding to IC under this CRADA and upon the
request of Collaborator, then concurrent with the exchange of final research and development reports according to Paragraph 4.2, IC will submit to Collaborator a statement of all costs incurred by IC for the CRADA. If the CRADA has been terminated,
IC will specify any costs incurred before the date of termination for which IC has not received funds from Collaborator, as well as for all reasonable termination costs including the cost of returning Collaborator property or removal of abandoned
Collaborator property, for which Collaborator will be responsible. 

  

	4.4	 Safety Reports. 

 

	 	4.4.1	 In accordance with FDA requirements IC, as the IND Sponsor, will establish and maintain records and submit
safety reports to the FDA, as required by 21 C.F.R. § 312.32 and 21 C.F.R. § 812.150(b)(1), or other applicable regulations. In the conduct of research under this CRADA, the Parties will comply with specific IC guidelines and policies for
reporting AEs, as well as procedures specified in the Protocol(s). IC must provide Collaborator with copies of all Safety Reports concurrently with their submission to the FDA, and with any other information affecting the safety of Human Subjects in
research conducted under this CRADA. 

  

	 	4.4.2	 During and for a period of two years after the completion of a Protocol, the Collaborator shall promptly
provide to the IC any information that Collaborator has reasonably determined could directly affect the health or safety of past or current Human Subjects or influence the conduct of the Protocol. Such information may arise from any source, for
example, Safety Reports provided to the FDA, study results, information in site monitoring reports or data safety monitoring committee reports. IC shall be free to communicate the relevant safety information to each Human Subject and the IRB.

  

	4.5	 Annual Reports. IC will provide Collaborator a copy of the Annual Report concurrently with the
submission of the Annual Report to the FDA. Annual Reports will be kept confidential in accordance with Article 8. 

 Article 5.
STAFFING, FINANCIAL, AND MATERIALS OBLIGATIONS 
  

	5.1	 IC and Collaborator Contributions. The contributions of any staff, funds, materials, and equipment by
the Parties are set forth in Appendix B. The Federal Technology Transfer Act of 1986, 15 U.S.C. § 3710a(d)(1) prohibits IC from providing funds to Collaborator for any research and development activities under this CRADA. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 8 of 42	  		  	Revised May 15, 2014

	5.2	 IC Staffing. No IC employees will devote 100% of their effort or time to the research and development
activities under this CRADA. IC will not use funds provided by Collaborator under this CRADA for IC personnel to pay the salary of any permanent IC employee. Although personnel hired by IC using CRADA funds will focus principally on CRADA research
and development activities, Collaborator acknowledges that these personnel may nonetheless make contributions to other research and development activities, and the activities will be outside the scope of this CRADA. 

 

	5.3	 Collaborator Funding. Collaborator acknowledges that Government funds received by Collaborator from an
agency of the Department of Health and Human Services may not be used to fund IC under this CRADA. If Collaborator has agreed to provide funds to IC then the payment schedule appears in Appendix B and Collaborator will make payments according to
that schedule. If Collaborator fails to make any scheduled payment, IC will not be obligated to perform any of the research and development activities specified herein or to take any other action required by this CRADA until the funds are received.
IC will use these funds exclusively for the purposes of this CRADA. Each Party will maintain separate and distinct current accounts, records, and other evidence supporting its financial obligations under this CRADA and, upon written request, will
provide the other Party a Fiscal Report according to Paragraph 4.3, which delineates all payments made and all obligated expenses, along with the Final Research Report described in Paragraph 4.2. 

 

	5.4	 Capital Equipment. Collaborator’s commitment, if any, to provide IC with capital equipment to
enable the research and development activities under the Research Plan appears in Appendix B. If Collaborator transfers to IC the capital equipment or provides funds for IC to purchase it, then IC will own the equipment. If Collaborator loans
capital equipment to IC for use during the CRADA, Collaborator will be responsible for paying all costs and fees associated with the transport, installation, maintenance, repair, removal, or disposal of the equipment, and IC will not be liable for
any damage to the equipment. 

 Article 6. INTELLECTUAL PROPERTY 

 

	6.1	 Ownership of CRADA Subject Inventions, CRADA Data, and CRADA Materials. Subject to the Government
license described in Paragraph 7.5, the sharing requirements of Paragraph 8.1 and the regulatory filing requirements of Paragraph 8.2, the producing Party will retain sole ownership of and title to all CRADA Subject Inventions, all copies of CRADA
Data, and all CRADA Materials produced solely by its employee(s). The Parties will own jointly all CRADA Subject Inventions invented jointly and all CRADA Materials developed jointly. 

 

	6.2	 Reporting. The Parties will promptly report to each other in writing each CRADA Subject Invention
reported by their respective personnel, and any Patent Applications filed thereon, resulting from the research and development activities conducted under this CRADA. Each Party will report all CRADA Subject Inventions to the other Party in
sufficient detail to determine inventor ship, which will be determined in accordance with U.S. patent law. These reports will be treated as Confidential Information in accordance with Article 8. Formal reports will be made by and to the Patenting
and Licensing Offices identified on the Contacts Information Page herein. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 9 of 42	  		  	Revised May 15, 2014

	6.3	 Filing of Patent Applications. Each Party will make timely decisions regarding the filing of Patent
Applications on the CRADA Subject Inventions made solely by its employee(s), and will notify the other Party in advance of filing. Collaborator will have the first opportunity to file a Patent Application on joint CRADA Subject Inventions and will
notify PHS of its decision within sixty (60) days of an Invention being reported or at least thirty (30) days before any patent filing deadline, whichever occurs sooner. If Collaborator fails to notify PHS of its decision within that time
period or notifies PHS of its decision not to file a Patent Application, then PHS has the right to file a Patent Application on the joint CRADA Subject Invention. Neither Party will be obligated to file a Patent Application. Collaborator will place
the following statement in any Patent Application it files on a CRADA Subject Invention: “This invention was created in the performance of a Cooperative Research and Development Agreement with the National Institutes of Health, an Agency
of the Department of Health and Human Services. The Government of the United States has certain rights in this invention.” If either Party files a Patent Application on a joint CRADA Subject Invention, then the filing Party will include a
statement within the Patent Application that clearly identifies the Parties and states that the joint CRADA Subject Invention was made under this CRADA. 

  

	6.4	 Patent Expenses. Unless agreed otherwise, the Party filing a Patent Application will pay all preparation
and filing expenses, prosecution fees, issuance fees, post issuance fees, patent maintenance fees, annuities, interference expenses, and attorneys’ fees for that Patent Application and any resulting Patent(s). If a license to any CRADA Subject
Invention is granted to Collaborator, then Collaborator will be responsible for all expenses and fees, past and future, in connection with the preparation, filing, prosecution, and maintenance of any Patent Applications and Patents claiming
exclusively licensed CRADA Subject Inventions and will be responsible for a pro-rated share, divided equally among all licensees, of those expenses and fees for non-exclusively licensed CRADA Subject Inventions. Collaborator may waive its exclusive
option rights at any time, and incur no subsequent financial obligation for those Patent Application(s) or Patent(s). 

  

	6.5	 Prosecution of Patent Applications. The Party filing a Patent Application will provide the non-filing
Party with a copy of any official communication relating to prosecution of the Patent Application within thirty (30) days of transmission of the communication. Each Party will also provide the other Party with the power to inspect and make
copies of all documents retained in the applicable Patent Application or Patent file. The Parties agree to consult with each other regarding the prosecution of Patent Applications directed to joint CRADA Subject Inventions. If Collaborator elects to
file and prosecute Patent Applications on joint CRADA Subject Inventions, then Collaborator agrees to use the U.S.P.T.O. Customer Number Practice and/or grant PHS a power(s) of attorney (or equivalent) necessary to assure PHS access to its
intellectual property rights in these Patent Applications. PHS and Collaborator will cooperate with each other to obtain necessary signatures on Patent Applications, assignments, or other documents. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 10 of 42	  		  	Revised May 15, 2014

 Article 7. LICENSING 
  

	7.1	 Background Inventions. Other than as specifically stated in this Article 7, nothing in this CRADA will
be construed to grant any rights in one Party’s Background Invention(s) to the other Party, except to the extent necessary for the Parties to conduct the research and development activities described in the Research Plan. 

 

	7.2	 Collaborator’s License Option to CRADA Subject Inventions. With respect to Government rights
to any CRADA Subject Invention made solely by an IC employee(s) or made jointly by an IC employee(s) and a Collaborator employee(s) for which a Patent Application was filed, PHS hereby grants to Collaborator an exclusive option to elect an exclusive
or nonexclusive commercialization license. The license will be substantially in the form of the appropriate model PHS license agreement and will fairly reflect the nature of the CRADA Subject Invention, the relative contributions of the Parties to
the CRADA Subject Invention and the CRADA, a plan for the development and marketing of the CRADA Subject Invention, the risks incurred by Collaborator, and the costs of subsequent research and development needed to bring the CRADA Subject Invention
to the marketplace. The field of use of the license will not exceed the scope of the Research Plan. 

  

	7.3	 Exercise of Collaborator’s License Option. To exercise the option of Paragraph 7.2 Collaborator
must submit a written notice to the PHS Patenting and Licensing Contact identified on the Contacts Information Page (and provide a copy to the IC Contact for CRADA Notices) within three (3) months after either (i) Collaborator receives written
notice from PHS that the Patent Application has been filed or (ii) the date on which Collaborator files the Patent Application. The written notice exercising this option will include a completed “Application for License to Public Health
Service Inventions” and will initiate a negotiation period that expires nine (9) months after the exercise of the option. If PHS has not responded in writing to the last proposal by Collaborator within this nine (9) month period, the
negotiation period will be extended to expire one (1) month after PHS so responds, during which month Collaborator may accept in writing the final license proposal of PHS. In the absence of Collaborator’s exercise of the option, or upon
election of a nonexclusive license, PHS will be free to license the CRADA Subject Invention to others. These time periods may be extended at the sole discretion of PHS upon good cause shown in writing by Collaborator. 

 

	7.4	 Government License in IC Sole CRADA Subject Inventions and Joint CRADA Subject Inventions. Pursuant to
15 U.S.C. § r3710a(b)(1)(A), for CRADA Subject Inventions owned solely by IC or jointly by IC and Collaborator, and licensed pursuant to the option of Paragraph 7.2, Collaborator grants to the Government a nonexclusive, nontransferable,
irrevocable, paid-up license to practice the CRADA Subject Invention or have the CRADA Subject Invention practiced throughout the world by or on behalf of the Government. In the exercise of this license, the Government will not publicly disclose
trade secrets or commercial or financial information that is privileged or confidential within the meaning of 5 U.S.C. § 552(b)(4) or which would be considered privileged or confidential if it had been obtained from a non-federal party.

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 11 of 42	  		  	Revised May 15, 2014

	7.5	 Government License in Collaborator Sole CRADA Subject Inventions. Pursuant to 15 U.S.C. §
3710a(b)(2), for CRADA Subject Inventions made solely by an employee of Collaborator, Collaborator grants to the Government a nonexclusive, nontransferable, irrevocable, paid-up license to practice the CRADA Subject Invention or have the CRADA
Subject Invention practiced throughout the world by or on behalf of the Government for research or other Government purposes. 

  

	7.6	 Third Party License. Pursuant to 15 U.S.C. § 3710a(b)(1)(B), if PHS grants Collaborator an
exclusive license to a CRADA Subject Invention made solely by an IC employee or jointly with a Collaborator employee, the Government will retain the right to require Collaborator to grant to a responsible applicant a nonexclusive, partially
exclusive, or exclusive sublicense to use the CRADA Subject Invention in Collaborator’s licensed field of use on terms that are reasonable under the circumstances; or, if Collaborator fails to grant a license, to grant a license itself. The
exercise of these rights by the Government will only be in exceptional circumstances and only if the Government determines (i) the action is necessary to meet health or safety needs that are not reasonably satisfied by Collaborator,
(ii) the action is necessary to meet requirements for public use specified by federal regulations, and such requirements are not reasonably satisfied by Collaborator; or (iii) Collaborator has failed to comply with an agreement containing
provisions described in 15 U.S.C. § 3710a(c)(4)(B). The determination made by the Government under this Paragraph is subject to administrative appeal and judicial review under 35 U.S.C. § 203(b). 

 

	7.7	 Third-Party Rights In IC Sole CRADA Subject Inventions. For a CRADA Subject Invention conceived prior to
the Effective Date solely by an IC employee that is first actually reduced to practice after the Effective Date in the performance of the Research Plan, the option offered to Collaborator in Paragraph 7.2 may be restricted if, prior to the Effective
Date, PHS had filed a Patent Application and has either offered or granted a license in the CRADA Subject Invention to a third party. Collaborator nonetheless retains the right to apply for a license to any such CRADA Subject Invention in accordance
with the terms and procedures of 35 U.S.C. § 209 and 37 C.F.R. Part 404. 

 Article 8. RIGHTS OF ACCESS AND PUBLICATION

  

	8.1	 Right of Access to CRADA Data and CRADA Materials. IC and Collaborator agree to exchange all CRADA Data
and to share all CRADA Materials. If the CRADA is terminated, both Parties agree to provide CRADA Materials in quantities needed to complete the Research Plan. Such provision will occur before the termination date of the CRADA or sooner, if required
by the Research Plan. If Collaborator possesses any human biological specimens from clinical trials under the CRADA, the specimens must be handled as described in the Protocol or as otherwise directed by IC before the termination date of the CRADA.

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 12 of 42	  		  	Revised May 15, 2014

	8.2	 Use of CRADA Data and CRADA Materials. The Parties will be free to utilize CRADA Data and CRADA
Materials internally for their own purposes, consistent with their obligations under this CRADA. The Parties may share CRADA Data or CRADA Materials with their Affiliates, agents or contractors provided the obligations of this Article 8.2 are
simultaneously conveyed. 

  

	 	8.2.1	 CRADA Data. 

Collaborator and IC will use reasonable efforts to keep CRADA Data confidential until published or until corresponding Patent Applications are
filed. To the extent permitted by law, each Party will have the right to use any and all CRADA Data in and for any regulatory filing by or on behalf of the Party. 
  

	 	8.2.2	 CRADA Materials. 

Collaborator and IC will use reasonable efforts to keep descriptions of CRADA Materials confidential until published or until corresponding
Patent Applications are filed. Collaborator acknowledges that the basic research mission of PHS includes sharing with third parties for further research those research resources made in whole or in part with NIH funding. Consistent with this mission
and the tenets articulated in “Sharing of Biomedical Research Resources: Principles and Guidelines for Recipients of NIH Research Grants and Contracts”, December 1999, available at http://www.ott.nih.gov/policy/research tool.aspx,
following publication either Party may make available to third parties for further research those CRADA Materials made jointly by both PHS and Collaborator. Notwithstanding the above, if those joint CRADA Materials are the subject of a pending
Patent Application or a Patent, or were created using a patent-pending or patented material or technology, the Parties may agree to restrict distribution or freely distribute them. Either Party may distribute those CRADA Materials made solely by the
other Party only upon written consent from that other Party or that other Party’s designee. 
  

	8.3	 Confidential Information. Each Party agrees to limit its disclosure of Confidential Information to the
amount necessary to carry out the Research Plan, and will place a confidentiality notice on all this information. A Party orally disclosing Confidential Information to the other Party will summarize the disclosure in writing and provide it to the
other Party within fifteen (15) days of the disclosure. Each Party receiving Confidential Information agrees to use it only for the purposes described in the Research Plan. Either Party may object to the designation of information as
Confidential Information by the other Party. 

  

	8.4	 Protection of Confidential Information. Confidential Information will not be disclosed, copied,
reproduced or otherwise made available to any other person or entity without the consent of the owning or providing Party except as required by a court or administrative body of competent jurisdiction, or federal law or regulation. Each Party agrees
to use reasonable efforts to maintain the confidentiality of Confidential Information, which will in no instance be less effort than the Party uses to protect its own Confidential Information. Each Party agrees that a Party receiving Confidential
Information will not be liable for the disclosure of that portion of the Confidential Information which, after notice to and consultation with the disclosing Party, the receiving Party determines may not be lawfully withheld, provided the disclosing
Party has been given a reasonable opportunity to seek a court order to enjoin disclosure. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 13 of 42	  		  	Revised May 15, 2014

	8.5	 Human Subject Protection. The research to be conducted under this CRADA involves Human Subjects or human
tissues within the meaning of 45 C.F.R. Part 46, and all research to be performed under this CRADA will conform to applicable federal laws and regulations. Additional information is available from the HHS Office for Human Research Protections
(http://www.hhs.gov/ohrp/). 

  

	8.6	 Duration of Confidentiality Obligation. The obligation to maintain the confidentiality of Confidential
Information will expire at the earlier of the date when the information is no longer Confidential Information as defined in Article 2 or three (3) years after the expiration or termination date of this CRADA, except for IPI, for which the
obligation to maintain confidentiality will extend indefinitely. Collaborator may request an extension to this term when necessary to protect Confidential Information relating to products not yet commercialized. 

 

	8.7	 Publication. The Parties are encouraged to make publicly available the results of their research and
development activities. Before either Party submits a paper or abstract for publication or otherwise intends to publicly disclose information about a CRADA Subject Invention, CRADA Data, or CRADA Materials, the other Party will have thirty
(30) days to review proposed manuscripts and three (3) days to review proposed abstracts to assure that Confidential Information is protected. Either Party may request in writing that the proposed publication or other disclosure be delayed
for up to thirty (30) additional days as necessary to file a Patent Application. 

 Article 9. REPRESENTATIONS AND WARRANTIES

  

	9.1	 Representations of IC. IC hereby represents to Collaborator that: 

 

	 	9.1.1	 IC has the requisite power and authority to enter into this CRADA and to perform according to its terms, and
that IC’s official signing this CRADA has authority to do so. 

  

	 	9.1.2	 To the best of its knowledge and belief, neither IC nor any of its personnel involved in this CRADA is
presently subject to debarment or suspension by any agency of the Government which would directly affect its performance of the CRADA. Should IC or any of its personnel involved in this CRADA be debarred or suspended during the term of this CRADA,
IC will notify Collaborator within thirty (30) days of receipt of final notice. 

  

	9.2	 Representations and Warranties of Collaborator. Collaborator hereby represents and warrants to IC that:

  

	 	9.2.1	 Collaborator has the requisite power and authority to enter into this CRADA and to perform according to its
terms, and that Collaborator’s official signing this CRADA has authority to do so. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 14 of 42	  		  	Revised May 15, 2014

	 	9.2.2	 Neither Collaborator nor any of its personnel involved in this CRADA, including Affiliates, agents, and
contractors are presently subject to debarment or suspension by any agency of the Government. Should Collaborator or any of its personnel involved in this CRADA be debarred or suspended during the term of this CRADA, Collaborator will notify IC
within thirty (30) days of receipt of final notice. 

  

	 	9.2.3	 Subject to Paragraph 12.3, and if and to the extent Collaborator has agreed to provide funding under Appendix
B, Collaborator is financially able to satisfy these obligations in a timely manner. 

  

	 	9.2.4	 The Test Article provided has been produced in accordance with the FDA’s current Good Manufacturing
Practice set out in 21 C.F.R. §§ 210-211 and ICH QA7, and meets the specifications cited in the Certificate of Analysis and Investigator’s Brochure provided. 

Article 10. EXPIRATION AND TERMINATION 
  

	10.1	 Expiration. This CRADA will expire on the last date of the term set forth on the Summary Page. In no
case will the term of this CRADA extend beyond the term indicated on the Summary Page unless it is extended in writing in accordance with Paragraph 13.6. 

  

	10.2	 Termination by Mutual Consent. IC and Collaborator may terminate this CRADA at any time by mutual
written consent. 

  

	10.3	 Unilateral Termination. Either IC or Collaborator may unilaterally terminate this CRADA at any time by
providing written notice at least sixty (60) days before the desired termination date. IC may, at its option, retain funds transferred to IC before unilateral termination by Collaborator for use in completing the Research Plan. If Collaborator
terminates this Agreement before the completion of all approved or active Protocol(s), then Collaborator will supply enough Test Article (and Placebo, if applicable) to complete these Protocol(s) unless termination is for safety concerns.

  

	10.4	 Funding for IC Personnel. If Collaborator has agreed to provide funding for IC personnel and this CRADA
is mutually or unilaterally terminated by Collaborator before its expiration, then Collaborator agrees that funds for that purpose will be available to IC for a period of six (6) months after the termination date or until the expiration date of
the CRADA, whichever occurs sooner. If there are insufficient funds to cover this expense, Collaborator agrees to pay the difference. 

  

	10.5	 New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual
termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that IC will have the authority to retain and expend any funds
for up to one (1) year subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan.

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 15 of 42	  		  	Revised May 15, 2014

	10.6	 Collaborator Failure to Continue Development. If Collaborator suspends development of the Test Article
without the transfer of its active development efforts, assets, and obligations to a third party within ninety (90) days of discontinuation, Collaborator agrees that IC may continue developing the Test Article. In that event, the following will
apply: 

  

	 	10.6.1	 Collaborator agrees to transfer to IC all information necessary to enable IC to contract for the manufacture of
the Test Article and, unless abandoned for reasons relating to safety as determined by the data safety monitoring board, to provide the Test Article (and Placebo, if any) in Collaborator’s inventory to IC. 

 

	 	10.6.2	 Further, Collaborator hereby grants to IC a nonexclusive, irrevocable, world-wide, paid-up license to practice,
or have practiced for or on behalf of the Government, any Background Invention that Collaborator may currently have or will obtain on the Test Article, its manufacture, or on any method of using the Test Article for the indication(s) described in
the Research Plan, including the right to sublicense to third parties. 

 Article 11. DISPUTES 

 

	11.1	 Settlement. Any dispute arising under this CRADA which is not disposed of by agreement of the CRADA
Principal Investigators will be submitted jointly to the signatories of this CRADA. If the signatories, or their designees, are unable to jointly resolve the dispute within thirty (30) days after notification thereof, the Assistant Secretary
for Health (or his/her designee or successor) will propose a resolution. Nothing in this Paragraph will prevent any Party from pursuing any additional administrative remedies that may be available and, after exhaustion of such administrative
remedies, pursuing all available judicial remedies. 

  

	11.2	 Continuation of Work. Pending the resolution of any dispute or claim pursuant to this Article 11, the
Parties agree that performance of all obligations will be pursued diligently. 

 Article 12. LIABILITY 

 

	12.1	 NO WARRANTIES. EXCEPT AS SPECIFICALLY STATED IN ARTICLE 9, THE PARTIES MAKE NO EXPRESS OR IMPLIED
WARRANTY AS TO ANY MATTER WHATSOEVER, INCLUDING THE CONDITIONS OF THE RESEARCH OR ANY INVENTION OR MATERIAL, WHETHER TANGIBLE OR INTANGIBLE, MADE OR DEVELOPED UNDER OR OUTSIDE THE SCOPE OF THIS CRADA, OR THE OWNERSHIP, MERCHANTABILITY, OR FITNESS
FOR A PARTICULAR PURPOSE OF THE RESEARCH OR ANY INVENTION OR MATERIAL, OR THAT A TECHNOLOGY UTILIZED BY A PARTY IN THE PERFORMANCE OF THE RESEARCH PLAN DOES NOT INFRINGE ANY THIRD-PARTY PATENT RIGHTS. 

 

	12.2	 Indemnification and Liability. Collaborator agrees to hold the Government harmless and to indemnify the
Government for all liabilities, demands, damages, expenses and losses arising out of the use by Collaborator for any purpose of the CRADA Data, CRADA Materials or CRADA Subject Inventions produced in whole or part by IC

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 16 of 42	  		  	Revised May 15, 2014

	 	
employees under this CRADA, unless due to the negligence or willful misconduct of IC, its employees, or agents. The Government has no statutory authority to indemnify Collaborator. Each Party
otherwise will be liable for any claims or damages it incurs in connection with this CRADA, except that IC, as an agency of the Government, assumes liability only to the extent provided under the Federal Tort Claims Act, 28 U.S.C. Chapter 171.

  

	12.3	 Force Majeure. Neither Party will be liable for any unforeseeable event beyond its
reasonable control and not caused by its own fault or negligence, which causes the Party to be unable to perform its obligations under this CRADA, and which it has been unable to overcome by the exercise of due diligence. If a force majeure
event occurs, the Party unable to perform will promptly notify the other Party. It will use its best efforts to resume performance as quickly as possible and will suspend performance only for such period of time as is necessary as a result of the
force majeure event. 

 Article 13. MISCELLANEOUS 

 

	13.1	 Governing Law. The construction, validity, performance and effect of this CRADA will be governed by U.S.
federal law, as applied by the federal courts in the District of Columbia. If any provision in this CRADA conflicts with or is inconsistent with any U.S. federal law or regulation, then the U.S. federal law or regulation will preempt that provision.

  

	13.2	 Compliance with Law. IC and Collaborator agree that they will comply with, and advise any contractors,
grantees, or agents they have engaged to conduct the CRADA research and development activities to comply with, all applicable Executive Orders, statutes, and HHS regulations relating to research on human subjects (45 C.F.R. Part 46, 21 C.F.R. Parts
50 and 56) and relating to the appropriate care and use of laboratory animals (7 U.S.C. § 2131 et seq.; 9 C.F.R. Part 1, Subchapter A). IC and Collaborator will advise any contractors, grantees, or agents they have engaged to conduct
clinical trials for this CRADA that they must comply with all applicable federal regulations for the protection of Human Subjects, which may include the Standards for Privacy of Individually Identifiable Health Information set forth in 45 C.F.R.
Part 164. Collaborator agrees to ensure that its employees, contractors, and agents who might have access to a “select agent or toxin” (as that term is defined in 42 C.F.R. §§ 73.4-73.5) transferred from IC is properly licensed
to receive the “select agent or toxin”. 

  

	13.3	 Waivers. None of the provisions of this CRADA will be considered waived by any Party unless a waiver is
given in writing to the other Party. The failure of a Party to insist upon strict performance of any of the terms and conditions hereof, or failure or delay to exercise any rights provided herein or by law, will not be deemed a waiver of any rights
of any Party. 

  

	13.4	 Headings. Titles and headings of the articles and paragraphs of this CRADA are for convenient reference
only, do not form a part of this CRADA, and will in no way affect its interpretation. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 17 of 42	  		  	Revised May 15, 2014

	13.5	 Severability. The illegality or invalidity of any provisions of this CRADA will not impair, affect, or
invalidate the other provisions of this CRADA. 

  

	13.6	 Amendments. Minor modifications to the Research Plan may be made by the mutual written consent of the
CRADA Principal Investigators. Substantial changes to the CRADA, extensions of the term, or any changes to Appendix C will become effective only upon a written amendment signed by the signatories to this CRADA or by their representatives duly
authorized to execute an amendment. A change will be considered substantial if it directly expands the range of the potential CRADA Subject Inventions, alters the scope or field of any license option governed by Article 7, or requires a significant
increase in the contribution of resources by either Party. 

  

	13.7	 Assignment. Neither this CRADA nor any rights or obligations of any Party hereunder shall be assigned or
otherwise transferred by either Party without the prior written consent of the other Party. The Collaborator acknowledges the applicability of 41 U.S.C. § 15, the Anti Assignment Act, to this Agreement. The Parties agree that the identity of
the Collaborator is material to the performance of this CRADA and that the duties under this CRADA are nondelegable. 

  

	13.8	 Notices. All notices pertaining to or required by this CRADA will be in writing, signed by an authorized
representative of the notifying Party, and delivered by first class, registered, or certified mail, or by an express/overnight commercial delivery service, prepaid and properly addressed to the other Party at the address designated on the Contacts
Information Page, or to any other address designated in writing by the other Party. Notices will be considered timely if received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service
postmark or dated receipt from a commercial carrier. Notices regarding the exercise of license options will be made pursuant to Paragraph 7.3. Either Party may change its address by notice given to the other Party in the manner set forth above.

  

	13.9	 Independent Contractors. The relationship of the Parties to this CRADA is that of independent
contractors and not agents of each other or joint venturers or partners. Each Party will maintain sole and exclusive control over its personnel and operations. 

 

	13.10	 Use of Name; Press Releases. By entering into this CRADA, the Government does not directly or indirectly
endorse any product or service that is or will be provided, whether directly or indirectly related to either this CRADA or to any patent or other intellectual-property license or agreement that implements this CRADA by Collaborator, its successors,
assignees, or licensees. Collaborator will not in any way state or imply that the Government or any of its organizational units or employees endorses any product or services. Each Party agrees to provide proposed press releases that reference or
rely upon the work under this CRADA to the other Party for review and comment at least five (5) business days before publication. Either Party may disclose the Title and Abstract of the CRADA to the public without the approval of the other
Party. 

  

	13.11	 Reasonable Consent. Whenever a Party’s consent or permission is required under this CRADA, its
consent or permission will not be unreasonably withheld. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 18 of 42	  		  	Revised May 15, 2014

	13.12	 Export Controls. Collaborator agrees to comply with U.S. export law and regulations. If Collaborator has
a need to transfer any CRADA Materials made in whole or in part by IC, or IC Materials, or IC’s Confidential Information to a person located in a country other than the United States, to an Affiliate organized under the laws of a country other
than the United States, or to an employee of Collaborator in the United States who is not a citizen or permanent resident of the United States, Collaborator will acquire any and all necessary export licenses and other appropriate authorizations.

  

	13.13	 Entire Agreement. This CRADA constitutes the entire agreement between the Parties concerning the subject
matter of this CRADA and supersedes any prior understanding or written or oral agreement. 

  

	13.14	 Survivability. The provisions of Paragraphs 3.3, 3.4, 3.8, 4.2, 4.3, 4.4.2, 5.3, 5.4, 6.1-9.2,
10.3-10.6, 11.1, 11.2, 12.1-12.3, 13.1-13.3, 13.7, 13.10 and 13.14 will survive the expiration or early termination of this CRADA. 

SIGNATURES BEGIN ON THE NEXT PAGE 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 19 of 42	  		  	Revised May 15, 2014

 SIGNATURE PAGE 

ACCEPTED AND AGREED 
 BY
EXECUTING THIS AGREEMENT, EACH PARTY REPRESENTS THAT ALL STATEMENTS MADE HEREIN
ARE TRUE, COMPLETE, AND ACCURATE TO THE BEST OF ITS KNOWLEDGE.
COLLABORATOR ACKNOWLEDGES THAT IT MAY BE SUBJECT TO CRIMINAL, CIVIL, OR
ADMINISTRATIVE PENALTIES FOR KNOWINGLY MAKING A FALSE, FICTITIOUS, OR FRAUDULENT
STATEMENT OR CLAIM. 
 FOR IC: 
  

									
	 /s/ James H. Doroshow
	 	    	 	    	 	    	 	 1/9/17

	James H. Doroshow, M.D.	 		 		 		 	Date
	Deputy Director for Clinical and Translational Research, NCI	 		 		 		 	
					
	FOR INTREXON CORPORATION:	 		 		 		 	
					
	 /s/ Donald P. Lehr
	 		 		 		 	 January 9, 2017

	Donald P. Lehr	 		 		 		 	Date
	Chief Legal Officer	 		 		 		 	
					
	FOR ZIOPHARM ONCOLOGY INC.:	 		 		 		 	
					
	 /s/ Laurence Cooper
	 		 		 		 	 January 9, 2017

	 Laurence Cooper, M.D., Ph.D.
 Chief Executive
Officer
	 		 		 		 	Date

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 20 of 42	  	Confidential	  	Revised May 15, 2014

 CONTACTS INFORMATION PAGE 

CRADA Notices 
  

			
	For NCI:	  	 For Collaborators:

		
	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	
		
		  	 and

		
		  	 [***]

		  	 [***]

		  	 [***]

		  	 [***]

		  	 [***]

		  	 [***]

		  	 [***]

 Patent and Licensing 
  

			
	 For NCI:
	  	 For Collaborators:

		
	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	[***]
	 [***]
	  	 [***]

	 [***]
	  	 [***]

 Delivery of Materials Identified in Appendix B (if any) 

 

			
	 For NCI:
	  	 For Collaborators:

		
	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

 [***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 21 of 42	  	Confidential	  	Revised May 15, 2014

 Clinical Contact (as needed for Article 4.4.2) 

 

			
	For NCI:	  	For Collaborators:
		
	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	 [***]

 [***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 22 of 42	  	Confidential	  	Revised May 15, 2014

 SUMMARY PAGE 

EITHER PARTY MAY, WITHOUT FURTHER CONSULTATION OR PERMISSION, 

RELEASE THIS SUMMARY PAGE TO THE PUBLIC. 

TITLE OF CRADA: Development and Evaluation of Intrexon Corporation’s Proprietary Non-viral Sleeping Beauty Vectors for Genetic Modification
of Peripheral Blood Lymphocytes with Genes Encoding Mutated Tumor Neoantigen-specific T Cell Receptors (also referred to as Mutation Reactive T Cell Receptors) that Have Been Identified Using NCI Proprietary Methods 

 

			
	PHS NCI Component:	  	National Cancer Institute (NCI)
	IC Principal Investigator:	  	Steven A. Rosenberg, M.D., Ph.D.
		
	Collaborator:	  	Intrexon Corporation
	Collaborator Principal Investigator:	  	Tim Chan, Ph.D.
		
	Collaborator:	  	ZIOPHARM Oncology, Inc.
	Collaborator Principal Investigator:	  	Laurence Cooper, M.D., Ph.D.
		
	TERM OF CRADA:	  	Three (3) years from the Effective Date.

 ABSTRACT OF THE RESEARCH PLAN: 

The principal goal of this CRADA is to develop and evaluate adoptive cell transfer-based immunotherapies (ACT) using NCI proprietary methods for the isolation
of tumor-reactive T Cell Receptors (TCRs) targeting unique, patient specific mutated neoantigen(s) and introduction of said TCRs into T cell subsets isolated from peripheral blood using proprietary Intrexon Corporation (“Intrexon”)
Non-Viral Sleeping Beauty Transposon and Transposascs for the treatment of patients with solid tumor malignancies. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 23 of 42	  		  	Revised May 15, 2014

 APPENDIX A 

RESEARCH PLAN 
 Title of
CRADA 
 Development and Evaluation of Intrexon Corporation’s Proprietary Non-viral Sleeping Beauty Vectors for Genetic Modification of
Peripheral Blood Lymphocytes with Genes Encoding Mutated Tumor Neoantigen-specific T Cell Receptors (also referred to as Mutation Reactive T Cell Receptors) that Have Been Identified Using NCI Proprietary Methods 

NCI Principal Investigator 

Steven A. Rosenberg, M.D., Ph.D. 

Chief, Surgery Branch 
 Center for
Cancer Research (CCR) 
 National Cancer Institute (NCI) 

Collaborator Investigator 

Tim Chan, Ph.D. 
 Intrexon
Corporation, Inc. (Intrexon) 
 Collaborator Investigator 

Laurence Cooper, M.D., Ph.D. 

ZIOPHARM Oncology, Inc. (Ziopharm) 

Term of CRADA 
 Three
(3) years from the date of the final CRADA signature. 
  
  

GOALS AND SCOPE OF THIS CRADA 

[***Eight (8) Pages Redacted in their Entirety***] 

[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 24 of 42	  	Confidential	  	Revised May 15, 2014

 APPENDIX B 

STAFFING, FUNDING AND MATERIALS/EQUIPMENT CONTRIBUTIONS OF THE PARTIES 

Staffing Contributions 
 IC will provide
scientific staff and other support necessary to conduct the research and other activities described in the Research Plan. IC’s scientific staff will include IC’s Principal Investigator and technical staff. 

IC estimates that 6-8 person-years of effort per year will be required to complete the CRADA research. 

Collaborator will provide scientific staff and other support necessary to conduct the research and other activities described in the Research Plan.
Collaborator’s scientific staff will include Collaborator’s Principal Investigator and technical staff. 
 Collaborator estimates that 3-4
person-years of effort per year will be required to complete the CRADA research. 
 Funding Contributions 

Ziopharm agrees to provide funds in the amount of $2,500,000.00 per year of the CRADA for IC to use to acquire technical, statistical, and administrative
support for the research activities, as well as to pay for supplies and travel expenses. Ziopharm will provide funds in the amount of $625,000.00 on a quarterly basis. The first quarterly installment of $625,000.00 will be due within thirty
(30) days of the Effective Date. Each subsequent installment will be due within thirty (30) days of each quarterly anniversary of the Effective Date. Collaborator agrees that IC can allocate the funding between the various categories in
support of the CRADA research as IC’s CRADA Principal Investigator sees fit. 
 CRADA PAYMENTS: 

Collaborator has three options for making CRADA payments. See CRADA Payment Options at http://ttc.nci.nih.gov/forms/crada.php for specific information
on making payments using each option. 
 Option 1: Collaborator sends checks to the NCI. 

Option 2: Collaborator makes payments via wire transfer. 
 Option
3: Collaborator makes payments using www.pay.gov. 
 Collaborator may make CRADA payments via www.pay.gov. If Collaborator makes CRADA
payments by check, Collaborator will make the checks payable to the National Cancer Institute and will reference the CRADA number 03111 and title “Development and Evaluation of Intrexon Corporation’s Proprietary Non-Viral Sleeping
Beauty Vectors for Genetic Modification of Peripheral Blood Lymphocytes with Genes Encoding Mutated Tumor Neoantigen-specific T Cell Receptors (also referred to as Mutation Reactive T Cell Receptors) that Have Been Identified Using
NCI Proprietary Methods” on each check, and will send them via trackable mail or courier to: 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 33 of 42	  	Confidential	  	Revised May 15, 2014

 CRADA Funds Coordinator 

Technology Transfer Center, NCI 
 9609 Medical Center Drive, Rm
1-E530 
 Rockville, MD 20850-9702 
 CRADA Travel Payments:

 Travel arrangements for all Government staff will be made in accordance with the Federal Travel Rules and Regulations, whether arranged by ICD and funded
using either appropriated funds or CRADA funds, or arranged and funded directly by Collaborator. 
 Materials/Equipment Contributions:

 IC will provide the following ICD Materials for use under this CRADA: 

Test Article: None. 
 IC
Materials: PBL collected under NCI protocol 03-C-0277 entitled “Cell Harvest and Preparation for Surgery Branch Adoptive 

                      Cell
Therapy Protocols.” 
 Capital Equipment: None 

Collaborator will provide the following Collaborator Materials and/or capital equipment for use under this CRADA: 

Test Article: Research grade and cGMP grade Intrexon proprietary SB system. Collaborator agrees to provide SB system cassettes, cGMP materials,
protocols, specifications and certificates of analysis sufficient to treat the number of patients agreed upon during the three-year term of the CRADA for IC to use for the approved protocol(s). 

Collaborator Materials: For cellular assays, preclinical studies, and clinical studies, sequences each containing the Sleeping Beauty
Transposon/Transposase system. 
 Capital Equipment: None 

If either Party decides to provide additional Materials for use under this CRADA, those materials will be transferred under a cover letter that identifies
them and states that they are being provided under the terms of the CRADA. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 34 of 42	  	Confidential	  	Revised May 15, 2014

 APPENDIX C 

MODIFICATIONS TO THE MODEL CRADA 

Underlining indicates additions and strikeout indicates deletions. 

Amend Article 1 “Introduction” to read as follows: 

This CRADA between IC and Collaborator will be effective when signed by the Parties, which are identified on both the Cover Page and the Signature Page. The
official contacts for the Parties are identified on the Contacts Information Page. Publicly available information regarding this CRADA appears on the Summary Page. The research and development activities that will be undertaken by IC and
Collaborator in the course of this CRADA are detailed in the Research Plan, attached as Appendix A. The staffing, funding, and materials contributions of the Parties are set forth in Appendix B. Any changes to the model CRADA are set forth in
Appendix C. Should the Collaborator hire an employee to work on the premises of the IC for the purposes of performing activities under the Research Plan of this Agreement, the “NIH Research Collaborator (RC) Agreement” will be used for
this purpose and is attached as Appendix D. A Letter of Intent (“LOI”) to enter into this CRADA was executed by the Parties, as of October 6th, 2016, which LOI is attached hereto as Appendix
E. Articles 2, 6, 7, 8, and 9 of the Model PHS CRADA shall be deemed to have become effective between the Parties on the date of execution of the LOI and shall survive through the Effective Date of this CRADA; provided, that as of the Effective
Date, such LOI and the Model PHS CRADA terms shall be of no further force or effect and shall be superseded by the terms of this CRADA. The Research Plan of this CRADA hereby replaces and supersedes the Research Plan of the LOI. 

Add the Definition of “Multi-Party Data” in Article 2 to read as follows: 

“Multi-Party Data” means data from studies sponsored by IC pursuant to Clinical Trial Agreements (CTA) or CRADAs, where such data are
collected under Protocols involving combinations of investigational agents supplied from more than one CTA or CRADA collaborator. “Multi-Party Data” also means data from studies where such data are collected pursuant to research involving
combinations of proprietary materials from more than one collaborator as documented in more than one agreement. 
 Amend the Definition of
“Annual Report” in Article 2 to read as follows: 
 “Annual Report” means the report of progress of an IND-associated
investigation that IC or Collaborator, as the IND Sponsor, must submit to the FDA within sixty (60) days of the anniversary of the effective date of the IND (pursuant to 21 C.F.R.§ 312.33). 

Add the Definition of “Collaborator” in Article 2 to read as follows: 

“Collaborator” means, as context dictates, collectively Intrexon and ZIOPHARM, or individually Intrexon or ZIOPHARM. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 35 of 42	  	Confidential	  	Revised May 15, 2014

 Add the Definition of “ Third Party” in Article 2 to read as follows: 

“Third Party” means an entity not a Party to this CRADA. 

Amend Section 3.7 to read as follows: 
  

	3.7	 Investigational Applications. 

 

	 	3.7.1	 If an IND is required, IC will be the IND Sponsor and will submit an
INDthe Parties will file and/or amend sponsorship of INDs as agreed upon in Appendix A of this CRADA. All Clinical Investigators must have completed registration documents on file (1572 forms). 

 

	 	3.7.2	 When ICD a Party files the IND, Collaborator the other Party
agrees to provide ICD the filing party background data and information necessary to support the IND. Collaborator The Parties further agrees to provide a letter of cross-reference to all data
and pertinent regulatory filings sponsored by Collaborator. Collaborator’s a Party under this CRADA. Both Parties’ employees will be reasonably available to respond to inquiries from the FDA regarding
information and data contained in the Collaborator’s Party’s IND, DMF, other filings, or other information and data provided to ICD one Party by the Collaborator other Party pursuant
to this Article 3. 

  

	 	3.7.3	 If Collaborator a Party supplies Confidential Information to ICDthe
other Party in support of an IND that is filed, by ICD this information will be protected in accordance with the corresponding confidentiality provisions of Article 8. 

 

	 	3.7.4	 Collaborator may sponsor its own clinical trials and hold its own IND for studies performed outside the
scope of this CRADA. These studies, however, should not adversely effect the ability to accomplish the goal of the Research Plan, for example, by competing for the same study population. All data from those clinical trials are proprietary to
Collaborator for purposes of this CRADA. 

 Amend Section 3.11 to read as follows: 

 

	3.11	 FDA Meetings/Communications. All meetings with the FDA concerning any clinical trial within the scope of
the Research Plan will be discussed by Collaborator and IC in advance. Each Party reserves the right to take part in setting the agenda for, to attend, and to participate in these meetings, as appropriate. IC Sponsor
will provide Collaborator the other Party with copies of FDA meeting minutes, all transmittal letters for IND submissions, IND safety reports, formal questions and responses that have been submitted to the FDA, Annual
Reports, and official FDA correspondence, pertaining either to the INDs under this CRADA or to the Clinical Investigators on Protocols performed in accordance with the Research Plan, except to the extent that those documents contain the proprietary
information of a third party or dissemination is prohibited by law. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 36 of 42	  	Confidential	  	Revised May 15, 2014

 Amend Section 7.2 to read as follows: 

7.2 Collaborator’s License Option to CRADA Subject Inventions. Intrexon Corporation shall take the lead in exercising Collaborator’s
License Option under Article 7. Thus “Collaborator” shall mean Intrexon Corporation in Articles 7.2, 7.3, 7.4, 7.6 and 7.7. With respect to Government rights to any CRADA Subject Invention made solely by an IC employee(s) or made
jointly by an IC employee(s) and a Collaborator employee(s) for which a Patent Application was filed, PHS hereby grants to Collaborator an exclusive option to elect an exclusive or nonexclusive commercialization license or
co-exclusive, if applicable, commercialization license. The option to elect a co-exclusive license shall apply when a CRADA Subject Invention is also an Invention made under another agreement resulting from mutually agreed upon studies, as described
in Section 8.8 (regarding Multi-Party Data Rights), and the field of use of this co-exclusive license shall be limited to the use of the combination of the Test Article with another agent(s) commensurate with the scope of the Research Plan.
The license will be substantially in the form of the appropriate model PHS license agreement and will fairly reflect the nature of the CRADA Subject Invention, the relative contributions of the Parties to the CRADA Subject Invention and the CRADA, a
plan for the development and marketing of the CRADA Subject Invention, the risks incurred by Collaborator, and the costs of subsequent research and development needed to bring the CRADA Subject Invention to the marketplace. The field of use of the
exclusive or non-exclusive license will not exceed the scope of the Research Plan. 
 Amend Section 7.6 to read as follows: 

7.6 Third Party License. Pursuant to 15 U.S.C. § 3710a(b)(1)(B), if PHS grants Collaborator an exclusive license or co-exclusive license to
a CRADA Subject Invention made solely by an IC employee or jointly with a Collaborator employee, the Government will retain the right to require Collaborator to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive
sublicense to use the CRADA Subject Invention in Collaborator’s licensed field of use on terms that are reasonable under the circumstances; or, if Collaborator fails to grant a license, to grant a license itself. The exercise of these rights by
the Government will only be in exceptional circumstances and only if the Government determines (i) the action is necessary to meet health or safety needs that are not reasonably satisfied by Collaborator, (ii) the action is necessary to
meet requirements for public use specified by federal regulations, and such requirements are not reasonably satisfied by Collaborator; or (iii) Collaborator has failed to comply with an agreement containing provisions described in 15 U.S.C.
§ 3710a(c)(4)(B). The determination made by the Government under this Paragraph is subject to administrative appeal and judicial review under 35 U.S.C. § 203(b). 

Amend Section 8.3 to read as follows: 
 8.3
Confidential Information. Each Party agrees to limit its disclosure of Confidential Information to the amount necessary to carry out the Research Plan, and will place a confidentiality notice on all this information. A Party orally disclosing
Confidential Information to the other Party will reduce the disclosure to writing within fifteen (15) days of the disclosure. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 37 of 42	  	Confidential	  	Revised May 15, 2014

 Each Party receiving Confidential Information agrees to use it only for the purposes described in the
Research Plan. Either Party may object to the designation of information as Confidential Information by the other Party. Notwithstanding any other provision in this Agreement, although certain information concerning Collaborator Materials or Test
Article provided under this Agreement is confidential and will be so stamped, Collaborator recognizes that the NCI PI may need to disclose certain information concerning CONFIDENTIAL materials to patients (or to physicians or scientists where such
disclosure is made in order to directly facilitate the ongoing treatment of a patient, or the development of a treatment for a patient). Collaborator hereby authorizes such limited disclosures, and the NCI PI agrees to promptly acknowledge to
Collaborator the making of any such disclosure.  
 Amend Section 8.4 to read as follows: 

8.4 Protection of Confidential Information. Subject to Paragraph 8.3, Confidential Information will not be disclosed, copied, reproduced or otherwise
made available to any other person or entity without the consent of the owning or providing Party except as required by a court or administrative body of competent jurisdiction, or federal law or regulation. Each Party agrees to use reasonable
efforts to maintain the confidentiality of Confidential Information, which will in no instance be less effort than the Party uses to protect its own Confidential Information. Each Party agrees that a Party receiving Confidential Information will not
be liable for the disclosure of that portion of the Confidential Information which, after notice to and consultation with the disclosing Party, the receiving Party determines may not be lawfully withheld, provided the disclosing Party has been given
a reasonable opportunity to seek a court order to enjoin disclosure. 
 Amend Section 8.6 to read as follows: 

8.6 Duration of Confidentiality Obligation. The obligation to maintain the confidentiality of Confidential Information as described in Paragraph 8.3,
will expire at the earlier of the date when the information is no longer Confidential Information as defined in Article 2 or three (3) years after the expiration or termination date of this CRADA, except for IPI, for which the obligation to
maintain confidentiality will extend indefinitely. Collaborator may request an extension to this term when necessary to protect Confidential Information relating to products not yet commercialized. 

Add Section 8.8 as follows: 
 8.8
Multi-Party Data Rights. For clinical Protocol(s) mutually agreed upon by IC and Collaborator where Test Article is used in combination with another investigational agent supplied to IC pursuant to a CTA or CRADA between IC and an entity not a
Party to this CRADA (hereinafter referred to as “Third Party”), or for non-clinical study(ies) where research involving combinations of proprietary materials from more than one collaborator as documented in more than one agreement, the
access and use of Multi-Party Data by the Collaborator and Third Party shall be co-exclusive as follows: 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 38 of 42	  	Confidential	  	Revised May 15, 2014

	 	8.8.1	 IC will provide both Collaborator and Third Party with notice regarding the existence and nature of the
agreements governing the use of the Test Article and Third Party’s investigational agent, the design of the proposed combination Protocol(s) or non-clinical study(ies), and the existence of any obligations that might restrict IC’s
participation in the proposed combination Protocols or non-clinical study(ies). 

  

	 	8.8.2	 Collaborator shall agree to permit use of the Multi-Party Data from these trials by Third Party to the extent
necessary to allow Third Party to develop, obtain regulatory approval for, or commercialize its own investigational agent(s). However, this provision will not apply unless Third Party also agrees to Collaborator’s reciprocal use of Multi-Party
Data. 

  

	 	8.8.3	 Collaborator and Third Party must agree in writing prior to the commencement of the combination Protocol(s) or
non-clinical study(ies) that each will use the Multi-Party Data solely for the development, regulatory approval, and commercialization of its own investigational agent(s). 

 

	 	8.84	 The sharing of Multi-Party Data does not alter the ownership of the Multi-Party Data or obligations of IC,
Collaborator and Third Party to keep Confidential Information owned by any other Party or Parties confidential. 

 Amend the Definition
of “Independent Contractors” in Section 13.9 to read as follows: 
 13.9 Independent Contractors. The relationship of the
Parties to this CRADA is that of independent contractors and not agents of each other or joint venturers or partners. Each Party shall maintain sole and exclusive control over its personnel and operations. If Collaborator elects to perform any
portion of the Research Plan through an agent, contractor or consultant, Collaborator agrees to incorporate into such contracts all provisions necessary to ensure that the work of such agents, contractors or consultants is governed by the terms of
the CRADA, including, but not limited to a provision for the assignment of Inventions of the agent, contractor or consultant to the Collaborator.  

Amend the Definition of “Entire Agreement” in 13.13 to read as follows: 

13.13 Entire Agreement. This CRADA constitutes the entire agreement between the Parties concerning the subject matter of this CRADA and supersedes any
prior understanding or written or oral agreement between the Parties relating to the subject matter of this CRADA, including, without limitation the LOI executed on October 6th, 2016, and
the corresponding terms of the Model PHS CRADA referred to in Article 1. The Material Transfer Agreement (MTA) between the parties (NCI no. 32360-11), effective date 6/29/11, is hereby superseded and succeeded by the terms of this CRADA.
Specifically, the transfer of materials and data shall be governed by the terms of this CRADA as if they had been exchanged after the execution of the CRADA, and not by terms of the MTA.  

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 39 of 42	  	Confidential	  	Revised May 15, 2014

 APPENDIX D 

(from NIH Manual 2300-308-4, Appendix 2) 

NIH Research Collaborator (RC) Agreement for Use with IC CRADA # 03111 

The Parties acknowledge that an employee of (print CRADA Collaborator name) (“Collaborator”) will work at the NIH to advance the research goals
enumerated in the Research Plan of the Cooperative Research and Development Agreement reference number (# 03111) (“CRADA”), between the Collaborator and NCI (“IC”) as a Research Collaborator (Non-Clinical) OR
Research Collaborator (Clinical) (“RC”). The RC will be assigned to work within the Surgery Branch, Center for Cancer Research of the NCI. The RC agrees to the following terms: 

I, (print RC full name) (select one and delete the other:) CRADA Research Collaborator (Non-Clinical) OR CRADA Research Collaborator (Clinical), in
consideration of acceptance by NIH as a RC understand and agree to the following terms. 

 

	1.	 The intent of the work performed under this RC Agreement will be according to the Research Plan (Appendix A) of
the CRADA referenced above. In addition, the RC is bound by the Confidentiality terms of the CRADA and shall treat all confidential or proprietary material accordingly. CRADA Subject Inventions resulting from the RC’s activities done under the
Research Plan of the CRADA during the term of assignment at IC as a RC funded by the CRADA Collaborator, shall be treated as CRADA Subject Inventions of the Collaborator (either joint or sole) and will be governed by the terms of the CRADA.

  

	2.	 RC will make written disclosure promptly to the Technology Development Coordinator of the NIH Institute/Center
(IC), of all inventions which are conceived or first actually reduced to practice during the term of work at IC. 

  

	3.	 Publication of results from the RC’s activities done under the Research Plan of the CRADA during the term
of assignment at IC shall be addressed by the terms of CRADA. 

  

	4.	 In the event that an invention results from work done outside the scope of the Research Plan of the CRADA and
thus is not a CRADA Subject Invention, the following will govern reporting and disposition of the confidential and proprietary information/material:

 (a.) RC agrees to be bound by all provisions of USPHS Technology Transfer Manual Chapter 203
approved March 22, 2007, in accordance to which patent rights for all inventions conceived or first actually reduced to practice by the RC while at the NIH are NIH property. RC agrees to disclose promptly to the appropriate NIH officials, all
inventions which RC may conceive or first actually reduce to practice during RC’s visit to the NIH. RC hereby assigns all right, title and interest worldwide in such inventions to the U.S. Government and agrees to sign any papers necessary to
comply with attendant formalities. 
 (b.) The work the RC will perform may require access to knowledge and information of a confidential
nature to the IC. RC agrees to maintain such knowledge and information in confidence, and the RC shall not publish or disclose, or authorize anyone else to publish, disclose or make use of any such information or knowledge without prior written
authorization from the IC. This responsibility to protect said confidential information extends for a period of 5 years beyond the RC status with the IC.

 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 40 of 42	  	Confidential	  	Revised May 15, 2014

 (c.) All documents, written information and other items, including but not limited to notes,
sketches, laboratory reports, experiments, notebooks, papers, publications, project reports, records, and information relating to inventions or improvements, kept or obtained by the RC while engaged as a RC by the IC, shall be the exclusive property
of the U.S. Government and shall be delivered to the IC upon termination of RC status or at any time as requested by the IC. 
 (d.) RC
will submit publications resulting from work at NIH to be cleared for conformance with NIH’s publication policies and practices, including Public Access requirements. 
  

	5.	 RC will waive any and all claims for compensation from the Government of the United States for any services
performed incidental to the personal research RC performs, and absolve NIH of any responsibility in case of personal injury or death arising out of those research activities, and/or failure or damage to RC’s experiments or equipment.

	6.	 While on NIH premises, RC will conform to all applicable administrative instructions and requirements of the
Department of Health and Human Services and NIH, including all regulations and procedures concerning conduct, safety, patient care, and animal care. 

  

	7.	 RC agrees to obtain, prior to the beginning of this assignment, health insurance coverage substantially
comparable to that provided by the Federal Employee’s Health Benefits Plan and show proof of coverage prior to beginning RC appointment. Furthermore, non-immigrant foreign nationals sponsored as J-1 Exchange Visitors must maintain adequate
health insurance coverage for themselves and any J-2 dependents as required by the U.S. Department of State. 

  

	8.	 If not a U.S. citizen or permanent resident, RC agrees to provide evidence of valid non-immigrant status and RC
eligibility to the Division of International Services, ORS, for the duration of the RC appointment. 

 

 

  

                          
                                         
                                         
                                         
                                         
       
 Research Collaborator
Signature                                        
                                         
                                Date 

It is understood that the RC is an employee of (print CRADA Collaborator name) and that (print CRADA Collaborator Name) accepts these terms for
the work the RC will be conducting during the term of the RC appointment. 
  

                          
                                         
                                         
                                         
                                         
                                         
      
 Printed Name of CRADA Collaborator Responsible Official and Position Title 

 

                          
                                         
                                         
                                         
                                         
               
 Authorized Signature of CRADA Collaborator Responsible Official
                                         
                                       Date 

 

                          
                                         
                                         
                                         
                                         
                                         
      
 Signature of NIH IC Approving Official and Printed Name and Position Title
                                         
                       Date 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No. NCI # 03111	  	MODEL ADOPTED June 18, 2009
	Page 41 of 42	  	Confidential	  	Revised May 15, 2014

 APPENDIX E 

LOI Executed October 6th, 2016 between the Parties. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                	  	MODEL ADOPTED June 18, 2009
	Page 42 of 42	  	Confidential	  	Revised May 15, 2014

 

 
 September 30th, 2016 

Dr. Laurence Cooper, CEO 
 ZIOPHARM Oncology, Inc. 

One First Avenue, Parris Building 34, Navy Yard Plaza 
 Boston, MA
02129 
 Donald Lehr, Chief Legal Officer 
 Intrexon
Corporation 
 20374 Seneca Meadows Parkway 
 Germantown, MD
20876 
 Letter of Intent for a Cooperative Research and Development Agreement (“CRADA”) 

NCI CRADA #: 03111 
 NCI Principal Investigator: Steven A.
Rosenberg 
 Collaborator Investigators: Laurence Cooper (for Ziopharm), and Tim Chan (for Intrexon) 

Title: Development and Evaluation of Intrexon Corporation’s Proprietary Non-viral Sleeping Beauty Vectors for Genetic Modification of Peripheral Blood
Lymphocytes with Genes Encoding Mutated Tumor Neoantigen-specific T Cell Receptors (also referred to as Mutation Reactive T Cell Receptors) that Have Been Identified Using NCI Proprietary Methods 

Dear Dr. Cooper and Mr. Lehr: 
 It is my understanding
that a cooperative research and development project between the parties referenced below is being considered. Accordingly, until the formal Cooperative Research and Development Agreement (CRADA) is reviewed by the NIH CRADA Subcommittee and approved
by the Director, National Cancer Institute (NCI), this Letter is offered to permit the joint research to commence. If human clinical trials are a part of the joint research, the parties agree that all such trials which may begin prior to the
execution of the formal CRADA shall be preceded by the appropriate regulatory approvals (U.S. Food and Drug Administration IND approval or international equivalents thereof). 

 It is acknowledged by the parties below that cooperative research pursuant to the Research Plan, attached as
Appendix A, will be conducted informally by the NCI, Intrexon, and Ziopharm pending formal approval of the CRADA. It is further acknowledged that patentable inventions may be made by NCI employees and employees of the Intrexon and/or Ziopharm.
Pursuant to its authority under the Federal Technology Transfer Act of 1986, as amended, NCI agrees that should this CRADA be approved, it will have retroactive effect to the date that the last party has executed this Letter for any inventions that
may be made under this Research Plan. NCI further agrees that should this CRADA be approved it will have retroactive effect to the date that the last party has executed this Letter for confidentiality obligations specified in the NIH Model CRADA.
The NIH Model CRADA provisions for the protection of proprietary information are incorporated in this Letter by reference and are considered controlling during the period of informal joint research. These provisions include, but are not limited to
Article 2 and Article 8. The NIH Model CRADA is attached as Appendix B. In addition, a separate Confidential Disclosure Agreement (CDA) and Material Transfer Agreement (MTA) will accompany this Letter. If the CRADA is subsequently executed, it will
supersede the CDA and MTA. 
 You understand, however, that this Letter is not a commitment on the part of either party to enter into a CRADA. Further, this
Letter is effective for a term not to exceed six (6) months. The six-month term may be extended, provided the CRADA is under active negotiation and the collaborative research is continuing. Assuming that the necessary approvals are forthcoming,
we look forward to a successful collaboration. 
 Sincerely, 

/s/ Kathleen Carroll 
 Kathleen Carroll, Ph.D., MBA 

Associate Director, Technology Transfer Center 
 National Cancer
Institute 

 AGREED AND ACCEPTED: 

National Cancer Institute 
  

	
	     /s/ James Doroshow

	James Doroshow, M.D.
	Deputy Director for Clinical and Translational Research, NCI
	
	            10/5/16                
	Date
	
	ZIOPHARM Oncology, Inc. (“Ziopharm”)
	
	     /s/ Laurence Cooper

	Laurence Cooper, M.D., Ph.D.
	CEO
	
	      October 6. 2016      
	Date
	
	Intrexon Corporation (“Intrexon”)
	
	     /s/ Donald Lehr

	Donald Lehr
	CLO
	
	      October 6. 2016      
	Date

  

	Attachments:    Appendix	 A - Letter of Intent Research Plan 

Appendix B - Model NIH CRADA (version MODEL ADOPTED June 18, 2009, Revised May 15, 2014) 

			
	Confidential	  	LOI for proposed CRADA 03111
		  	JC/Collaborators

  

 APPENDIX A 

[***Four (4) Pages Redacted in their Entirety***] 

[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED. 

 APPENDIX B 

PUBLIC HEALTH SERVICE 

COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT 

FOR INTRAMURAL-PHS CLINICAL RESEARCH 
 This
Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of
Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).

 This Cover Page identifies the Parties to this CRADA: 

The U.S. Department of Health and Human Services, as represented by 

[INSERT the full name of the IC] 

an Institute or Center (hereinafter referred to as the “IC”) of the 

[INSERT as appropriate: NM, CDC, or FDA] 

and 
 [INSERT
Collaborator’s official name], 
 hereinafter referred to as the “Collaborator”, 

having offices at [INSERT Collaborator’s address], 

created and operating under the laws of [INSERT State of Incorporation]. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 1 of 25	  		  	Revised May 15, 2014

 COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT 

FOR INTRAMURAL-PUS CLINICAL RESEARCH 

Article 1. Introduction 
 This CRADA between IC and
Collaborator will be effective when signed by the Parties, which are identified on both the Cover Page and the Signature Page. The official contacts for the Parties are identified on the Contacts Information Page. Publicly available information
regarding this CRADA appears on the Summary Page. The research and development activities that will be undertaken by IC and Collaborator in the course of this CRADA are detailed in the Research Plan, attached as Appendix A. The staffing, funding,
and materials contributions of the Parties are set forth in Appendix B. Any changes to the model CRADA are set forth in Appendix C. 
 Article 2.
Definitions 
 The terms listed in this Article will carry the meanings indicated throughout the CRADA. To the extent a definition of a term as provided
in this Article is inconsistent with a corresponding definition in the applicable sections of either the United States Code (U.S.C.) or the Code of Federal Regulations (C.F.R.), the definition in the U.S.C. or C.F.R. will control. 

“Adverse Event” or “AE” means any untoward medical occurrence associated with the use of a Test Article in
humans, whether or not considered related to the Test Article (21 C.F.R §§ 312.32, 308.3; see also FDA Good Clinical Practice Guideline, International Conference on Harmonisation (ICH) E6: “Good Clinical Practice: Consolidated
Guidance, 62 Federal Register 25,691 (1997)). 
 “Affiliate” means any corporation or other business entity controlled by,
controlling, or under common control with Collaborator at any time during the term of the CRADA. For this purpose, “control” means direct or indirect beneficial ownership of at least fifty percent (50%) of the voting stock or at least
fifty percent (50%) interest in the income of the corporation or other business entity. 
 “Annual Report” means the
report of progress of an IND-associated investigation that IC, as the IND Sponsor, must submit to the FDA within sixty (60) days of the anniversary or the effective date of the IND (pursuant to 21 C.F.R.§ 312.33). 

“Background Invention” means an Invention conceived and first actually reduced to practice before the Effective Date. 

“Clinical Investigator” means, in accordance with 21 C.F.R. § 312.3, an individual who actually conducts a clinical
investigation, that is, who directs the administration or dispensation of Test Article to a subject, and who assumes responsibility for studying Human Subjects, for recording and ensuring the integrity of research data, and for protecting the
welfare and safety of Human Subjects. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 2 of 25	  		  	Revised May 15, 2014

 “Collaborator Materials” means all tangible materials not first produced in
the performance of this CRADA that are owned or controlled by Collaborator and used in the performance of the Research Plan. The term “Collaborator Materials” does not include “Test Article” (defined below). 

“Confidential Information” means confidential scientific, business, financial information, or Identifiable Private Information
provided that the information does not include: 
  

	 	(a)	 information that is publicly known or that is available from public sources; 

 

	 	(b)	 information that has been made available by its owner to others without a confidentiality obligation;

  

	 	(c)	 information that is already known by the receiving Party, or information that is independently created or
compiled by the receiving Party without reference to or use of the provided information; or 

  

	 	(d)	 information that relates to potential hazards or cautionary warnings associated with the production, handling,
or use of the subject matter of the Research Plan. 

 “Cooperative Research and Development Agreement” or
“CRADA” means this Agreement, entered into pursuant to the Federal Technology Transfer Act of 1986, as amended (15 U.S.C. §§ 3710a et seq.), and Executive Order 12591 of April 10, 1987. 

“CRADA Data” means all recorded information first produced in the performance of the Research Plan. 

“CRADA Materials” means all tangible materials first produced in the performance of the Research Plan other than CRADA Data.

 “CRADA Principal Investigator(s)” or “CRADA PI(s)” means the person(s) designated by the Parties who
will be responsible for the scientific and technical conduct of the Research Plan. The CRADA PI may also be a Clinical Investigator. 

“CRADA Subject Invention” means any Invention of either or both Parties, conceived or first actually reduced to practice in
the performance of the Research Plan. 
 “Drug Master File” or “DMF” is described in 21 C.F.R. Part
314.420. A DMF is a submission to the FDA that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs. 

“Effective Date” means the date of the last signature of the Parties executing this Agreement. 

“Government” means the Government of the United States of America. 

“Human Subject” means, in accordance with the definition in 45 C.F.R. § 46.102(f), a

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 3 of 25	  		  	Revised May 15, 2014

 
living individual about whom an investigator conducting research obtains: 
  

	 	(a)	 data through intervention or interaction with the individual; or 

 

	 	(b)	 Identifiable Private Information. 

“IC Materials” means all tangible materials not first produced in the performance of this CRADA that are owned or controlled
by IC and used in the performance of the Research Plan. 
 “IND” means an “Investigational New Drug
Application”, filed in accordance with 21 C.F.R. Part 312 under which clinical investigation of an experimental drug or biologic (Test Article) is performed in Human Subjects in the United States or intended to support a United States
licensing action. 
 “Identifiable Private Information” or “IPI” about a Human Subject means private
information from which the identity of the subject is or may readily be ascertained. Regulations defining and governing this information include 45 C.F.R. Part 46 and 21 C.F.R. Part 50. 

“Institutional Review Board” or “IRB” means, in accordance with 45 C.F.R. Part 46, 21 C.F.R. Part 56, and
other applicable regulations, an independent body comprising medical, scientific, and nonscientific members, whose responsibility is to ensure the protection of the rights, safety, and well-being of the Human Subjects involved in a study. 

“Invention” means any invention or discovery that is or may be patentable or otherwise protected under Title 35 of the United
States Code, or any novel variety of plant which is or may be protectable under the Plant Variety Protection Act, 7 U.S.C. §§ 2321 et seq. 

“Investigator’s Brochure” means, in accordance with the definition in 21 C.F.R. § 312.23(a)(5), a document
containing information about the Test Article, including animal screening, preclinical toxicology, and detailed pharmaceutical data, including a description of possible risks and side effects to be anticipated on the basis of prior experience with
the drug or related drugs, and precautions, such as additional monitoring, to be taken as part of the investigational use of the drug. 

“Patent Application” means an application for patent protection for a CRADA Subject Invention with the United States Patent
and Trademark Office (“U.S.P.T.O.”) or the corresponding patent-issuing authority of another nation. 
 “Patent”
means any issued United States patent, any international counterpart(s), and any corresponding grant(s) by a non-U.S. government in place of a patent. 

“Placebo” means an inactive substance identical in appearance to the material being tested that is used to distinguish between
drug action and suggestive effect of the material under study. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 4 of 25	  		  	Revised May 15, 2014

 “Protocol” means the formal, detailed description of a study to be
performed as provided for in the Research Plan. It describes the objective(s), design, methodology, statistical considerations, and organization of a trial. For the purposes of this CRADA, the term, Protocol, for clinical research involving Human
Subjects, includes any and all associated documents, including informed consent forms, to he provided to Human Subjects and potential participants in the study. 

“Raw Data” means the primary quantitative and empirical data first collected from experiments and clinical trials conducted
within the scope of this CRADA. 
 “Research Plan” means the statement in Appendix A of the respective research and
development commitments of the Parties. The Research Plan should describe the provisions for sponsoring the IND, clinical and safety monitoring, and data management. 

“Sponsor” means, in accordance with the definition in 21 C.F.R. § 312.3, an organization or individual who assumes legal
responsibility for supervising or overseeing clinical trials with Test Articles, and is sometimes referred to as the IND holder. 

“Steering Committee” means the research and development team whose composition and responsibilities with regard to the
research performed under this CRADA are described in Appendix A. 
 “Summary Data” means any extract or summary of the Raw
Data, generated either by, or on behalf of, IC or by, or on behalf of, Collaborator. Summary Data may include extracts or summaries that incorporate IPI. 

“Test Article” means, in accordance with 21 C.F.R. § 50.3 (j), any drug (including a biological product), medical device,
food additive, color additive, electronic product, or any other article subject to regulation under the Federal Food, Drug, and Cosmetic Act that is intended for administration to humans or animals, including a drug or biologic as identified in the
Research Plan and Appendix B, that is used within the scope of the Research Plan. The Test Article may also be referred to as Investigational Agent, Study Material, or Study Product. 

Article 3. Cooperative Research and Development 
  

	3.1	 Performance of Research and Development. The research and development activities to be carried out under
this CRADA will be performed solely by the Parties identified on the Cover Page, unless specifically stated elsewhere in the Agreement. The CRADA PIs will be responsible for coordinating the scientific and technical conduct of this project on behalf
of their employers. Any Collaborator employees who will work at IC facilities will be required to sign an agreement appropriately modified in view of the terms of this CRADA. 

 

	3.2	 Research Plan. The Parties recognize that the Research Plan describes the collaborative research and
development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them
through an amendment, according to Paragraph 13.6. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 5 of 25	  		  	Revised May 15, 2014

	3.3	 Use and Disposition of Collaborator Materials and IC Materials. The Parties agree to use Collaborator
Materials and IC Materials only in accordance with the Research Plan and Protocol(s), not to transfer these materials to third parties except in accordance with the Research Plan and Protocol(s) or as approved by the owning or providing Party, and,
upon expiration or termination of the CRADA, to dispose of these materials as directed by the owning or providing Party. 

  

	3.4	 Third-Party Rights in Collaborator’s CRADA Subject Inventions. If Collaborator has received (or
will receive) support of any kind from a third party in exchange for rights in any of Collaborator’s CRADA Subject Inventions, Collaborator agrees to ensure that its obligations to the third party are both consistent with Articles 6 through 8
and subordinate to Article 7 of this CRADA. 

  

	3.5	 Disclosures to IC. Prior to execution of this CRADA, Collaborator agrees to disclose to IC all instances
in which outstanding royalties are due under a PHS license agreement and in which Collaborator had a PHS license terminated in accordance with 37 C.F.R. § 404.10. These disclosures will be treated as Confidential Information upon request by
Collaborator in accordance with the definition in Article 2 and Paragraphs 8.3 and 8.4. 

  

	3.6	 Clinical Investigator Responsibilities. The Clinical Investigator will be required to submit, or to
arrange for submission of, each Protocol associated with this CRADA to the IRB. In addition to the Protocol all associated documents, including informational documents and advertisements, must be reviewed and approved by the IRB before starting the
research. The research will be done in strict accordance with the Protocol(s) and no substantive changes in a finalized Protocol will be made unless mutually agreed upon, in writing, by the Parties. Research will not commence (or will continue
unchanged, if already in progress) until each substantive change to a Protocol, including those required by either the FDA or the IRB, has been integrated in a way acceptable to the Parties, submitted to the FDA (if applicable) and approved by the
IRB. 

  

	3.7	 Investigational Applications. 

 

	 	3.7.1	 If an IND is required, IC will be the IND Sponsor and will submit an IND. All Clinical Investigators must have
completed registration documents on file (1572 forms). 

  

	 	3.7.2	 When IC files the IND, Collaborator agrees to provide IC background data and information necessary to support
the IND. Collaborator further agrees to provide a letter of cross-reference to all pertinent regulatory filings sponsored by Collaborator. Collaborator’s employees will be reasonably available to respond to inquiries from the FDA regarding
information and data contained in the Collaborator’s IND, DMF, other filings, or other information and data provided to IC by the Collaborator pursuant to this Article 3. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 6 of 25	  		  	Revised May 15, 2014

	 	3.7.3	 If Collaborator supplies Confidential Information to IC in support of an IND filed by IC, this information will
be protected in accordance with the corresponding confidentiality provisions of Article 8. 

  

	 	3.7.4	 Collaborator may sponsor its own clinical trials and hold its own IND for studies performed outside the scope
of this CRADA. These studies, however, should not adversely affect the ability to accomplish the goal of the Research Plan, for example, by competing for the same study population. All data from those clinical trials are proprietary to Collaborator
for purposes of this CRADA. 

  

	3.8	 Test Article Information and Supply. Collaborator agrees to provide IC without charge and on a schedule
that will ensure adequate and timely performance of the research, a sufficient quantity of formulated and acceptably labeled, clinical-grade Test Article (and, as required by the Protocol(s), Placebo) to complete the clinical trial(s) agreed to and
approved under this CRADA, Collaborator will provide a Certificate of Analysis to IC for each lot of the Test Article provided. 

  

	3.9	 Test Article Delivery and Usage. Collaborator will ship the Test Article and, if required, Placebo to IC
in containers marked in accordance with 21 C.F.R. § 312.6. IC agrees that the Clinical Investigators will keep appropriate records and take reasonable steps to ensure that the Test Article is used in accordance with the Protocol(s) and
applicable FDA regulations. In addition, IC agrees that the Test Article (and all Confidential Information supplied by Collaborator relating to the Test Article) will be used solely for the conduct of the CRADA research and development activities.
Furthermore, IC agrees that no analysis or modification of the Test Article will be performed without Collaborator’s prior written consent. At the completion of the Research Plan, any unused quantity of Test Article will be returned to
Collaborator or disposed as directed by Collaborator. Pharmacy contacts at IC will be determined by IC and communicated to Collaborator. 

  

	3.10	 Monitoring. Subject to the restrictions in Article 8 concerning IN, and with reasonable advance notice
and at reasonable times, IC will permit Collaborator or its designee(s) to monitor the conduct of the research, as well as to audit source documents containing Raw Data, to the extent necessary to verify compliance with FDA Good Clinical Practice
(International Conference on Harmonisation (ICH) E6: “Good Clinical Practice: Consolidated Guidance; 62 Federal Register 25, 691 (1997)) and the Protocol(s). 

 

	3.11	 FDA Meetings/Communications. All meetings with the FDA concerning any clinical trial within the scope of
the Research Plan will be discussed by Collaborator and IC in advance. Each Party reserves the right to take part in setting the agenda for, to attend, and to participate in these meetings. IC will provide Collaborator with copies of FDA meeting
minutes, all transmittal letters for IND submissions, IND safety reports, formal questions and responses that have been submitted to the FDA, Annual Reports, and official FDA correspondence, pertaining either to the INDs under this CRADA or to the
Clinical Investigators on Protocols performed in accordance with the Research Plan, except to the extent that those documents contain the proprietary information of a third party or dissemination is prohibited by law. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 7 of 25	  		  	Revised May 15, 2014

 Article 4. Reports 
  

	4.1	 Interim Research and Development Reports. The CRADA PIs should exchange information regularly, in
writing. This exchange may be accomplished through meeting minutes, detailed correspondence, circulation of draft manuscripts, Steering Committee reports, copies of Annual Reports and any other reports updating the progress of the CRADA research.
However, the Parties must exchange updated Investigator’s Brochure, formulation and preclinical data, and toxicology findings, as they become available. 

  

	4.2	 Final Research and Development Reports. The Parties will exchange final reports of their results within
six (6) months after the expiration or termination of this CRADA. These reports will set forth the technical progress made; any publications arising from the research; and the existence of invention disclosures of potential CRADA Subject
Inventions and/or any corresponding Patent Applications. 

  

	4.3	 Fiscal Reports. If Collaborator has agreed to provide funding to IC under this CRADA and upon the
request of Collaborator, then concurrent with the exchange of final research and development reports according to Paragraph 4.2, IC will submit to Collaborator a statement of all costs incurred by IC for the CRADA. If the CRADA has been terminated,
IC will specify any costs incurred before the date of termination for which IC has not received funds from Collaborator, as well as for all reasonable termination costs including the cost of returning Collaborator property or removal of abandoned
Collaborator property, for which Collaborator will be responsible. 

  

	4.4	 Safety Reports. 

 

	4.4.1	 In accordance with FDA requirements IC, as the IND Sponsor, will establish and maintain records and submit
safety reports to the FDA, as required by 21 C.F.R. § 312.32 and 21 C.F.R. § 812.150(b)(1), or other applicable regulations. In the conduct of research under this CRADA, the Parties will comply with specific IC guidelines and policies for
reporting AEs, as well as procedures specified in the Protocol(s). IC must provide Collaborator with copies of all Safety Reports concurrently with their submission to the FDA, and with any other information affecting the safety of Human Subjects in
research conducted under this CRADA. 

  

	4.4.2	 During and for a period of two years after the completion of a Protocol, the Collaborator shall promptly
provide to the IC any information that Collaborator has reasonably determined could directly affect the health or safety of past or current Human Subjects or influence the conduct of the Protocol. Such information may arise from any source, for
example, Safety Reports provided to the FDA, study results, information in site monitoring reports or data safety monitoring committee reports. IC shall be free to communicate the relevant safety information to each Human Subject and the IRB.

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 8 of 25	  		  	Revised May 15, 2014

	4.5	 Annual Reports. IC will provide Collaborator a copy of the Annual Report concurrently with the
submission of the Annual Report to the FDA. Annual Reports will be kept confidential in accordance with Article 8. 

 Article 5.
Staffing, Financial, and Materials Obligations 
  

	5.1	 IC and Collaborator Contributions. The contributions of any staff, funds, materials, and equipment by
the Parties are set forth in Appendix B. The Federal Technology Transfer Act of 1986, 15 U.S.C. § 3710a(d)(1) prohibits IC from providing funds to Collaborator for any research and development activities under this CRADA. 

 

	5.2	 IC Staffing. No IC employees will devote 100% of their effort or time to the research and development
activities under this CRADA. IC will not use funds provided by Collaborator under this CRADA for IC personnel to pay the salary of any permanent IC employee. Although personnel hired by IC using CRADA funds will focus principally on CRADA research
and development activities, Collaborator acknowledges that these personnel may nonetheless make contributions to other research and development activities, and the activities will be outside the scope of this CRADA. 

 

	5.3	 Collaborator Funding. Collaborator acknowledges that Government funds received by Collaborator from an
agency of the Department of Health and Human Services may not be used to fund IC under this CRADA. If Collaborator has agreed to provide funds to IC then the payment schedule appears in Appendix B and Collaborator will make payments according to
that schedule. If Collaborator fails to make any scheduled payment, IC will not be obligated to perform any of the research and development activities specified herein or to take any other action required by this CRADA until the funds are received.
IC will use these funds exclusively for the purposes of this CRADA. Each Party will maintain separate and distinct current accounts, records, and other evidence supporting its financial obligations under this CRADA and, upon written request, will
provide the other Party a Fiscal Report according to Paragraph 4.3, which delineates all payments made and all obligated expenses, along with the Final Research Report described in Paragraph 4.2. 

 

	5.4	 Capital Equipment. Collaborator’s commitment, if any, to provide IC with capital equipment to
enable the research and development activities under the Research Plan appears in Appendix B. If Collaborator transfers to IC the capital equipment or provides funds for IC to purchase it, then IC will own the equipment. If Collaborator loans
capital equipment to IC for use during the CRADA, Collaborator will be responsible for paying all costs and fees associated with the transport, installation, maintenance, repair, removal, or disposal of the equipment, and IC will not be liable for
any damage to the equipment. 

 Article 6. Intellectual Property 

 

	6.1	 Ownership of CRADA Subject Inventions, CRADA Data, and CRADA Materials. Subject to the Government
license described in Paragraph 7.5, the sharing requirements of Paragraph 8.1 and the regulatory filing requirements of Paragraph 8.2, the producing Party will retain sole ownership of and title to all CRADA Subject Inventions, all copies of CRADA
Data, and all CRADA Materials produced solely by its employee(s). The Parties will own jointly all CRADA Subject Inventions invented jointly and all CRADA Materials developed jointly. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 9 of 25	  		  	Revised May 15, 2014

	6.2	 Reporting. The Parties will promptly report to each other in writing each CRADA Subject Invention
reported by their respective personnel, and any Patent Applications filed thereon, resulting from the research and development activities conducted under this CRADA. Each Party will report all CRADA Subject Inventions to the other Party in
sufficient detail to determine inventor ship, which will be determined in accordance with U.S. patent law. These reports will be treated as Confidential Information in accordance with Article 8. Formal reports will be made by and to the Patenting
and Licensing Offices identified on the Contacts Information Page herein. 

  

	6.3	 Filing of Patent Applications. Each Party will make timely decisions regarding the filing of Patent
Applications on the CRADA Subject Inventions made solely by its employee(s), and will notify the other Party in advance of filing. Collaborator will have the first opportunity to file a Patent Application on joint CRADA Subject Inventions and will
notify PHS of its decision within sixty (60) days of an Invention being reported or at least thirty (30) days before any patent filing deadline, whichever occurs sooner. If Collaborator fails to notify PHS of its decision within that time
period or notifies PHS of its decision not to file a Patent Application, then PHS has the right to file a Patent Application on the joint CRADA Subject Invention. Neither Party will be obligated to file a Patent Application. Collaborator will place
the following statement in any Patent Application it files on a CRADA Subject Invention: “This invention was created in the performance of a Cooperative Research and Development Agreement with the [INSERT into Agency’s model as
appropriate: National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention], an Agency of the Department of Health and Human Services. The Government of the United States has certain rights in this
invention.” If either Party files a Patent Application on a joint CRADA Subject Invention, then the filing Party will include a statement within the Patent Application that clearly identifies the Parties and states that the joint CRADA Subject
Invention was made under this CRADA. 

  

	6.4	 Patent Expenses. Unless agreed otherwise, the Party filing a Patent Application will pay all preparation
and filing expenses, prosecution fees, issuance fees, post issuance fees, patent maintenance fees, annuities, interference expenses, and attorneys’ fees for that Patent Application and any resulting Patent(s). If a license to any CRADA Subject
Invention is granted to Collaborator, then Collaborator will be responsible for all expenses and fees, past and future, in connection with the preparation, filing, prosecution, and maintenance of any Patent Applications and Patents claiming
exclusively licensed CRADA Subject Inventions and will be responsible for a pro-rated share, divided equally among all licensees, of those expenses and fees for non-exclusively licensed CRADA Subject Inventions. Collaborator may waive its exclusive
option rights at any time, and incur no subsequent financial obligation for those Patent Application(s) or Patent(s). 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 10 of 25	  		  	Revised May 15, 2014

	6.5	 Prosecution of Patent Applications. The Party filing a Patent Application will provide the non-filing
Party with a copy of any official communication relating to prosecution of the Patent Application within thirty (30) days of transmission of the communication. Each Party will also provide the other Party with the power to inspect and make
copies of all documents retained in the applicable Patent Application or Patent file. The Parties agree to consult with each other regarding the prosecution of Patent Applications directed to joint CRADA Subject Inventions. If Collaborator elects to
file and prosecute Patent Applications on joint CRADA Subject Inventions, then Collaborator agrees to use the U.S.P.T.O. Customer Number Practice and/or grant PHS a power(s) of attorney (or equivalent) necessary to assure PHS access to its
intellectual property rights in these Patent Applications. PHS and Collaborator will cooperate with each other to obtain necessary signatures on Patent Applications, assignments, or other documents. 

Article 7. Licensing 
  

	7.1	 Background Inventions. Other than as specifically stated in this Article 7, nothing in this CRADA will
be construed to grant any rights in one Party’s Background Invention(s) to the other Party, except to the extent necessary for the Parties to conduct the research and development activities described in the Research Plan. 

 

	7.2	 Collaborator’s License Option to CRADA Subject Inventions. With respect to Government rights to any
CRADA Subject Invention made solely by an IC employee(s) or made jointly by an IC employee(s) and a Collaborator employee(s) for which a Patent Application was filed, PHS hereby grants to Collaborator an exclusive option to elect an exclusive or
nonexclusive commercialization license. The license will be substantially in the form of the appropriate model PHS license agreement and will fairly reflect the nature of the CRADA Subject Invention, the relative contributions of the Parties to the
CRADA Subject Invention and the CRADA, a plan for the development and marketing of the CRADA Subject Invention, the risks incurred by Collaborator, and the costs of subsequent research and development needed to bring the CRADA Subject Invention to
the marketplace. The field of use of the license will not exceed the scope of the Research Plan. 

  

	7.3	 Exercise of Collaborator’s License Option. To exercise the option of Paragraph 7.2 Collaborator
must submit a written notice to the PHS Patenting and Licensing Contact identified on the Contacts Information Page (and provide a copy to the IC Contact for CRADA Notices) within three (3) months after either (i) Collaborator receives
written notice from PHS that the Patent Application has been filed or (ii) the date on which Collaborator files the Patent Application. The written notice exercising this option will include a completed “Application for License to Public
Health Service Inventions” and will initiate a negotiation period that expires nine (9) months after the exercise of the option. If PHS has not responded in writing to the last proposal by Collaborator within this nine (9) month
period, the negotiation period will be extended to expire one (1) month after PHS so responds, during which month Collaborator may accept in writing the final license proposal of PHS. In the absence of Collaborator’s exercise of the
option, or upon election of a nonexclusive license, PHS will be free to license the CRADA Subject Invention to others. These time periods may be extended at the sole discretion of PHS upon good cause shown in writing by Collaborator.

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 11 of 25	  		  	Revised May 15, 2014

	7.4	 Government License in IC Sole CRADA Subject Inventions and Joint CRADA Subject Inventions. Pursuant to
15 U.S.C. § 3710a(b)(1)(A), for CRADA Subject Inventions owned solely by IC or jointly by IC and Collaborator, and licensed pursuant to the option of Paragraph 7.2, Collaborator grants to the Government a nonexclusive, nontransferable,
irrevocable, paid-up license to practice the CRADA Subject Invention or have the CRADA Subject Invention practiced throughout the world by or on behalf of the Government. In the exercise of this license, the Government will not publicly disclose
trade secrets or commercial or financial information that is privileged or confidential within the meaning of 5 U.S.C. § 552(b)(4) or which would be considered privileged or confidential if it had been obtained from a non-federal party.

  

	7.5	 Government License in Collaborator Sole CRADA Subject Inventions. Pursuant to 15 U.S.C. §
3710a(b)(2), for CRADA Subject Inventions made solely by an employee of Collaborator, Collaborator grants to the Government a nonexclusive, nontransferable, irrevocable, paid-up license to practice the CRADA Subject Invention or have the CRADA
Subject Invention practiced throughout the world by or on behalf of the Government for research or other Government purposes. 

  

	7.6	 Third Party License. Pursuant to 15 U.S.C. § 3710a(b)(1)(B), if PHS grants Collaborator an
exclusive license to a CRADA Subject Invention made solely by an IC employee or jointly with a Collaborator employee, the Government will retain the right to require Collaborator to grant to a responsible applicant a nonexclusive, partially
exclusive, or exclusive sublicense to use the CRADA Subject Invention in Collaborator’s licensed field of use on terms that are reasonable under the circumstances; or, if Collaborator fails to grant a license, to grant a license itself. The
exercise of these rights by the Government will only be in exceptional circumstances and only if the Government determines (i) the action is necessary to meet health or safety needs that are not reasonably satisfied by Collaborator,
(ii) the action is necessary to meet requirements for public use specified by federal regulations, and such requirements are not reasonably satisfied by Collaborator; or (iii) Collaborator has failed to comply with an agreement containing
provisions described in 15 U.S.C. § 3710a(c)(4)(B). The determination made by the Government under this Paragraph is subject to administrative appeal and judicial review under 35 U.S.C. § 203(b). 

 

	7.7	 Third-Party Rights In IC Sole CRADA Subject Inventions. For a CRADA Subject Invention conceived prior to
the Effective Date solely by an IC employee that is first actually reduced to practice after the Effective Date in the performance of the Research Plan, the option offered to Collaborator in Paragraph 7.2 may be restricted if, prior to the Effective
Date, PHS had filed a Patent Application and has either offered or granted a license in the CRADA Subject Invention to a third party. Collaborator nonetheless retains the right to apply for a license to any such CRADA Subject Invention in accordance
with the terms and procedures of 35 U.S.C. § 209 and 37 C.F.R. Part 404. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 12 of 25	  		  	Revised May 15, 2014

 Article 8. Rights of Access and Publication 

 

	8.1	 Right of Access to CRADA Data and CRADA Materials. IC and Collaborator agree to exchange all CRADA Data
and to share all CRADA Materials. If the CRADA is terminated, both Parties agree to provide CRADA Materials in quantities needed to complete the Research Plan. Such provision will occur before the termination date of the CRADA or sooner, if required
by the Research Plan. If Collaborator possesses any human biological specimens from clinical trials under the CRADA, the specimens must be handled as described in the Protocol or as otherwise directed by IC before the termination date of the CRADA.

  

	8.2	 Use of CRADA Data and CRADA Materials. The Parties will be free to utilize CRADA Data and CRADA
Materials internally for their own purposes, consistent with their obligations under this CRADA. The Parties may share CRADA Data or CRADA Materials with their Affiliates, agents or contractors provided the obligations of this Article 8.2 are
simultaneously conveyed. 

  

	 	8.2.1	 CRADA Data. 

Collaborator and IC will use reasonable efforts to keep CRADA Data confidential until published or until corresponding Patent Applications are
filed. To the extent permitted by law, each Party will have the right to use any and all CRADA Data in and for any regulatory filing by or on behalf of the Party. 
  

	 	8.2.2	 CRADA Materials. 

Collaborator and IC will use reasonable efforts to keep descriptions of CRADA Materials confidential until published or until corresponding
Patent Applications are filed. Collaborator acknowledges that the basic research mission of PHS includes sharing with third parties for further research those research resources made in whole or in part with NIH funding. Consistent with this mission
and the tenets articulated in “Sharing of Biomedical Research Resources: Principles and Guidelines for Recipients of NIH Research Grants and Contracts”, December 1999, available at
https://www.gpo.gov/fdsys/pkg/FR-1999-12-23/pdf/99-33292.pdf; following publication either Party may make available to third parties for further research those CRADA Materials made jointly by both PHS
and Collaborator. Notwithstanding the above, if those joint CRADA Materials are the subject of a pending Patent Application or a Patent, or were created using a patent-pending or patented material or technology, the Parties may agree to restrict
distribution or freely distribute them. Either Party may distribute those CRADA Materials made solely by the other Party only upon written consent from that other Party or that other Party’s designee. 

 

	8.3	 Confidential Information. Each Party agrees to limit its disclosure of Confidential Information to the
amount necessary to carry out the Research Plan, and will place a confidentiality notice on all this information. A Party orally disclosing Confidential Information to the other Party will summarize the disclosure in writing and provide it to the
other Party within fifteen (15) days of the disclosure. Each Party receiving Confidential Information agrees to use it only for the purposes described in the Research Plan. Either Party may object to the designation of information as
Confidential Information by the other Party. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 13 of 25	  		  	Revised May 15, 2014

	8.4	 Protection of Confidential Information. Confidential Information will not be disclosed, copied,
reproduced or otherwise made available to any other person or entity without the consent of the owning or providing Party except as required by a court or administrative body of competent jurisdiction, or federal law or regulation. Each Party agrees
to use reasonable efforts to maintain the confidentiality of Confidential Information, which will in no instance be less effort than the Party uses to protect its own Confidential Information. Each Party agrees that a Party receiving Confidential
Information will not be liable for the disclosure of that portion of the Confidential Information which, after notice to and consultation with the disclosing Party, the receiving Party determines may not be lawfully withheld, provided the disclosing
Party has been given a reasonable opportunity to seek a court order to enjoin disclosure. 

  

	8.5	 Human Subject Protection. The research to be conducted under this CRADA involves Human Subjects or human
tissues within the meaning of 4S C.F.R. Part 46, and all research to be performed under this CRADA will conform to applicable federal laws and regulations. Additional information is available from the NHS Office for Human Research Protections
(http://www.hhs.gov/ohrp/). 

  

	8.6	 Duration of Confidentiality Obligation. The obligation to maintain the confidentiality of Confidential
Information will expire at the earlier of the date when the information is no longer Confidential Information as defined in Article 2 or three (3) years after the expiration or termination date of this CRADA, except for IPI, for which the
obligation to maintain confidentiality will extend indefinitely. Collaborator may request an extension to this term when necessary to protect Confidential Information relating to products not yet commercialized, 

 

	8.7	 Publication. The Parties are encouraged to make publicly available the results of their research and
development activities. Before either Party submits a paper or abstract for publication or otherwise intends to publicly disclose information about a CRADA Subject Invention, CRADA Data, or CRADA Materials, the other Party will have thirty
(30) days to review proposed manuscripts and three (3) days to review proposed abstracts to assure that Confidential Information is protected. Either Party may request in writing that the proposed publication or other disclosure be delayed
for up to thirty (30) additional days as necessary to file a Patent Application. 

 Article 9. Representations and Warranties

  

	9.1	 Representations of IC. IC hereby represents to Collaborator that: 

 

	 	9.1.1	 IC has the requisite power and authority to enter into this CRADA and to perform according to its terms, and
that IC’s official signing this CRADA has authority to do so. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 14 of 25	  		  	Revised May 15, 2014

	 	9.1.2	 To the best of its knowledge and belief, neither IC nor any of its personnel involved in this CRADA is
presently subject to debarment or suspension by any agency of the Government which would directly affect its performance of the CRADA. Should IC or any of its personnel involved in this CRADA be debarred or suspended during the term of this CRADA,
IC will notify Collaborator within thirty (30) days of receipt of final notice. 

  

	9.2	 Representations and Warranties of Collaborator. Collaborator hereby represents and warrants to IC that:

  

	 	9.2.1	 Collaborator has the requisite power and authority to enter into this CRADA and to perform according to its
terms, and that Collaborator’s official signing this CRADA has authority to do so. 

  

	 	9.2.2	 Neither Collaborator nor any of its personnel involved in this CRADA, including Affiliates, agents, and
contractors are presently subject to debarment or suspension by any agency of the Government. Should Collaborator or any of its personnel involved in this CRADA be debarred or suspended during the term of this CRADA, Collaborator will notify IC
within thirty (30) days of receipt of final notice. 

  

	 	9.2.3	 Subject to Paragraph 12.3, and if and to the extent Collaborator has agreed to provide funding under Appendix
B, Collaborator is financially able to satisfy these obligations in a timely manner. 

  

	 	9.2.4	 The Test Article provided has been produced in accordance with the FDA’s current Good Manufacturing
Practice set out in 21 C.F.R. §§ 210-211 and ICH QA7, and meets the specifications cited in the Certificate of Analysis and Investigator’s Brochure provided. 

Article 10. Expiration and Termination 
  

	10.1	 Expiration. This CRADA will expire on the last date of the term set forth on the Summary Page. In no
case will the term of this CRADA extend beyond the term indicated an the Summary Page unless it is extended in writing in accordance with Paragraph 13.6. 

  

	10.2	 Termination by Mutual Consent. IC and Collaborator may terminate this CRADA at any time by mutual
written consent. 

  

	10.3	 Unilateral Termination. Either IC or Collaborator may unilaterally terminate this CRADA at any time by
providing written notice at least sixty (60) days before the desired termination date. IC may, at its option, retain funds transferred to IC before unilateral termination by Collaborator for use in completing the Research Plan. If Collaborator
terminates this Agreement before the completion of all approved or active Protocol(s), then Collaborator will supply enough Test Article (and Placebo, if applicable) to complete these Protocol(s) unless termination is for safety concerns.

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 15 of 25	  		  	Revised May 15, 2014

	10.4	 Funding for IC Personnel. If Collaborator has agreed to provide funding for IC personnel and this CRADA
is mutually or unilaterally terminated by Collaborator before its expiration, then Collaborator agrees that funds for that purpose will be available to IC for a period of six (6) months after the termination date or until the expiration date of
the CRADA, whichever occurs sooner. If there are insufficient funds to cover this expense, Collaborator agrees to pay the difference. 

  

	10.5	 New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual
termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that IC will have the authority to retain and expend any funds
for up to one (1) year subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan.

  

	10.6	 Collaborator Failure to Continue Development. If Collaborator suspends development of the Test Article
without the transfer of its active development efforts, assets, and obligations to a third party within ninety (90) days of discontinuation, Collaborator agrees that IC may continue developing the Test Article. In that event, the following will
apply: 

  

	 	10.6.1	 Collaborator agrees to transfer to IC all information necessary to enable IC to contract for the manufacture of
the Test Article and, unless abandoned for reasons relating to safety as determined by the data safety monitoring board, to provide the Test Article (and Placebo, if any) in Collaborator’s inventory to IC. 

 

	 	10.6.2	 Further, Collaborator hereby grants to IC a nonexclusive, irrevocable, world-wide, paid-up license to practice,
or have practiced for or on behalf of the Government, any Background Invention that Collaborator may currently have or will obtain on the Test Article, its manufacture, or on any method of using the Test Article for the indication(s) described in
the Research Plan, including the right to sublicense to third parties. 

 Article 11. Disputes 

 

	11.1	 Settlement. Any dispute arising under this CRADA which is not disposed of by agreement of the CRADA
Principal Investigators will be submitted jointly to the signatories of this CRADA. If the signatories, or their designees, are unable to jointly resolve the dispute within thirty (30) days after notification thereof, the Assistant Secretary
for Health (or his/her designee or successor) will propose a resolution. Nothing in this Paragraph will prevent any Party from pursuing any additional administrative remedies that may be available and, after exhaustion of such administrative
remedies, pursuing all available judicial remedies. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 16 of 25	  		  	Revised May 15, 2014

	11.2	 Continuation of Work. Pending the resolution of any dispute or claim pursuant to this Article 11, the
Parties agree that performance of all obligations will be pursued diligently. 

 Article 12. Liability 

 

	12.1	 NO WARRANTIES. EXCEPT AS SPECIFICALLY STATED IN ARTICLE 9, THE PARTIES MAKE NO EXPRESS OR IMPLIED
WARRANTY AS TO ANY MATTER WHATSOEVER, INCLUDING THE CONDITIONS OF THE RESEARCH OR ANY INVENTION OR MATERIAL WHETHER TANGIBLE OR INTANGIBLE, MADE OR DEVELOPED UNDER OR OUTSIDE THE SCOPE OF THIS CRADA, OR THE OWNERSHIP, MERCHANTABILITY, OR FITNESS FOR
A PARTICULAR PURPOSE OF THE RESEARCH OR ANY INVENTION OR MATERIAL, OR THAT A TECHNOLOGY UTILIZED BY A PARTY IN THE PERFORMANCE OF THE RESEARCH PLAN DOES NOT INFRINGE ANY THIRD-PARTY PATENT RIGHTS. 

 

	12.2	 Indemnification and Liability. Collaborator agrees to hold the Government harmless and to indemnify the
Government for all liabilities, demands, damages, expenses and losses arising out of the use by Collaborator for any purpose of the CRADA Data, CRADA Materials or CRADA Subject Inventions produced in whole or part by IC employees under this CRADA,
unless due to the negligence or willful misconduct of IC, its employees, or agents. The Government has no statutory authority to indemnify Collaborator. Each Party otherwise will be liable for any claims or damages it incurs in connection with this
CRADA, except that IC, as an agency of the Government, assumes liability only to the extent provided under the Federal Tort Claims Act , 28 U.S.C. Chapter 171. 

 

	12.3	 Force Majeure. Neither Party will be liable for any unforeseeable event beyond its
reasonable control and not caused by its own fault or negligence, which causes the Party to be unable to perform its obligations under this CRADA, and which it has been unable to overcome by the exercise of due diligence. If a force majeure
event occurs, the Party unable to perform will promptly notify the other Party. It will use its best efforts to resume performance as quickly as possible and will suspend performance only for such period of time as is necessary as a result of the
force majeure event. 

 Article 13. Miscellaneous 

 

	13.1	 Governing Law. The construction, validity, performance and effect of this CRADA will be governed by U.S.
federal law, as applied by the federal courts in the District of Columbia. If any provision in this CRADA conflicts with or is inconsistent with any U.S. federal law or regulation, then the U.S. federal law or regulation will preempt that provision.

  

	13.2	 Compliance with Law. IC and Collaborator agree that they will comply with, and advise any contractors,
grantees, or agents they have engaged to conduct the CRADA research and development activities to comply with, all applicable Executive Orders, statutes, and NHS regulations relating to research on human subjects (45 C.F.R. Part 46,

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 17 of 25	  		  	Revised May 15, 2014

	 	
21 C.F.R. Parts 50 and 56) and relating to the appropriate care and use of laboratory animals (7 U.S.C. § 2131 et seq.; 9 C.F.R. Part 1, Subchapter A). IC and Collaborator will advise
any contractors, grantees, or agents they have engaged to conduct clinical trials for this CRADA that they must comply with all applicable federal regulations for the protection of Human Subjects, which may include the Standards for Privacy of
Individually Identifiable Health Information set forth in 45 C.F.R. Part 164. Collaborator agrees to ensure that its employees, contractors, and agents who might have access to a “select agent or toxin” (as that term is defined in 42
C.F.R. §§ 73.4-73.5) transferred from IC is properly licensed to receive the “select agent or toxin”. 

  

	13.3	 Waivers. None of the provisions of this CRADA will be considered waived by any Party unless a waiver is
given in writing to the other Party. The failure of a Party to insist upon strict performance of any of the terms and conditions hereof, or failure or delay to exercise any rights provided herein or by law, will not be deemed a waiver of any rights
of any Party. 

  

	13.4	 Headings. Titles and headings of the articles and paragraphs of this CRADA are for convenient reference
only, do not form a part of this CRADA, and will in no way affect its interpretation. 

  

	13.5	 Severability. The illegality or invalidity of any provisions of this CRADA will not impair, affect, or
invalidate the other provisions of this CRADA. 

  

	13.6	 Amendments. Minor modifications to the Research Plan may be made by the mutual written consent of the
CRADA Principal Investigators. Substantial changes to the CRADA, extensions of the term, or any changes to Appendix C will become effective only upon a written amendment signed by the signatories to this CRADA or by their representatives duly
authorized to execute an amendment. A change will be considered substantial if it directly expands the range of the potential CRADA Subject Inventions, alters the scope or field of any license option governed by Article 7, or requires a significant
increase in the contribution of resources by either Party. 

  

	13.7	 Assignment. Neither this CRADA nor any rights or obligations of any Party hereunder shall be assigned or
otherwise transferred by either Party without the prior written consent of the other Party. The Collaborator acknowledges the applicability of 41 U.S.C. § 15, the Anti Assignment Act, to this Agreement. The Parties agree that the identity of
the Collaborator is material to the performance of this CRADA and that the duties under this CRADA are nondelegable. 

  

	13.8	 Notices. All notices pertaining to or required by this CRADA will be in writing, signed by an authorized
representative of the notifying Party, and delivered by first class, registered, or certified mail, or by an express/overnight commercial delivery service, prepaid and properly addressed to the other Party at the address designated on the Contacts
Information Page, or to any other address designated in writing by the other Party. Notices will be considered timely if received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service
postmark or dated receipt from a commercial carrier. Notices regarding the exercise of license options will be made pursuant to Paragraph 7.3. Either Party may change its address by notice given to the other Party in the manner set forth above.

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 18 of 25	  		  	Revised May 15, 2014

	13.9	 Independent Contractors. The relationship of the Parties to this CRADA is that of independent
contractors and not agents of each other or joint venturers or partners. Each Party will maintain sole and exclusive control over its personnel and operations. 

 

	13.10	 Use of Name; Press Releases. By entering into this CRADA, the Government does not directly or indirectly
endorse any product or service that is or will be provided, whether directly or indirectly related to either this CRADA or to any patent or other intellectual-property license or agreement that implements this CRADA by Collaborator, its successors,
assignees, or licensees. Collaborator will not in any way state or imply that the Government or any of its organizational units or employees endorses any product or services. Each Party agrees to provide proposed press releases that reference or
rely upon the work under this CRADA to the other Party for review and comment at least five (5) business days before publication. Either Party may disclose the Title and Abstract of the CRADA to the public without the approval of the other
Party. 

  

	13.11	 Reasonable Consent. Whenever a Party’s consent or permission is required under this CRADA, its
consent or permission will not be unreasonably withheld. 

  

	13.12	 Export Controls. Collaborator agrees to comply with U.S export law and regulations. If Collaborator has
a need to transfer any CRADA Materials made in whole or in part by IC, or IC Materials, or IC’s Confidential Information to a person located in a country other than the United States, to an Affiliate organized under the laws of a country other
than the United States, or to an employee of Collaborator in the United States who is not a citizen or permanent resident of the United States, Collaborator will acquire any and all necessary export licenses and other appropriate authorizations.

  

	13.13	 Entire Agreement. This CRADA constitutes the entire agreement between the Parties concerning the subject
matter of this CRADA and supersedes any prior understanding or written or oral agreement. 

  

	13.14	 Survivability. The provisions of Paragraphs 3.3, 3.4, 3.8, 4.2, 4.3, 4.4.2, 5.3, 5.4, 6.1-9.2,
10.3-10.6, 11.1, 11.2, 12.1-12.3, 13.1-13.3, 13.7, 13.10 and 13.14 will survive the expiration or early termination of this CRADA. 

SIGNATURES BEGIN ON THE NEXT PAGE 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 19 of 25	  		  	Revised May 15, 2014

 SIGNATURE PAGE 

ACCEPTED AND AGREED 
 BY
EXECUTING THIS AGREEMENT, EACH PARTY REPRESENTS THAT ALL STATEMENTS MADE HEREIN
ARE TRUE, COMPLETE, AND ACCURATE TO THE BEST OF ITS KNOWLEDGE.
COLLABORATOR ACKNOWLEDGES THAT IT MAY BE SUBJECT TO CRIMINAL, CIVIL, OR
ADMINISTRATIVE PENALTIES FOR KNOWINGLY MAKING A FALSE, FICTITIOUS, OR FRAUDULENT
STATEMENT OR CLAIM. 
 FOR IC: 
  

									
	  
	 		 		 	                            	 	
	Signature	 		 	        	 	Date	 	
					
	Typed Name:	 		 		 		 	
	Title:	 		 		 		 	
					
	FOR COLLABORATOR:	 		 		 		 	                
					
	  
	 		 		 	                            	 	
	Signature	 		 		 	Date	 	
					
	Typed Name:	 		 		 		 	
	Title:	 		 		 		 	

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.             	  	MODEL ADOPTED June 18, 2009
	Page 20 of 25	  	Confidential	  	Revised May 15, 2014

 CONTACTS INFORMATION PAGE 

CRADA Notices 
  

			
	 For NCI:
	  	 For Collaborator:

		
	Technology Transfer Specialist	  	                    
		
	National Cancer Institute	  	                    
		
	9609 Medical Center Drive	  	
		
	Bethesda, MD 20892-9702 MSC 9702	  	
		
	Rockville, MD 20850-9702 (express mail)	  	
		
	Tel: [***]	  	Tel:
		
	Fax: [***]	  	Fax:

 Patenting and Licensing 
  

			
	 For IC:
	  	 For Collaborator (if separate from above)

		
	                                      
                              	  	                    
		
	Technology Transfer Specialist	  	                    
		
	National Cancer Institute	  	
		
	9609 Medical Center Drive	  	
		
	Room 1-E530, MSC 9702	  	
		
	Rockville, MD 20850-9702	  	Tel:
		
	Tel: [***]	  	Fax:
		
	Fax: [***]	  	

 Delivery of Materials Identified in Appendix B (if any) 

 

			
	 For IC:
	  	 For Collaborator:

		
	                    	  	                    
		
	 Tel:
	  	
		
	 Fax:
	  	

 Clinical Contact (as needed for Article 4.4.2) 

For IC: 
 Tel: 

Fax: 
 [***] = CERTAIN CONFIDENTIAL INFORMATION
OMITTED. 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.             	  	MODEL ADOPTED June 18, 2009
	Page 21 of 25	  	Confidential	  	Revised May 15, 2014

 SUMMARY PAGE 

EITHER PARTY MAY, WITHOUT FURTHER CONSULTATION OR PERMISSION, 

RELEASE THIS SUMMARY PAGE TO THE PUBLIC. 
  

			
	TITLE OF CRADA:	  	  

		  	  

			
		
	PHS [IC] Component:	 	  

		
	IC Principal Investigator:	 	  

		
	Collaborator:	 	  

		
	Collaborator Principal Investigator:	 	  

		
	TERM OF CRADA:	 	                     (___) years from the Effective Date.

 ABSTRACT OF THE RESEARCH PLAN: 

 
  
  

 
  

 
  

 
  

 
  

 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 22 of 25	  		  	Revised May 15, 2014

 APPENDIX A 

RESEARCH PLAN 
 [The Research Plan should
be a short, concise explanation of the research project that will be conducted by NIH with the materials provided under the CRADA. Each Research Plan should include the following sentence, “The scope of the Research Plan is......”] 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 23 of 25	  	Confidential	  	Revised May 15, 2014

 APPENDIX B 

STAFFING, FUNDING AND MATERIALS/EQUIPMENT CONTRIBUTIONS OF THE PARTIES 

  

					
	PHS ICT-CRADA	  	Agreement Ref.                 	  	MODEL ADOPTED June 18, 2009
	Page 24 of 25	  	Confidential	  	Revised May 15, 2014

 APPENDIX C 

MODIFICATIONS TO THE MODEL INTRAMURAL-PHS CLINICAL CRADA 

  

					
	PHS ICT-CRADA	  	Agreement Ref. No.                 	  	MODEL ADOPTED June 18, 2009
	Page 25 of 25	  	Confidential	  	Revised May 15, 2014

			
	LOI Confidential Disclosure Agreement	  	Proposed CRADA #03111

  

CONFIDENTIAL DISCLOSURE AGREEMENT 

FOR CRADA LETTER OF INTENT 
 This Agreement
is made by and between the National Cancer Institute, NCI, an agency of the United States Government, (hereinafter referred to as “IC”), ZIOPHARM Oncology, Inc. (hereinafter referred to as “Ziopharm”) and Intrexon Corporation
(hereinafter referred to as “Intrexon”). Ziopharm and Intrexon each may be hereinafter referred to individually as “Collaborator” and collectively as “Collaborators.” Collectively or individually, the IC and
Collaborator shall also be referred to as “Parties” or “Party.” 
 WHEREAS, Collaborators have certain confidential information relating
to non-viral Sleeping Beauty vectors for genetic modification of peripheral blood lymphocytes and the therapeutic use thereof (hereinafter referred to as the “Confidential Information” belonging to Collaborator); and 

WHEREAS, IC has certain confidential information relating to methods for identifying mutation reactive T-cell receptors and use of T cells for cancer therapy
(hereinafter referred to as the “Confidential Information” belonging to IC); and 
 WHEREAS, each Party is interested in examining the
Confidential Information of the other Party in order to conduct research described in the attached Research Plan under a Letter of Intent for proposed Cooperative Research And Development Agreement #03111 entitled Development and Evaluation of
Intrexon Corporation’s Proprietary Non-viral Sleeping Beauty Vectors for Genetic Modification of Peripheral Blood Lymphocytes with Genes Encoding Mutated Tumor Neoantigen-specific T Cell Receptors (also referred to as Mutation Reactive T Cell
Receptors) that Have Been identified Using NCI Proprietary Methods; 
 NOW, THEREFORE, in consideration of the premises and mutual covenants contained
herein, the Parties hereto agree as follows: 
  

	1.	 Each Party shall disclose and transmit Confidential Information to the other Party in sufficient detail to
enable such other Party to conduct the research described in the Research Plan of the CRADA Letter of Intent. 

  

	2.	 Each Party agrees to accept the Confidential information and employ all reasonable efforts to maintain the
Confidential information of the other Party secret and confidential, such efforts to be no less than the degree of care employed by each Party to preserve and safeguard its own confidential information. The Confidential Information of the disclosing
Party shall not be disclosed, revealed, or given to anyone by the receiving Party except employees, contract employees, and volunteers who are under an obligation of confidentiality to the receiving Party and who have a need for the Confidential
Information in connection with the receiving Party’s research activities. Such individuals shall be advised by the receiving Party of the confidential nature of the Confidential Information and that the Confidential Information shall be treated
accordingly, 

  

	3.	 Each Party agrees that it will not use the Confidential Information of the other Party for any purpose except
as set forth herein. 

  
 Page 1 of 4 

			
	LOI Confidential Disclosure Agreement	  	Proposed CRADA #03111

  
  

	4.	 “Confidential Information” means confidential scientific, business, or financial information
provided that such information does not include information which: 

  

	 	a)	 is publicly known or is available from public sources; 

 

	 	b)	 has been made available by its owner to others without a confidentiality obligation; 

 

	 	e)	 is already known by the receiving Party, or information that is independently created or compiled by the
receiving Party without reference to or use of the provided information; 

  

	 	d)	 relates to potential hazards or cautionary warnings associated with the production, handling, or use of the
subject matter of the Research Plan of the proposed CRADA; 

  

	 	e)	 is required to be disclosed by law or court order. 

 

	5.	 The term of this Confidential Disclosure Agreement shall be the same as that of the CRADA Letter of Intent,
including any extensions. If the CRADA is executed, this Agreement shall be superseded by the terms of the CRADA. If the CRADA is not executed, or the Letter of Intent is terminated or expires, each Party’s obligations under Paragraphs 2 and 3
shall extend for a period of three (3) years from the date of final signature of this Agreement. 

  

	6.	 All information to be deemed confidential under this Agreement shall be clearly marked
“CONFIDENTIAL,” by the disclosing Party. Any Confidential Information which is orally disclosed must be reduced to writing and marked “CONFIDENTIAL” by the disclosing Party and such notice must be provided to the
other Party within thirty (30) days of such disclosure. 

 Notwithstanding any other provision in this Agreement,
although certain information provided under this Agreement is confidential and will be so marked, the Collaborators recognize that the NCI may need to disclose certain information concerning Confidential Information to patients (or to physicians or
scientists where such disclosure is made in order to directly facilitate the ongoing treatment of a patient, or the development of a treatment for a patient). The Collaborators hereby authorize such limited disclosures, and the NCI agrees to
promptly acknowledge to the Collaborators the making of any such disclosure. 
  

	7.	 It is understood that nothing herein shall be deemed to constitute, by implication or otherwise, the grant to
either Party by the other of any license or other rights under any patent, patent application or other intellectual property right or interest. The grant of such right or license, if any, shall be formalized in a separate license agreement between
the Parties. 

  

	8.	 It is understood and agreed by both Parties that each represents and warrants to the other Party that each
Official signing this Agreement has authority to do so. 

  
 Page 2 of 4 

			
	LOI Confidential Disclosure Agreement	  	Proposed CRADA #03111

  
  

	9.	 The illegality or invalidity of any provision of this Agreement shall not impair, affect or invalidate the
other provisions of this Agreement. 

  

	10.	 The construction, validity, performance and effect of this Agreement shall be governed by Federal law, as
applied by the Federal Courts in the District of Columbia. 

 SIGNATURES BEGIN ON THE FOLLOWING PAGE 

  
 Page 3 of 4 

			
	LOI Confidential Disclosure Agreement	  	Proposed CRADA #03111

  

ACCEPTED AND AGREED 
 The undersigned
expressly certify or affirm that the contents of any statements made or reflected in this document are truthful and accurate. The undersigned further agree to examine and consider the subject matter of the Confidential Information on the foregoing
basis. 
  

									
	FOR THE IC:	 		 		 		 	
					
	 /s/ Kathleen Carroll
	 		 		 	         
	 	
		 		 	            	 	Date	 	
	Kathleen Carroll, Ph.D., MBA	 		 		 		 	
	Associate Director, Technology Transfer Center	 		 		 		 	                            
	National Cancer Institute	 		 		 		 	
	National Institutes of Health	 		 		 		 	
					
	FOR ZIOPHARM	 		 		 		 	
					
	 /s/ Laurence Cooper
	 		 		 	 October 6, 2016
	 	
	(Authorized Signatory for Ziopharm)	 		 		 	Date	 	
					
	Laurence Cooper, M.D., Ph.D.	 		 		 		 	
	Chief Executive Officer	 		 		 		 	
	ZIOPHARM Oncology, Inc.	 		 		 		 	
	One First Street, Parris Building 34, Navy Yard Plaza	 		 		 		 	
	Boston, MA 02129	 		 		 		 	
					
	FOR INTREXON	 		 		 		 	
					
	 /s/ Donald Lehr
	 		 		 	 October 6, 2016
	 	
	(Authorized Signatory for Intrexon)	 		 		 	Date	 	
					
	Donald Lehr	 		 		 		 	
	Chief Legal Officer	 		 		 		 	
	Intrexon Corporation	 		 		 		 	
	20374 Seneca Meadows Parkway	 		 		 		 	
	Germantown, MD 20876	 		 		 		 	

  
 Page 4 of 4 

			
	LOI Material Transfer Agreement	  	Proposed CRADA #03111

  

MATERIAL TRANSFER AGREEMENT 

for CRADA Letter of Intent 
 This Material
Transfer Agreement (“MTA”) has been adopted for use by the National Cancer Institute (“IC”) for transfers of research material for research to be performed under a Cooperative Research and Development Agreement (CRADA) Letter of
Intent. Collectively or individually, the IC and Collaborators shall also be referred to as “Parties” or “Party.” 
 IC: National Cancer
Institute 
 Collaborators:   ZIOPHARM Oncology, Inc., and 

    Intrexon Corporation, Inc. 

Proposed CRADA title: Development and Evaluation of Intrexon Corporation’s Proprietary Non-viral Sleeping Beauty Vectors for Genetic Modification
of Peripheral Blood Lymphocytes with Genes Encoding Mutated Tumor Neoantigen-specific T Cell Receptors (also referred to as Mutation Reactive T Cell Receptors) that Have Been Identified Using NCI Proprietary Methods 

1. a. IC agrees to transfer to Collaborator the following IC Materials: 

None. 
  

	 	b.	 Collaborators agree to transfer to IC the following Collaborator Materials: 

 

	 	i.	 clinical grade DNA plasmid for Sleeping Beauty transposon expressing CAR 

 

	 	ii.	 clinical grade DNA plasmid Sleeping Beauty transposase expressing SB11 

 

	 	iii.	 sequence information for both Sleeping Beauty transposase and transposon 

In this MTA, IC Materials and Collaborator Materials will jointly be referred to as “Research Material.” 

2. THIS RESEARCH MATERIAL MAY NOT BE USED IN HUMAN SUBJECTS. The Research Material will only be used for research purposes by the receiving Party’s
Investigator in his/her laboratory, for the research project described in the Research Plan of the CRADA Letter of Intent (Appendix A), under suitable containment conditions. The Receiving Party agrees to comply with all Federal rules and
regulations applicable to the Research Plan and the handling of the Research Material. 
 3. In all oral presentations or written publications concerning the
Research Plan, the receiving Party will acknowledge the providing Party’s contribution of this Research Material unless requested otherwise. 

  
 Page 1 of 4 

			
	LOI Material Transfer Agreement	  	Proposed CRADA #03111

  
 4. This Research
Material represents a significant investment on the part of the providing Party and is considered proprietary to the providing Party. The receiving Party’s Investigator therefore agrees to retain control over this Research Material and further
agrees not to transfer the Research Material to other people not under her or his direct supervision without advance written approval of the providing Party. The providing Party reserves the right to distribute the Research Material to others and to
use it for its own purposes. When the Research Plan is completed, the Research Material will be disposed of, if directed by the providing Party. 
 5. The
Research Material IS BEING SUPPLIED TO THE RECEIVING PARTY WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. The providing Party makes no representations that the use of the
Research Material will not infringe any patent or proprietary rights of third parties. 
 6. No indemnification for any loss, claim, damage, or liability is
intended or provided by any Party under this agreement. Each Party shall be liable for any loss, claim, damage, or liability that said Party incurs as a result of its activities under this Agreement, except that IC, as an agency of the United
States, assumes liability only to the extent as provided under the Federal Tort Claims Act, 28 U.S.C. 2671 et seq. 
 7. The term of this MTA shall be the
same as that of the Letter of Intent including any extensions. If the CRADA is executed, this Agreement shall be superseded by the terms of the CRADA. If the CRADA is not executed, this Agreement shall expire at the same time as the expiration or
termination of the Letter of Intent. 
 8. The undersigned providing Party and receiving Party expressly certify and affirm that the contents of any
statements made herein are truthful and accurate. 
 10. This MTA shall be construed in accordance with Federal law as applied by the Federal courts in the
District of Columbia. 
 SIGNATURES BEGIN ON NEXT PAGE 

  
 Page 2 of 4 

			
	LOI Material Transfer Agreement	  	Proposed CRADA #03111

  
  

							
	 10/5/16            
	 	         /s/ Steven Rosenberg
	 		 	
	Date	 	Steven Rosenberg, M.D., Ph.D.	 		 	
		 	Chief, Surgery Branch, NCI	 		 	
				
	  
	 	         /s/ Kathleen Carroll
	 	            	 	
	Date	 	Kathleen Carroll, Ph.D., MBA	 		 	
		 	Associate Director, Technology Transfer Center	 		 	
		 	National Cancer Institute	 		 	
		 	National Institutes of Health	 		 	

 IC’s Official and Mailing Address: 

9609 Medical Center Drive, Rm 1E530 
 Rockville, MD 20850-9702
(for couriers) 
 Bethesda, MD 201192-9702 (for USPS mail) 
  

							
	 October 7, 2016    
	 	         /s/ Tim Chan
	 	        	 	
	Date	 	Tim Chan, Ph.D.	 		 	
		 	Senior Director, Intrexon	 		 	
				
	 October 7, 2016
	 	         /s/ Donald Lehr
	 		 	
	Date	 	Authorized Signature for Intrexon Corporation and Title	 		 	

 Intrexon Corporation’s Official and Mailing Address; 

20374 Seneca Meadows Parkway 

Germantown, MD 20876 
  

							
	 October 6, 2016    
	 	         /s/ Laurence Cooper
	 	                                      
                                         
     	 	
	Date	 	Laurence Cooper, M.D., Ph.D.	 		 	
		 	CEO ZIOPHARM Oncology, Inc.	 		 	
				
	              
	 	              
	 		 	
	Date	 	Authorized Signature for ZIOPHARM Oncology, Inc. and Title	 		 	

  
 Page 3 of 4 

			
	LOI Material Transfer Agreement	  	Proposed CRADA #03111

  
 ZIOPHARM
Oncology, Inc.’s Official and Mailing Address: 
 One First Avenue, Parris Building 34, Navy Yard Plaza 

Boston, MA 02129 
 Any raise or misleading
statements made, presented, or submitted to the Government, including any relevant omissions, under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal
statutes 31 U.S.C. § 3801-3812 (civil liability) and 18 U.S.C. § 1001 (criminal liability including line(s) and/or imprisonment). 

  
 Page 4 of 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]